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The chief and largely terminal element of normal blood clotting is considered to involve the polymeri-
sation of the mainly a-helical ﬁbrinogen to ﬁbrin, with a binding mechanism involving ‘knobs and holes’
but with otherwise little change in protein secondary structure. We recognise, however, that extremely
unusual mutations or mechanical stressing can cause ﬁbrinogen to adopt a conformation containing
extensive b-sheets. Similarly, prions can change morphology from a largely a-helical to largely b-sheet
conformation, and the latter catalyses both the transition and the self-organising polymerisation of the
b-sheet structures. Many other proteins can also do this, where it is known as amyloidogenesis. When
ﬁbrin is formed in samples from patients harbouring different diseases it can have widely varying di-
ameters and morphologies. We here develop the idea, and summarise the evidence, that in many cases
the anomalous ﬁbrin ﬁbre formation seen in such diseases actually amounts to amyloidogenesis. In
particular, ﬁbrin can interact with the amyloid-b (Ab) protein that is misfolded in Alzheimer's disease.
Seeing these unusual ﬁbrin morphologies as true amyloids explains a great deal about ﬁbrin(ogen)
biology that was previously opaque, and provides novel strategies for treating such coagulopathies. The
literature on blood clotting can usefully both inform and be informed by that on prions and on the many
other widely recognised (b-)amyloid proteins. A preprint has been lodged in bioRxiv (Kell and Pretorius,
2016).
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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recent years” (Weisel, 2011)
1. Introduction: the thermodynamics of protein folding and
prion proteins, and the existence of multiple macrostates
Starting with Anﬁnsen's famous protein re-folding experiments
(Anﬁnsen, 1973; Anﬁnsen et al., 1961), showing that an unfolded
protein would refold reliably to its commonest (and original) state
as found in the cell, it was widely assumed that the normal mac-
rostate of a folded protein was that of its lowest free energy.
If one allows each amino acid to have n distinct conformational
substates, the total number nm scales exponentially with the
number m of amino acids (Kell, 2012), and until recently exhaustive
calculations to determine whether the ‘preferred’ conformation
was of lowest free energy were prohibitively expensive (Piana et al.,
2014, 2012, 2013; Verma and Wenzel, 2009); indeed, they still are
save for small proteins, so this question of whether the ‘normal’
conformation is that of lowest free energy (±kT) is certainly not
settled in general terms, and (as we shall see in many cases) formsFig. 1. PrPc conformation of human prion protein (1HJM at PDB).of lower free energy than the ‘normal’ one are in fact both common
and of high biological signiﬁcance.
In particular, as is again well known (Aguzzi and Calella, 2009;
Caughey et al., 2009; Colby and Prusiner, 2011; Prusiner, 1998), and
startingwith Virchow's observations in 1854 (Sipe and Cohen, 2000),
a number of proteins of a given sequence can exist in at least two (or
more) highly distinct conformations (e.g. (Chiti and Dobson, 2006;
Eisenberg and Jucker, 2012)). Typically the normal (‘benign’) form,
as produced initially within the cell, will have a signiﬁcant a-helical
content and a very low amount of b-sheet, but the abnormal (‘rogue’)
form, especially when in the form of an insoluble amyloid (Dobson,
2013), will have a massively increased amount of b-sheet (Baldwin
et al., 1994; Groveman et al., 2014; Harrison et al., 1997; Jack et al.,
2006; Jahn et al., 2008; Pan et al., 1993) (but cf (Ow and Dunstan,
2014)), whether parallel or antiparallel (Tycko and Wickner, 2013).
The canonical example is the prion protein PrPc, whose abnormal
form is known as PrPSc, andwhose PrPc structure is shown in Fig 1. As
is also well known, the monomers of the abnormal form may ca-
talyse their own formation from the normal form, and will typically
go on to self-assemble to form oligomers, protoﬁbrils and ﬁnally
insoluble ﬁbrils (Colby and Prusiner, 2011). (A particular hallmark of
PrPSc, and indeed a common basis for its assay, is its very great
resistance to proteolysis relative to PrPc, typically assessed using
proteinase K (Basu et al., 2007; Grassi et al., 2000;Mishra et al., 2004;
Saa and Cervenakova, 2015; Saleem et al., 2014; Saverioni et al., 2013;
Silva et al., 2015)).Fig. 2. Kinetic isolation of PrPSc from PrPC (based on (Cohen and Prusiner, 1998).
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e4118What this means (Cohen and Prusiner, 1998) is that the ‘normal’
conformational macrostate of such proteins is not in fact that of the
lowest free energy, and that its transition to the energetically more
favourable ‘rogue’ state is thermodynamically favourable but under
kinetic control, normally (in terms of transition state theory) with a
very high energy barrier DGy of maybe 36e38 kcal mol1 (Cohen
and Prusiner, 1998) (Fig 2). Certainly, for a given and more trac-
table model sequence such as poly-L-alanine (Henzler Wildman
et al., 2002), a b-sheet is demonstrably more stable than is an a-
helix. However, the reversibility by pressure in some cases implies
that the free energy change for oligomerisation is not particularly
great (Foguel et al., 2003). The formal deﬁnition (Sipe et al., 2014) of
an amyloid ﬁbril (protein) is as follows: “An amyloid ﬁbril protein is
a protein that is deposited as insoluble ﬁbrils, mainly in the
extracellular spaces of organs and tissues as a result of sequential
changes in protein folding that result in a condition known as
amyloidosis.”
Multiple states or conformations of amyloid/prion ‘strains’ are
sometimes referred to in this ﬁeld as ‘polymorphisms’ (Tycko,
2014), albeit they can have the same sequence (Tycko and
Wickner, 2013). Importantly, they can be self-propagating (Chien
et al., 2003, 2004; Colby and Prusiner, 2011; Collinge, 2010;
Collinge and Clarke, 2007; Cushman et al., 2010; Eisenberg and
Jucker, 2012; Gill, 2014; Greenwald and Riek, 2010; Le et al., 2015;
Makarava and Baskakov, 2008; Moda et al., 2015; Petkova et al.,
2005; Poggiolini et al., 2013; Sano et al., 2014; Toyama et al.,
2007; Toyama and Weissman, 2011; Tycko, 2015; Weissmann,
2005; Wickner et al., 2014; Wiltzius et al., 2009). Even amyloido-
genic proteins as small as Ab1-40 can adopt as many as ﬁve stable
conformations (F€andrich et al., 2009; Kodali et al., 2010; Meinhardt
et al., 2009; Reinke and Gestwicki, 2011), that can vary in terms of
protoﬁlament number, arrangement and structure (F€andrich et al.,
2009), as can a model 17mer (Kammerer et al., 2004; Kammerer
and Steinmetz, 2006; Verel et al., 2008). Clearly self-seeding can
propagate similar conformations (Maji et al., 2009).
Many proteins are potentially amyloidogenic (Tzotzos and Doig,
2010). Thus, an increasing number of human diseases is known to
be associated with misfolded or amyloid-type proteins (Chiti and
Dobson, 2006; Herczenik and Gebbink, 2008; Knowles et al.,
2014; Moreno-Gonzalez and Soto, 2011; Nienhuis et al., 2016;
Olanow and Brundin, 2013; Rambaran and Serpell, 2008; Tipping
et al., 2015). There are commonalities, in that amyloid proteins can
cross-seed each other's polymerisation (e.g. (Frost and Diamond,
2010; Hu et al., 2015; Liu et al., 2007; Lundmark et al., 2005;
Morales et al., 2013, 2015; Murakami et al., 2015; Murakami et al.,
2014; Ono et al., 2012a; Soto et al., 2006; Westermark et al.,
2009; Zhang et al., 2015a)). By contrast, “expression of two PrPC
moieties subtly different from each other antagonizes prion repli-
cation, and humans heterozygous for a common Prnp poly-
morphism at codon 129 are largely protected from CJD” (Aguzzi and
Haass, 2003). Commonalities between prion proteinmisfolding and
other protein misfolding diseases (AD, PD, ALS, etc (Prusiner et al.,
2015)) that lead to amyloids are widely recognised; however,
because the latter are not thought to be strictly infectious between
individuals or across species, they have sometimes been referred to
as prionoid diseases (Aguzzi and Lakkaraju, 2016; Ashe and Aguzzi,
2013). This said, their effects are clearly transmissible if injected
(Eisele et al., 2015; Murakami et al., 2014, 2015; Soto, 2012; Soto
et al., 2006; Sponarova et al., 2008; Westermark et al., 2009) (and
see above). For completeness, in biotechnology, one should add
that amyloid formation can interfere with the activity of protein
biologics (e.g. (Nielsen et al., 2001a, 2001b, 2001c; Wang, 2005)),
that bacterial inclusion bodies of recombinant proteins can also
contain b-amyloid structures (e.g. (de Groot et al., 2009; Morell
et al., 2008; Ventura and Villaverde, 2006; Wang, 2009; Wanget al., 2008)), and that at least some amyloid proteins are in fact
beneﬁcial to the host (Fowler et al., 2007).
b-structures are inherently stable (Tsemekhman et al., 2007). A
characteristic “cross-b” X-ray diffraction pattern is observed from
amyloid ﬁbres (Maji et al., 2009; Tycko and Wickner, 2013). A
diffuse reﬂection at 4.7e4.8 Å spacing comes from extended protein
chains running roughly perpendicular to the ﬁbril and spaced
4.7e4.8 Å apart. A more diffuse reﬂection at 10 Å illustrates that the
extended chains are organized into sheets spaced ~10 Å apart
(Eisenberg and Jucker, 2012; Langkilde et al., 2015; Morris and
Serpell, 2012; Serpell, 2000; Stromer and Serpell, 2005). Howev-
er, it is possible to form b-structures in multiple ways, that underlie
the different more-or-less stable conformations (Eisenberg and
Jucker, 2012).
The ﬁrst kind of conformational variation or polymorphism
(Eisenberg and Jucker, 2012) is packing polymorphism. Here, an
amyloid segment packs in two or more distinct ways, producing
ﬁbrils with different structures and distinctive properties, most
simply as a registration shift in which the two sheets forming the
steric zipper in the second polymorph shift their interdigitation
from that in the zipper of the ﬁrst polymorph, e.g. by a couple of
amino acids. The second structural model for strains is termed
segmental polymorphism; here, two or more different segments of
an amyloid protein are capable of forming spines, and do so, leading
to different ﬁbril structures. Finally, in a third type of amyloid
polymorphism, heterosteric zippers, the zipper is formed from the
interdigitation of nonidentical b-sheets.
As well as by quite subtle changes in sequence (Alexander et al.,
2009; Gill, 2014), the ﬁbril morphology is determined by environ-
mental factors, such as pH (Kammerer et al., 2004; Verel et al.,
2008), charge-neutralising polyanions (Groveman et al., 2015;
Silva et al., 2011), temperature (Kammerer et al., 2004; Verel
et al., 2008), agitation (Ladner-Keay et al., 2014), salts (Klement
et al., 2007), lipids (Gursky, 2015; Levine et al., 2015), other co-
solutes (Chiti et al., 1999), small molecule additives (Doig and
Derreumaux, 2015) or even quite large protein sequences (and
see below). To this end, a bacteriophage motif may be signiﬁcantly
anti-amyloidogenic and capable of remodelling formed amyloids
(Krishnan et al., 2014). At all events, the hallmark of these kinds of
amyloidogenic behaviour (Jucker and Walker, 2013) is the conver-
sion of a soluble protein, typically a monomer, into an insoluble
form that typically forms oligomers, protoﬁlaments and then
insoluble ﬁbrils.
In summary, it is increasingly recognised that proteins can self-
organise into ﬁbrils that require only a conformational change (no
sequence changes) and that these can vary as a function of both the
sequence and environmental conditions. However, many of these
processes occur on a rather sluggish timescale.
Another area in which a soluble precursor (ﬁbrinogen) is con-
verted into insoluble ﬁbres (ﬁbrin) occurs during the terminal
stages of blood clotting. Perhaps surprisingly, this has not really
been seen as a useful model for prion and amyloidogenic diseases,
and certainly ﬁbrin alone cannot ‘seed’ the growth of ﬁbrin mole-
cules, as each ﬁbrinogen molecule added to the growing ﬁbril re-
quires that thrombin ﬁrst releases two ﬁbrinopeptides (see below).
It is also a process that is necessarily and typically considerably
quicker than classical amyloidogenesis. However, the main pur-
poses of the present review are (i) to highlight the commonalities
that do exist, and (ii) to illustrate in particular the very substantial
changes in ﬁbre morphology, including the recently discovered
amyloid formation, that can be elicited by simple, and in many
cases highly substoichiometric additions of small molecules. We
believe that this will admit a substantial and useful cross-
fertilisation of these ﬁelds. We highlight in particular the facts
that (a) blood is much more easily available and amenable to study
Fig. 3. The coagulation cascade showing the ﬁnal conversion of ﬁbrinogen to ﬁbrin.
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bacterial lipopolysaccharide (LPS), may be involved in both blood
clotting and amyloidogenesis, and thus contribute to shared aeti-
ologies. A preprint has been lodged in bioRxiv (Kell & Pretorius
2016).2. The terminal stages of normal blood clotting: ﬁbrinogen,
ﬁbrin and thrombin
The terminal stage of the coagulation cascade involves the
conversion of ﬁbrinogen to ﬁbrin strands, and this involves a
number of regulated steps (see Fig 3). Both the expansion and
strength of the ﬁnal clot is ﬁnely regulated and depends mostly on
the conversion of ﬁbrinogen to ﬁbrin under the enzymatic action of
thrombin, which (apart from a subsequent crosslinking induced by
the transglutaminase factor XIII) is the ﬁnal step in the cascade.
Fibrinogen circulates at high concentrations 2e4 mg.L1
(Walton et al., 2015) or at about 9 mM in the plasma (Ferri et al.,
2002; Neeves et al., 2010), with a molecular mass of around
340 kDa. It has a centrosymmetric, trinodular, S-shaped structure
that is 46 nm in length and 4.5 nm in diameter (Guthold et al.,
2007). During coagulation, thrombin cleaves two N-terminal pep-
tides from the Aa- and Bb-chains, promoting the formation of
protoﬁbrils and subsequently ﬁbrin ﬁbres (Litvinov et al., 2007;
Undas and Ari€ens, 2011).
The ﬁbrinogen protein consists of two sets each of three poly-
peptide chains (Aa, Bb, g)2 (Walton et al., 2015), linked by 29 S-S
bonds (Litvinov et al., 2012) that has the basic structure shown in
Fig 4.
The main features are:
 A single central E-region, containing 6 N-termini and ﬁbrino-
peptides A and B Two D-regions ﬂanking the E-region; each D-region contains a
globular b C-terminal domain (b197e461; called bC) and the
globular g C-terminal domain (g143e411; called gC), both of
which consist of a b-sheet core ﬂanked by a few small a-helices
(Guthold et al., 2007).
 Two coiled coils consisting each of three a-helices; these coils
connect the E and D-regions.
 There are also 29 disulphide bonds that acts as stabilizers; and 5
of these disulphide bonds are within the central E-nodule that
forms a link between the two halves of the molecule.
 There are also 4 disulphide rings, consisting of 3 disulphide
bonds that link the a-to the b-chain, the a-to the g-chain, and
the b-to the g-chain. This forms a supporting unit that keeps the
three a-helices in the coiled coils together in each ﬁbrinogen
molecule; 1 ring at each end of the two coiled coils.
 Twelve intra-chain disulphide bonds, 3 in each of the 2 globular
bC domains of the D-regions, 2 in each of the two globular gC
domain of the D-regions, and one in each of the two aC domains.
Thrombin cleaves the ﬁbrinogen, resulting in the ﬁbrin mono-
mers containing Aa, Bb and g polypeptides, which are then curved
into the central E-region containing the 2 distal D-regions (Yang
et al., 2001; Yeromonahos et al., 2010). Fibrin monomers are
formed on the removal of 2 pairs of ﬁbrinopeptides (ﬁbrinopeptide
A and B from the N-termini of the Aa and Bb chains), converting it
into a ﬁbrin monomer that immediately polymerizes by self-
assembly, to form a complex or a meshwork of ﬁbrin ﬁbres.
Importantly, however, the ﬁbrin monomer maintains major struc-
tural features of ﬁbrinogen, including the coiled-coils (Litvinov
et al., 2012). When the 2 ﬁbrinopeptides are removed from the
N-terminal region of the Aa- and Bb-chains, knoblike binding sites
A and B, are exposed (Guthold et al., 2007). Finally, an insoluble
ﬁbrin gel complex is formed when the ﬁbrin strands aggregate and
Fig. 4. Diagrammatic representation of ﬁbrinogen packaging into the ﬁnal product, the cross-linked ﬁbrin mesh.
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XIIIa (Dickneite et al., 2015; Ferry and Morrison, 1947; Fowler et al.,
1981; Neeves et al., 2010; Phillips et al., 2003; Weisel, 1986).
Plasma FXIII (ﬁbrin stabilizing factor) is a plasma trans-
glutaminase (Dickneite et al., 2015) and consists of two catalytic
subunits (FXIII-A) and two non-catalytic subunits (FXIII-B) that are
tightly connected in a non-covalent, heterotetramer (FXIII-A2B2).
All FXIII-A2B2 in the circulation are bound to ﬁbrinogen (Walton
et al., 2015). FXIII-A2B2 is activated by thrombin-catalyzed release
of N-terminal peptides from the FXIII-A subunits and calcium-
mediated dissociation of the FXIII-B subunits, yielding activated
FXIII-A2 (or FXIIIa) (Walton et al., 2015).
Both plasma- and platelet-derived FXIIIa catalyse the formation
of ε-N-(g-glutamyl)-lysyl crosslinks within ﬁbrin (Walton et al.,
2015) and this crosslinking stabilizes ﬁbrin ﬁbres and therefore
clots (Walton et al., 2015). XIIIa has profound effects on ﬁbrin
integrity and it seems that g- and a-chain crosslinking make
distinct contributions to clot function and structure (Richardson
et al., 2013; Standeven et al., 2007). FXIIIa therefore plays in
important role in the regulation of thrombus stability, regulation
and cell-matrix interactions, including wound healing (Richardson
et al., 2013).
Recently, it was found that unperturbed (human) ﬁbrin contains
30± 3% a-helices, 37± 4% b-sheets, and 32± 3% turns, loops, and
random coils (Litvinov et al., 2012). As discussed in detail later,
under certain physiological (and also pathological) conditions,
ﬁbrin clots may undergo deformation, where molecular unfolding
may occur (Litvinov et al., 2012; Zhmurov et al., 2011, 2012). Sec-
ondary structural alterations including the a-helices to b-sheets
transition, is a common mechanism of protein structural rear-
rangement. Increased force can result in the uncoiling of the a-
helices (or coiled coils) resulting in an increase of b-sheets. How-
ever, the simple binding of the ﬁbrinopeptides to their corre-
sponding holes on the D-regions does not result in any signiﬁcant
increase in b-sheets (See Fig 5 for a visual representation of whenthe formation of increased b-sheets and the uncoiling of the a-
helices does occur, e.g. under mechanical loading.)
These deformations affect the viscoelasticity at both the ﬁbre
and molecular levels and will translate into functional changes at
the whole clot level. They also have implications for systemic
changes of coagulation. Therefore, during the molecular extension
of ﬁbrin, a-helix to b-strand conversion occurs in coiled-coils and
during both mechanical elongation and compression of ﬁbrin clots,
a rearrangement of the secondary clot structure occurs, comprising
mainly the a-helix-to-b-sheet transition (Litvinov et al., 2012). The
authors suggested that the a-b transition followed by formation of
an intermolecular b-sheet structure and protein aggregation could
be a common mechanism underlying the different types of ﬁbrin
deformation (Litvinov et al., 2012). Here, we suggest that this may
be the fundamental underlying reason for different ﬁbrin ﬁbre ul-
trastructures that we have previously reported on, where we found
a changed macroscopically observable ﬁbrin ﬁbre structure during
various systemic inﬂammatory conditions.
Many excellent reviews exist on the mechanisms of clot for-
mation and basic structure (e.g. (Cilia La Corte et al., 2011; Undas,
2014; Undas and Ari€ens, 2011; Undas et al., 2011; Weisel, 2005,
2007; Wolberg, 2007; Wolberg, 2012)), ﬁbrinolysis (Chapin et al.,
1989; Longstaff and Kolev, 2015; Undas et al., 2008), and the
importance of clotting in vascular diseases (Ari€ens, 2011, 2013;
Bridge et al., 2014). Because of this, we can be relatively brief, and
focus on the nub of our review, which is the argument that, like
prions, ﬁbrinogen can, under certain circumstances, form beta-
sheet-rich amyloid ﬁbrils.
3. Methods for determining the clotting process
Studying clot formation and degradation, using either plasma or
whole blood, is important in the treatment of hyper-as well as
hypocoagulability, and both optical and rheological/viscoelasto-
metric methods have been developed (e.g. (Bates and Weitz, 2005;
Fig. 5. The a-helices to b-sheets phase transition in ﬁbrin formation under deformation of e.g. low (healthy coagulation) and high force (pathological coagulation) (adapted from
(Zhmurov et al., 2012)).
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2008; McMichael and Smith, 2011)); for a recent review, see (Kell
and Pretorius, 2015b). Currently, visco-elastic technologies are
mainly used as point-of-care tests with immediately-available re-
sults; these include prothrombin time (PT), activated partial
thromboplastin time (APTT), thromboelastography (TEG) and
thromoboelastometry (ROTEM). Analyses that use plasma obtain
results based on PT and APTT (Johansson et al., 2009); however, PT
and APTT only test the coagulation protein component of the sys-
tem, and results have to be interpreted carefully in the context of
the clinical presentation and assay limitations (Chee, 2014).
Consequently, we rather favour the use of viscoelastic haemostatic
methods such as TEG (Afshari et al., 2011; Bolliger et al., 2012;
Johansson et al., 2009; Reikvam et al., 2009; Sankarankutty et al.,
2012), ROTEM (Afshari et al., 2011; Sankarankutty et al., 2012;
Sørensen and Ingerslev, 2005; van Veen et al., 2009) and the
Sonoclot (Hett et al., 1995; Kjellberg and Hellgren, 2000; Sharma
et al., 2013).
In the past, EP's laboratory has focussed speciﬁcally on using the
TEG (Bester et al., 2015; de Villiers et al., 2016; Nielsen andTable 1
TEG parameters typically generated for whole blood and platelet poor plasma (Bester et
Thromboelastic parameters
R value: reaction time Minutes Time of latency fro
K: kinetics Minutes Time taken to achi
А (Alpha): Angle (slope between
thetraces represented by R and K) (
Angle in degrees The angle measure
hence assesses the
MA: Maximal Amplitude mm Maximum strength
i.e. overall stability
Maximum rate of thrombus generation
(MRTG)
Dyn.cm2.s1 The maximum vel
using G, where G i
Time to maximum rate of thrombus
generation (TMRTG)
Minutes The time interval o
Total thrombus generation (TTG) Dyn.cm2 The clot strength:
generated during c
growth, representi
Lysis 30 (LY30) % Percentage lysis obPretorius, 2014a, 2014b; Nielsen et al., 2015; Swanepoel et al.,
2015). See Table 1 for a comprehensive list of measurements that
can be done using thromboelastography.
Another important technique that we have combined with the
TEG results, with great success, is scanning electron microscopy of
ﬁbrin ﬁbre structure (Bester et al., 2015; de Villiers et al., 2016;
Kell and Pretorius, 2015a, 2015b; Nielsen and Pretorius, 2014a;
Nielsen and Pretorius, 2014b; Nielsen et al., 2015; Potgieter
et al., 2015; Pretorius et al., 2014a, 2016b, 2016c; Pretorius et al.,
2013; Swanepoel et al., 2015). These methods give a visual rep-
resentation of clot structure, where the ﬁbrin packaging can be
studied at high resolution and magniﬁcation, and have illustrated
the very great differences that can be observed in plasma
from diseased vs healthy controls. As mentioned in the previous
paragraphs, PT, PTT, TEG, as well as ROTEM have been used suc-
cessfully as point-of-care methods, while electron microscopy has
been used mostly in the laboratory. However, the usefulness
of combining the technologies in an integrated approach is clear
(de Villiers et al., 2016; Pretorius et al., 2016d; Swanepoel et al.,
2015).al., 2015; de Villiers et al., 2016).
m start of test to initial ﬁbrin formation (amplitude of 2 mm); i.e. initiation time
eve a certain level of clot strength (amplitude of 20 mm); i.e. ampliﬁcation
s the speed at which ﬁbrin build up and cross linking takes place,
rate of clot formation; i.e. thrombin burst
/stiffness of clot. Reﬂects the ultimate strength of the ﬁbrin clot,
of the clot
ocity of clot growth observed or maximum rate of thrombus generation
s the elastic modulus strength of the thrombus in dynes per cm2
bserved before the maximum speed of the clot growth
the amount of total resistance (to movement of the cup and pin)
lot formation. This is the total area under the velocity curve during clot
ng the amount of clot strength generated during clot growth
tained 30 min after MA
Fig. 6. Examples of amyloid staining reagents.
Table 2
Wavelengths that have commonly been used for excitation and emission when
assessing Thioﬂavin T interaction with b-amyloids.
Excitation (nm) Emission (nm) References
455 485 (Ban et al., 2003)
440 490 (Berthoumieu et al., 2015)
440 485 (Biancalana et al., 2009)
435 480 (Di Carlo et al., 2015)
450 460e600 (Groenning et al., 2007)
440 460e570 (Jha et al., 2011)
440 490 (Jha et al., 2014)
450 482 (LeVine, 1993)
440/20 485/20 (LeVine, 1997)
440e450 480e490 (Lindberg et al., 2015)
450 482 (Naiki et al., 1989)
445 485 (Ozawa et al., 2011)
440 485 (Palhano et al., 2013)
450 480 (Sabate and Ventura, 2013)
449 480 (Sulatskaya et al., 2011)
440 <600 (Younan and Viles, 2015)
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As with ﬂuorescent proteins such as GFP, the ability to detect
amyloid (and cross-b motifs more generally) by optical means
would improve their ease of study enormously (Hammarstr€om
et al., 2013). Fortunately, a number of appropriate dyes are
known (Fig 6).
Congo Red (Bely and Makovitzky, 2006; Frid et al., 2007; Howie
and Brewer, 2009; Howie et al., 2008; Howie and Owen-Casey,
2010; Inouye and Kirschner, 2005; Kelenyi, 1967; Maezawa et al.,
2008; Nilsson, 2004;Wu et al., 2012a) (CR) was one of the ﬁrst dyes
known to bind to amyloid (Puchtler and Sweat, 1966). Its name
derives (Steensma, 2001) from the marketing activities of the
Berlin-based AGFA textile dyestuff company in 1885, following
various geopolitical events of that time, but otherwise has no
connection with central Africa. Bennhold (Bennhold, 1922) was the
ﬁrst to describe its binding to amyloid. This induces a characteristic
shift in CR's maximal optical absorbance from 490 nm to 540 nm,
and rather variable (Howie, 2015; Howie and Brewer, 2009; Howie
et al., 2008; Howie and Owen-Casey, 2010) birefringence and di-
chroism. As Howie and Brewer rather nicely put it (Howie and
Brewer, 2009), “Amyloid stained by Congo red has striking optical
properties that have mostly been badly described and inadequately
explained”, although in general terms the birefringence clearly
reﬂects the binding to the oriented b-sheets, with the orientation
being increased by the practice of making smears. There is evidence
for the particular involvement of histidine residues (Inouye and
Kirschner, 2005; Inouye et al., 2000). Because the colours seen
vary rather markedly with the relative orientations of polariser and
analyser in the birefringence measurements (Howie, 2015; Howie
and Brewer, 2009; Howie et al., 2008; Howie and Owen-Casey,
2010), and although apparently preferred as a ‘gold standard’ by
histologists, CR is seen as a stain that is less than perfectly repro-
ducible, and at least for research it has largely been overtaken by
ﬂuorescent stains. This said, we note with interest a recent
‘smartphone’ assay application (Acestor et al., 2016; Jonas et al.,
2016; Rood et al., 2015).
3.2. Thioﬂavin S, thioﬂavin T and derivatives
The thioﬂavin stains (based on a thiazole nucleus) probablycount most nearly as “God's gift to students of amyloid and amy-
loidogenesis”. Free thioﬂavin T (ThT) ﬂuoresces faintly with exci-
tation and emission maxima of 350 and 440 nm, respectively,
whereas upon interaction with amyloid ﬁbrils a substantially
enhanced ThT ﬂuorescence is observed, with excitation and emis-
sion maxima at about 440/450 and 480/490 nm, respectively
(Groenning, 2010; Khurana et al., 2005; Kuznetsova et al., 2016,
2012a, 2012b; LeVine, 1997; LeVine, 1999; Lindberg et al., 2015;
Naiki et al., 1989; Palhano et al., 2013; Picken and Herrera, 2012;
Robbins et al., 2012; Sulatskaya et al., 2011, 2012; Wolfe et al.,
2010; Younan and Viles, 2015; Zhang and Ran, 2013). Table 2
summarises the wavelengths used in a number of studies.
As with CR, the ﬂuorescence enhancement is caused by binding
to oriented b-rich ﬁbrils. Fig 7 shows the conversion of typical
amyloid-free ﬁbrin ﬁbres to highly-amyloid-rich ones as judged by
their staining with ThT, added to plasma from a patient with
thromboembolic stroke (Fig 7B) and compared with the same
treatment of plasma from a matched, healthy control. The differ-
ence is rather striking.
As a dibenzothiazole dye (Wu et al., 2007), Thioﬂavin S (ThS) is a
somewhat extended version of ThT (Fig 6). We are not aware of any
Fig. 7. Fibrin ﬁbres from a healthy individual (A) and an individual who had suffered a thromboembolic stroke (B), stained with ThT (5 mM exposure concentration) and viewed
using a confocal microscope. Scale bar: 10 mm.
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for tissue staining (Sun et al., 2002). Consequently, it may seem
sensible to use the smaller dye. Protein transporters are required to
get xenobiotics into cells (Dobson and Kell, 2008; Kell et al., 2011,
2013; Kell and Oliver, 2014). For tissue staining, even ThT does
not penetrate the blood-brain barrier, and a neutral version known
as Pittsburgh compound B (PIB) (Fig 6) has been developed that can
(Mathis et al., 2003; Murray et al., 2015; Wu et al., 2011). (Based on
its structure and the analyses presented elsewhere (O'Hagan and
Kell, 2015; O'Hagan and Kell, 2016; O'Hagan et al., 2015), the
three Recon 2(.2) metabolites (Swainston et al., 2013, 2016; Thiele
et al., 2013) and marketed drugs to which it is most similar are
given in Fig 8.) However, while its 11C-derivative has been widely
used in PET imaging of ﬁbrils (e.g. (Driscoll et al., 2012; Grimmer
et al., 2009; Mathis et al., 2007; Murray et al., 2015; Resnick et al.,
2010; Wu et al., 2011)), PIB lacks the large optical absorbanceFig. 8. The three endogenous metabolites and marketed drugs most closely related to PIB, ashift and ﬂuorescence enhancement characteristic of ThS and ThT
(Wu et al., 2011).
Other amyloid-selective dyes that have been used include X-34
(Excitation 400nm/Emission 455 nm), which is in fact a ﬂuorescent
derivative of CR (Ikonomovic et al., 2006; Link et al., 2001; Styren
et al., 2000), chrysamine G (Kang and Han, 2001; Klunk et al.,
1994) (Fig 6) (which is excited at 386 nm) and ANCA (excitation
380e430, emission 525e550). Since most of these latter are not
commercially available, it is not obvious that these dyes bring great
beneﬁts over ThT. This said, it is normally desirable to be able to
excite nearer the red (Kovalska et al., 2012; Ono et al., 2012b;
Rajasekhar et al., 2016) or beyond (Guo et al., 2014; Staderini
et al., 2015; Watanabe et al., 2013; Yuan et al., 2013b; Zhang
et al., 2015b) to decrease autoﬂuorescence, and such dyes are
likely to be very useful as they become more widely available.
In an interesting development, Stefansson and colleaguess assessed using the MACCS encoding (Durant et al., 2002) and the Tanimoto distance.
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to binding (Wolfe et al., 2010), and (ii) that a number of modern,
sensitive DNA-intercalating dyes also contain the thiazole nucleus.
They showed (Stefansson et al., 2012) that these dyes too would
bind to b-amyloid ﬁbrils, albeit not normally (but cf (Lindberg and
Esbjorner, 2016)) with quite with the same ﬂuorescence enhance-
ment as shown by ThT. However, they could be used in combination
with ThT to increase the Stokes shift (via ﬂuorescence resonance
energy transfer) quite hugely into the red. Note though that the
binding of these (Reuter and Dryden, 2010) and related dyes (Twist
et al., 2004) to double-stranded DNA can be detected at the level of
the single molecule, so such DNAmust be absent. There is no doubt
that continuing improvements in dye development will be of
considerable value to the ﬁeld.
3.3. Luminescent conjugated thiophenes
In an interesting and important development, Nilsson and col-
leagues (e.g. (Berg et al., 2010; Klingstedt et al., 2011, 2013a;
Klingstedt and Nilsson, 2012; Nilsson et al., 2005, 2006, 2007,
2009, 2010, 2012; Shirani et al., 2015; Simon et al., 2014;
Sj€olander et al., 2015, 2016)) have introduced a series of lumines-
cent oligothiophenes and polythiophenes. As well as possessing
excellent optical properties, they seem preferentially to stain the
smaller oligomers (Klingstedt and Nilsson, 2012) that may be more
cytotoxic (see below). They can also be used to discriminate
different ﬁbres and conformational states optically (e.g. (Åslund
et al., 2007, 2009; Klingstedt et al., 2013a, 2013b, 2015; 2012;
Magnusson et al., 2014)). Consequently, these and related mole-
cules seem to bewell worth exploring as part of the next generation
of amyloid-selective dyes, not least in the context of super-
resolution (Ries et al., 2013).
4. The conversion of ﬁbrinogen to ﬁbrin is normally not a
transition from a-helices to b-sheets except in special
circumstances that include mutants
A clear characteristic of the conversion of amyloidogenic pro-
teins to genuine insoluble amyloids is the conversion of structures
with (typically) predominantly a-helices to structures with a
(much) greater b-sheet content. The obvious question is to what
extent is this similarly true in normal and abnormal clotting
processes?
As seen in the section on normal blood clotting, the chief
mechanism involves a ‘knobs and stalks’ interaction (that includes
the ability to repair ﬁbrils isoenergetically (Chernysh et al., 2012)),
and that does not of itself require, nor does it seemingly provide,
anymajor conformational changes in the secondary structure of the
ﬁbrinogen monomers (Averett et al., 2008, 2009; Protopopova
et al., 2015; Weisel, 2005; Yermolenko et al., 2011). In a similar
vein, normal blood clotting is not considered to be an amyloido-
genic process, except in very rare cases of particular mutants of the
ﬁbrinogen a chain (Benson et al., 1993; Gillmore et al., 2009;
Haidinger et al., 2013; Hamidi Asl et al., 1997; Picken, 2010;
Serpell et al., 2007; Stangou et al., 2010).
5. Mechanical stretching can induce an a-to-b transition in a
large variety of biopolymers
As judged by infrared spectroscopy of the various amide bands,
standard human ﬁbrin is about 30% a-helix, 40% b-sheet and 30%
turns (Bramanti et al., 1997), similar to the numbers given (above)
by Litvinov et al. (Litvinov et al., 2012). This percentage changes
with pressure and mechanical unfolding (Litvinov et al., 2012;
Zhmurov et al., 2011, 2012), but only at extremes of stretching(that apparently do not happen in normal clot formation) are the
mechanical properties of ﬁbrin considered to reﬂect an a-to-b
transition (Guthold et al., 2007; Kreplak et al., 2004; Liu et al., 2010;
Miserez and Guerette, 2013). Speciﬁcally, at a certain extension
there is what amounts to a phase transition. To this end, there were
also some striking nonlinearities noted in the detailed studies of
Münster and colleagues (Münster et al., 2013) and of Kim and
colleagues (Kim et al., 2014).
It is of some interest that mechanical forces can also be used to
effect an a-to-b transition in prions (Tao et al., 2015) and a variety of
other elastomeric biopolymers (Feughelman, 2002; Hearle, 2000;
Miserez and Guerette, 2013; Qin and Buehler, 2010), not least ker-
atin (Bendit, 1957, 1960; Kreplak et al., 2004; Paquin and Colomban,
2007). It is particularly noteworthy that after two- and three-fold
longitudinal stretching the median ﬁbre diameter and pore area
in SEM images of ﬁbrin decreased two-to three-fold (Varjú et al.,
2011), just as in a number of the disease states mentioned above,
and that this conferred proteolytic resistance to the ﬁbrin,What the
above examples tell us is that under normal circumstances human
ﬁbrin does not adopt a form that has a b-sheet content greater than
~40%, but that it can indeed do so under the appropriate circum-
stances. What we shall see below, is that these are considerably
more common than had previously been surmised.
5.1. Effects of ﬂow on ﬁbrin properties
The above studies involved mechanical stretching, but (given
that blood does ﬂow in the circulation) there has been some in-
terest in the effects of ﬂow (velocity) on ﬁbrin structure. Increases
in ﬁbre thickness. Hints of b-sheet formation induced by ﬂow can
be seen in (Badiei et al., 2015), while in a very striking study,
Campbell et al. (Campbell et al., 2010). saw a huge increase in the
ﬂow-induced diameter of ﬁbrin ﬁbres, from a mean of 79e226 nm.
6. When clotting goes wrong: hypercoagulability and
hypoﬁbrinolysis in chronic, inﬂammatory diseases
In inﬂammatory conditions, hypercoagulability, as well as
hypoﬁbrinolysis is a common phenomenon and both are seen as
coagulopathies; see (Kell and Pretorius, 2015b) for a table with a
comprehensive list of inﬂammatory diseases with both known
hypercoagulable and hypoﬁbrinolytic characteristics. Our partic-
ular interest has been the study of clot structure using scanning
electron microscopy, and we have noted that this method shows us
precisely the diameter of individual ﬁbrin ﬁbres, as well as the
general clot architecture (e.g. (Lipinski and Pretorius, 2013a, 2013b;
Lipinski et al., 2012b; Pretorius, 2011; Pretorius et al., 2014a;
Pretorius and Lipinski, 2013a; Pretorius and Oberholzer, 2009;
Pretorius et al., 2010a, 2010b, 2011a, 2011b)). We and others have
shown that the diameter of ‘typical’ healthy ﬁbrin ﬁbres is
80e110 nm (Bester et al., 2015; Kell and Pretorius, 2015b; Pretorius
et al., 2011c; Weigandt et al., 2012) (those of most amyloidogenic
proteins are more like 10e20 nm or less, e.g. (Engel et al., 2008;
Foguel et al., 2003; Ivanova et al., 2004; Klement et al., 2007;
Kollmer et al., 2016; Uversky et al., 2001)), while during inﬂam-
mation, clot diameter changes. It may be increased, as seen in
Alzheimer's type dementia (Bester et al., 2015), or decreased as
seen in stroke (Pretorius et al., 2011c). Up to now we have had no
knowledge of the exact molecular conformational changes (e.g. the
a-helices and b-sheets) that happen during inﬂammation; we have
just reported on the more macroscopically observable structural
changes that are visible in the different conditions (See Fig 9). Now
it has become clear that the exact changes that happen during
inﬂammation in the a-helix and b-sheet interaction involve major
changes in secondary structure, and might be of great importance
Fig. 9. Representative micrographs of different inﬂammatory conditions. A) Healthy ﬁbrin ﬁbre structure; B) thromboembolic stroke; C) Alzheimer's type dementia; D) Type II
diabetes. White arrows: ﬁne netted areas; Red arrow: areas where ﬁbrin ﬁbres are thicker. Scale bar: 1 mm.
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In vivo, as part of normal wound healing, the clot is removed via
the ﬁbrinolytic system and this process is mediated by the serine
protease plasmin, which cleaves the ﬁbrin molecule at speciﬁc sites
(Bucay et al., 2015; Draxler and Medcalf, 2015) to form a variety of
degradation products collectively referred to as D-dimer (Adam
et al., 2009; Walker and Nesheim, 1999). (Whether D-dimer can
adopt a b-sheet of amyloid form is apparently unknown, and its
concentration varies but little during amyloidosis (Suga et al.,
2012)). During ﬁbrin polymerisation, normally cryptic plasmin-
ogen and plasmin binding sites are exposed. These binding sites are
situated on the aC regions that contain lysine-dependent tPA- and
plasminogen-binding sites (Bucay et al., 2015; Medved and
Nieuwenhuizen, 2003). During ﬁbrinolysis, plasmin initially
cleaves the aC regions, and then cleaves the three polypeptide
chains connecting the E-domains and the D-domains (Bucay et al.,
2015; Nieuwenhuizen, 2001). The exact process of ﬁbrinolysis is
controlled by various structural arrangements and physical prop-
erties of the clot itself. These properties include clot density, stiff-
ness and ﬁbrin ﬁbre diameter (Collet et al., 2003; Veklich et al.,
1998; Weisel, 2007). Bucay and co-workers in 2015 found that if
ﬁbres are exposed to plasmin, thin ﬁbres are easily cleaved, and that
thicker ﬁbres grew in length during ﬁbrinolysis. Therefore the lytic
susceptibility of a ﬁbre is directly related to the intrinsic strain on
the ﬁbre resulting from the polymerisation process (Bucay et al.,
2015). Here we also suggest that the lysine-dependent tPA- and
plasminogen-binding site accessibility on the ﬁbrin ﬁbres will be
crucial for successful ﬁbrinolysis and therefore the arrangement of
the a-helix and b-sheets will be of fundamental importance in this
process. The difﬁculty or resistance of hydrolysis of abnormal ﬁbrin
clots can be directly compared to this ‘hypohydrolysis” (proteinase
K resistance) characteristic of PrPSc, discussed in detail above.
As summarised by Campbell and colleagues (Campbell et al.,
2010), diameter per se can affect ﬁbrinolysis rates: “Fibre diam-
eter and network density play signiﬁcant roles in clot dissolution
(Weisel and Litvinov, 2008). Compared to thin ﬁbres, thick ﬁbressupport faster plasmin generation rates. Plasmin lyses ﬁbrin via
laterally transecting individual ﬁbres. Thin ﬁbres lyse faster than
thick ﬁbres; however, coarse networks of thick ﬁbres lyse faster
than tight networks of thin ﬁbres (Collet et al., 2000).”However, we
suggest here that it may also be secondary structure that plays the
major role.
One of the most damaging forms of hypercoagulation is known
as disseminated intravascular coagulation (Asakura, 2014; Bick,
2002; Kaneko and Wada, 2011; Levi and van der Poll, 2013a;
Wada et al., 2014). It is essentially a runaway form of hyper-
coagulation, and it too may be induced by LPS (endotoxin)
(Asakura, 2014; Duburcq et al., 2015; Wu et al., 2012b, 2014; Yu
et al., 2013). There is signiﬁcant evidence that it can itself lead to
multiple organ failure and death (Gando, 2010). It does not yet
seem to be known, but seems probable, that the form of ﬁbrin in
DIC is indeed a b-amyloid.
Clot retraction. Clot retraction (contraction) is a physiological
process initiated by platelets that results in compaction of the ﬁbrin
network and expulsion of the majority of serum from the clot -
together with the majority of unbound plasminogen, typically over
a 24 h period in vivo (Cines et al., 2014). It reﬂects in part the
crosslinking of ﬁbrin effected by Factor XIII (Hethershaw et al.,
2014; Kasahara et al., 2010, 2013). According to Weisel (Weisel,
2011), commenting on the important Varjú paper (Varjú et al.,
2011), so-called retracted clots are much more resistant to lysis
(Kunitada et al., 1992; Sabovic and Blinc, 2000; Sabovic et al., 1989),
and retracted clots probably provide a useful model for events such
as stroke. Clots are much stiffer in diseases such as multiple
myeloma (Carr and Zekert, 1994; Lackner et al., 1970). It is not yet
apparently known whether clot retraction is accompanied by b-
sheet formation.
7. Mutual effects of ﬁbrin(ogen) on b-amyloid in Alzheimer's
disease
We rehearsed above how there was a limited (non-zero) cross-
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example of particular interest is given by the interaction between
ﬁbrin(ogen) and b-amyloid, as developed by Strickland and col-
leagues (Ahn et al., 2010, 2014; Cortes-Canteli et al., 2015; Cortes-
Canteli et al., 2010; Cortes-Canteli and Strickland, 2009; Cortes-
Canteli et al., 2012; Paul et al., 2007; Zamolodchikov and Strick-
land, 2012). We rehearse their highly important arguments and
ﬁndings in some detail.
As pointed out by Paul and colleagues (Paul et al., 2007),
ﬁbrinogen is present in the brains of AD patients (Fiala et al., 2002),
but the pathologic signiﬁcance is or was not known. Using mutant
mice, they showed the deﬁnite contribution of ﬁbrin to the aberrant
pathology (Paul et al., 2007). As is well known, the extracellular
plaques in the AD brain are composed mainly of a 40e42 amino
acid peptide, the b-amyloid or amyloid-b (Ab) peptide that is
derived proteolytically from the N-terminus of the so-called amy-
loid-b precursor protein (APP). There is little doubt (the ‘amyloid
hypothesis’ (Eisele et al., 2015; Hardy and Selkoe, 2002; Hardy and
Higgins, 1992; Jonsson et al., 2012; Minter et al., 2016; Selkoe and
Hardy, 2016)) that Ab plays some kind of signiﬁcant role in AD,
albeit that measures designed to remove it have not led to useful
therapeutics (Hardy, 2009; Herrup, 2015; Itzhaki et al., 2016;
Karran and Hardy, 2014; Karran et al., 2011). The probable reason
for this is simply that it is not the sole actor (though see Note Added
in Proof) (Nussbaum et al., 2013), and certainly its interactions with
iron salts are central to disease development and loss of cognition
(e.g. (Bush, 2003; Bush and Tanzi, 2008; Crapper McLachlan et al.,
1991; Fine et al., 2012; Guo et al., 2013; Jomova and Valko, 2011;
Kell, 2009, 2010; Kell and Pretorius, 2015b; Malecki and Connor,
2002; Pretorius et al., 2016a; Smith et al., 1997; Smith et al., 2010;
Valko et al., 2016)). ‘Iron’ interacts with ﬁbrinogen too (Nielsen
and Jacobsen, 2016; Pretorius et al., 2013, 2014a; Pretorius and
Kell, 2014), as does ferritin (Okada et al., 2015). Here we rehearse
and develop the additional idea that it is the interactions of Abwith
ﬁbrin(ogen), leading to amyloid ﬁbril formation, that may provide a
signiﬁcant contribution to the neurodegeneration.
An important starting recognition (Cortes-Canteli and
Strickland, 2009) is that plasma ﬁbrinogen levels are raised in AD
(Davalos and Akassoglou, 2012; Lee et al., 2007; Marioni et al.,
2009; Noguchi et al., 2014; van Oijen et al., 2005; Xu et al., 2008),
as is coagulability (Gupta et al., 2005; Kell and Pretorius, 2015b).
The extent of ﬁbrin deposition reﬂects the plasma ﬁbrinogen level
as it is modiﬁed by genetic or pharmacological means (Cortes-
Canteli and Strickland, 2009). Fibrinogen is also accumulated in
AD plaques (Paul et al., 2007; Ryu and McLarnon, 2009), and this
can promote neurodegeneration (Cortes-Canteli et al., 2015).
As well as its general intra- and extra-cellular deposition, a
common pathology in AD patients is the deposition of Ab in the
walls of capillaries, arteries, and arterioles. This is known as cere-
bral amyloid angiopathy (CAA) (Vinters, 1987). Strickland and col-
leagues next showed (Cortes-Canteli et al., 2010), both in vitro and
in vivo, that ﬁbrin clots formed in the presence of Ab were struc-
turally abnormal and resistant to degradation, and that lowering
ﬁbrinogen improved cognitive function (in mice). (It is also of in-
terest that Ab promotes the binding of tissue plasminogen activator,
which recognises cross-beta sheets (Kranenburg et al., 2002;
Longstaff and Kolev, 2015)). Thioﬂavin S (like thioﬂavin T, below)
is a stain for amyloid ﬁbrils based on their high b-sheet content
(Bussiere et al., 2004; Ly et al., 2011; Sun et al., 2002). Immuno-
logical staining of ﬁbrinogen and thioﬂavin S staining of (pre-
sumed) Ab showed colocalisation (Cortes-Canteli et al., 2010, 2012),
though of course this would not have distinguished whether the
ﬁbrin too had adopted a b-sheet form.
Strickland and colleagues next showed (Ahn et al., 2010) that Ab
speciﬁcally interacts with ﬁbrinogen (Kd ~ 26 nM), that the bindingsite is located near the C terminus of the ﬁbrinogen b-chain, and
that the binding causes ﬁbrinogen to oligomerise (albeit not to
standard ﬁbrin ﬁbres) and to deposit. Although the Ab will bind to
preformed clots, only when it is added before clotting does it
produce thinner ﬁbres in tighter networks (Zamolodchikov and
Strickland, 2012); it also attenuates plasminogen binding (again
consistent with the idea that it induces a structural change in the
ﬁbrinogen).
As is well known, the apoE4 allele is associated with a greater
risk of AD; brains from AD cases homozygous for the APOE ε4 allele
showed increased deposition of ﬁbrin(ogen), especially in CAA- and
Ab-positive blood vessels (Hultman et al., 2013), fully consistent
with the role of this process in cognitive decline. Similarly, phar-
macological inhibition with a small molecule called Ru-505 of the
ﬁbrinogen-Ab interaction both altered the clot morphology and
arrested cognitive decline (Ahn et al., 2014), implying the potential
value of this target (which is also susceptible to enzymatic degra-
dation (Bhattacharjee and Bhattacharyya, 2015)). Overall, the case
for an important role of ﬁbrin(ogen)'s interactionwith Ab as part of
the aetiology of AD seems very well made. For our purposes, there
are two chief questions: (i) what is the extent to which the ﬁbrin
adopts an amyloid form when in complex with Ab?, and (ii) is it
more the ﬁbrinogen that precipitates the Ab or the Ab that pre-
cipitates the ﬁbrinogen?
8. Small molecules that affect the nature of blood clotting
and ﬁbrin ﬁbres in vitro
The effects of small molecules (both those produced endoge-
nously and introduced drugs) on the coagulation system represent
a vast ﬁeld, and arguably warrant a review of their own, since
molecules binding to the normal forms may be expected to inhibit
toxic amyloidogenesis (Alavez et al., 2011; Doig and Derreumaux,
2015; Ehrnhoefer et al., 2008; Gavrin et al., 2012; H€ard and
Lendel, 2012; Hawkes et al., 2009; Hayne et al., 2014; Hirohata
et al., 2007; Inbar and Yang, 2006; Jameson et al., 2012; LeVine
et al., 2009; Patel et al., 2015; Prade et al., 2016; Ryan et al., 2012;
Sarkar et al., 2015; Stempler et al., 2011; Woods et al., 2011) and
hence disease (Ahn et al., 2014; Ankarcrona et al., 2016; Flemming,
2014; Hanaki et al., 2016; Jiao et al., 2015; McKoy et al., 2012).
However, we here brieﬂy mention a few well-known molecules to
illustrate how sensitive ﬁbrin ﬁbre morphology can be to their
presence. Various endogenous (inﬂammatory) molecules,
including stress hormones (including the hypothalamic-pituitary-
adrenal axis activity) (Austin et al., 2013; von K€anel, 2015), acti-
vate both the coagulation and ﬁbrinolysis system resulting in net
hypercoagulability. It is also well-known that the inﬂammatory
marker ‘iron’may cause hypercoagulation in iron-overload diseases
(Borgna-Pignatti and Gamberini, 2011; Shah et al., 2015). We have
reviewed in detail the effects of increased (endogenous) ‘iron’,
including its effects on the coagulation system (Kell, 2009; Kell and
Pretorius, 2015b; Pretorius et al., 2013, 2014a; Pretorius and Kell,
2014). Many drugs introduced into the human body are known to
inﬂuence the coagulation system; for a comprehensive list of the
effects of various drugs on coagulation see (Undas and Ari€ens,
2011). The most well-known effect of various drugs on hyper-
coagulation is thrombotic microangiopathy, which is a pathology
that results in thrombosis in capillaries and arterioles, due to an
endothelial injury (Reese et al., 2015; Rosove, 2014). Venous
thromboembolism, is also a well-known result of the use of oral
contraceptives (ESHRE CAPRIWorkshop Group, 2013; O'Brien,
2014).
The above-mentioned molecules and others have direct effects
on the ﬁbrin ﬁbre structure and packaging; these includemolecules
like S-nitrosoglutathione (Bateman et al., 2012), iron and CO
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Nielsen et al., 2015), as well as oestrogen (Swanepoel et al., 2014).
We have shown that addition of unliganded iron salts to ﬁbrinogen,
to healthy plasma, and/or to whole blood, causes pathological ﬁbrin
formation (Lipinski and Pretorius, 2012; Lipinski et al., 2012a,
2012b); however, the addition of various iron chelators to this
plasma (Kell and Pretorius, 2015b; Pretorius et al., 2013) results in a
return of ﬁbrin ﬁbre structure to become similar to that of healthy
ﬁbrin. We also showed that adding chelators to blood/and or
plasma from individuals with iron overload (Bester et al., 2013;
Pretorius et al., 2014a; Pretorius and Kell, 2014) similarly resulted
in the return of the pathologic ﬁbrin structure to that resembling
healthy ﬁbrin packaging. See Fig 10, where Fig 10A shows the ﬁbrin
ﬁbre structure of an individual with hereditary hemochromatosis
and Fig 10 B when the chelators desferal (deferoxamine) is added to
plasma of this patient.
9. Induction of amyloidogenic clotting by added LPS
(endotoxin)
The very potent bacterial inﬂammagen, lipopolysaccharide (LPS)
is well known to cause cytokine activation, and this can cause
hypercoagulation (Chu et al., 2001, 2003); this has been referred to
as endotoxin-mediated hypercoagulation (Slotta et al., 2008). One
mechanism of activation by LPS of the coagulation pathway is via
tissue factor (TF) upregulation (Koch et al., 2009; Monroe and Key,
2007). Previously, it was found that LPS from Escherichia coli
(100 ng mL1) activated the coagulation system when added to
whole blood, via a complement- and CD14-dependent up-
regulation of TF, leading to prothrombin activation and hyper-
coagulation (Landsem et al., 2015). Recently, we also found that
really minute levels of LPS (0.2 ng.L1, representing a molar ratio to
ﬁbrinogen of 1 in 108) might bind directly to circulating plasma
proteins (when added to plasma from healthy individuals), and also
to pure ﬁbrinogen, and that this (rapid) binding might also cause
pathological changes in the coagulation process (Pretorius et al.,
2016b, 2016c). In our hands, the binding was virtually instanta-
neous and we conﬁrmed the direct binding of LPS to pure ﬁbrin-
ogen using isothermal calorimetry. It was clear from thioﬂavin T
measurements that LPS could massively affect the formation of b-
sheets during ﬁbrin packaging. Only a limited number of autocat-
alytic mechanisms can admit this, that whichwe favour (see below)
being essentially a very rapid form of amyloidogenesis and auto-
catalytic structural rearrangement to a b-rich conformation.
10. Anomalous blood clotting involves genuine amyloid
formation
What had been determined earlier, and the same was true forFig. 10. A) Fibrin ﬁbre structure of an individual with hereditary hemochromatosis; B)changes in erythrocyte morphology (Pretorius et al., 2014a, 2016d;
Pretorius and Kell, 2014) and see above, is that small molecules and
the presence of various disease states could havemassive effects on
the morphology of ﬁbrin as judged by (i) its distribution of ﬁbre
diameters and (ii) the formation of what we referred to as ‘dense
matted deposits’, in which the ﬁbres were typically much smaller
than the normal (whose median ~ 85 nm). What we recently
discovered (Pretorius et al., 2016b, 2016c) is that this was actually
accompanied by genuine amyloid formation.
As part of a lengthy series on the role of true dormancy in
bacterial physiology (e.g. (Kaprelyants et al., 1993; Kaprelyants and
Kell, 1992, 1993; Mukamolova et al., 1998, 2002a, 2002b, 2003,
2006; Votyakova et al., 1994)), we have recently come to recog-
nise that a dormant bloodmicrobiome is a signiﬁcant contributor to
a great many chronic, inﬂammatory diseases, not least by shedding
highly inﬂammatory molecules such as lipopolysaccharide (LPS)
(Kell et al., 2015; Kell and Pretorius, 2015a; Potgieter et al., 2015).
This led us to assess (Pretorius et al., 2016b, 2016c) whether LPS had
any effects on blood clotting directly.
As mentioned, it transpired (Pretorius et al., 2016b, 2016c) that
quite miniscule concentrations (amounting to fewer than 1 mole-
cule of freshly added LPS per 108 molecules of ﬁbrinogen!) had a
massive effect on ﬁbrinogen polymerisation to ﬁbrin, including the
production of (in many cases) the thinner ﬁbres and ‘dense matter
deposits’ seen in so many diseases. In particular, the use of the
amyloid-detecting dye thioﬂavine T (Biancalana and Koide, 2010;
Freire et al., 2014; Groenning, 2010; Krebs et al., 2005;
Kuznetsova et al., 2016; LeVine, 1997, 1999; Lindberg et al., 2015;
Picken and Herrera, 2012; Sulatskaya et al., 2011, 2012; Wu et al.,
2009) revealed a massive conversion of ﬁbrin to a b-sheet-rich
form.11. The extent of ampliﬁcation of protein transitions by LPS
can be mimicked by liquid crystals
As phrased by Maji and colleagues (Maji et al., 2009), repeating
motifs can translate a rather non-speciﬁc interaction into a speciﬁc
one through cooperativity. This process can nowadays be observed
directly (Pinotsi et al., 2016), and amounts to potentially quite a
massive ampliﬁcation. In the example of our ownmentioned above
(Pretorius et al., 2016b, 2016c), with LPS freshly added to whole
blood, platelet-poor plasma or ﬁbrinogen solutions, the ratio of
LPS:ﬁbrinogen at which the LPS could induce amyloidogenesis was
~1 in 108; this represents a truly massive ampliﬁcation (see also
(Galant et al., 2016)), and serves to help explain how very small
numbers of bacteria secreting comparatively small amounts of LPS
(albeit of potentially high concentration locally) can exert such a
massive inﬂammagenic effect.
Interestingly, Lin and colleagues also showed that similarly tinywhen desferal (deferoxamine) is added to plasma of this patient. Scale bar: 1 mm.
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cooperative conformation of millions of molecules inmicrodroplets
of nematic liquid crystals ((Lin et al., 2011), and see (Miller and
Abbott, 2013)). The same was true for molecular mimics of LPS
(Carter et al., 2015). Indeed, different liquid crystals can also be used
as ‘biosensors’ (Lowe and Abbott, 2012) to detect b-amyloid for-
mation (Sadati et al., 2015), protein-LPS interactions (Das et al.,
2015) and microvesicles (Tan et al., 2014).
12. Chronic infection and amyloidogenesis
As phrased by Michael Hann (Hann, 2011), ‘unknown knowns’
“… are those things that are known but have become unknown,
either becausewe have never learnt them, or forgotten about them,
or more dangerously chosen to ignore”. Thus, in 1967, Kelenyi could
write “Development of new therapeutical measures in chronic in-
fections has sharply reduced the incidence of secondary amyloid-
osis”. In other words, the fact that chronic infection could induce
amyloidosis was then so well known that it barely merited dis-
cussion! The same is true in comparable works of that era (e.g.
(Hobbs and Morgan, 1963)). Obviously it has since then been
somewhat forgotten, despite the overwhelming evidence (Hill and
Lukiw, 2015; Itzhaki et al., 2016) for a microbial component to AD,
and to amyloidogenesis more generally (Ebert and Nagar, 2008).
Recently (notwithstanding some caveats (Salter et al., 2014)) the
role of dormant or latent microbes in chronic, inﬂammatory dis-
easesmore generally has come to the fore (e.g. (Aagaard et al., 2014;
Domingue, 2010; Domingue and Woody, 1997; Hieken et al., 2016;
Itzhaki et al., 2016; Kell et al., 2015; Kell and Pretorius, 2015a;
Mangin et al., 2014; Mattman, 2001; Nicolson and Haier, 2009,
2010; Potgieter et al., 2015; Proal et al., 2009, 2011, 2013, 2014;
Urbaniak et al., 2014; Woolard and Frelinger, 2008)), and it is
appropriate to recognise this and older literature (e.g. (Billings,
1915; Price, 1923)), some of which is still being rediscovered.
Thus, Chlamydia pneumoniae induces Alzheimer-like amyloid pla-
ques in the brains of BALB/c mice (Little et al., 2004), while amyloid
can also be induced by herpes simplex virus (Wozniak et al., 2007)
and Borrelia (Miklossy, 2008, 2011; Miklossy et al., 2006). In the
present context it is of particular interest that LPS can induce the
conversion of prion protein to its amyloidogenic form (provided the
LPS concentration remains above its critical micelle concentration
(CMC)) (Saleem et al., 2014), and it can do this substoichiometri-
cally. The natural bacterial production of amyloids themselves has
also been reviewed (Blanco et al., 2012; Taylor andMatthews, 2015;
Van Gerven et al., 2015; Zhou et al., 2012).
13. Serum amyloid A
In a similar vein, ‘serum amyloid A’ (Benditt et al., 1971) de-
scribes a heterogeneous family of apolipoproteins (Sipe, 1999) (and
variants (Nedelkov et al., 2005)) that form amyloid ﬁbrils in the
blood, typically in response to inﬂammation or infection (Malle and
De Beer, 1996; R€ocken and Shakespeare, 2002; Sipe, 2000), binding
retinol in the process (Derebe et al., 2014). To this end, this rather
understudied series of proteins may provide very useful bio-
markers for chronic infection/sepsis, for which it is in fact a well-
established (and potent) biomarker (e.g. (Arnon et al., 2007;
Bozinovski et al., 2008; Çetinkaya et al., 2009; Cicarelli et al.,
2008; Derebe et al., 2014; Ebert and Nagar, 2008; Falsey et al.,
2001; Lannergård et al., 2008, 2009; Malle and De Beer, 1996;
Obici et al., 2005; Pizzini et al., 2000; Sipe, 2000; Urieli-Shoval
et al., 2000; Yamada, 1999; Yuan et al., 2013a)). Interestingly, and
in a manner akin to that of prions, it is able to catalyse its own a-to-
b-type conformational transitions (e.g. (Liu et al., 2007; Lundmark
et al., 2002, 2005; Murakami et al., 2015; Murakami et al., 2014;Tasaki et al., 2010; Westermark et al., 2009)), although the ki-
netics are rather sluggish compared to those of blood clotting. In a
similar vein, amyloid deposition in the kidney (Dember, 2006; von
Hutten et al., 2009) may account for the proteinuria seen in dis-
eases such as pre-eclampsia (Kell and Kenny, 2016).
14. Sequelae of amyloidogenesis
While the focus of this review is on amyloidogenesis per se, we
should recognise its sequelae at various levels. Pertinent to the
blood system is the fact that amyloid can induce gross morpho-
logical changes in erythrocytes, leading to their suicidal death
(‘eryptosis’) (Nicolay et al., 2007). Indeed, our own observations
show that major morphological changes in erythrocytes are a
regular accompaniment to the chronic inﬂammatory diseases that
we are discussing (e.g. (Bester et al., 2013, 2015; Pretorius et al.,
2015, 2014a, 2014b; Pretorius and Kell, 2014; Pretorius and
Lipinski, 2013b, 2013c; Pretorius et al., 2016d)), and these
sequelae can include eryptosis (Pretorius et al., 2014c). Eryptosis is
characterized by scrambling of the cell membrane with subsequent
exposure of phosphatidylserine (PS) at the cell surface (e.g. (Lang
et al., 2012; Qadri et al., 2016)), and is essentially a form of
apoptotic cell death (Lang et al., 2015a). Interestingly (and perhaps
surprisingly) this eryptosis involves the cyclin-dependent kinase
CDK4 (Lang et al., 2015b).
As indicated above, many human diseases are known to be
associated with misfolded or amyloid-type proteins (Chiti and
Dobson, 2006; Herczenik and Gebbink, 2008; Knowles et al.,
2014; Moreno-Gonzalez and Soto, 2011; Olanow and Brundin,
2013; Pawlicki et al., 2008; Rambaran and Serpell, 2008; Tipping
et al., 2015;Westermark andWestermark, 2011; Zhang et al., 2014),
and the cytotoxicity of amyloid ﬁbrils is very well established (e.g.
(Ahmed et al., 2010; Airoldi et al., 2011; Bester et al., 2015; Cao et al.,
2013; Fernandez, 2014; Hefti et al., 2013; Kayed et al., 2003; Kayed
and Lasagna-Reeves, 2013; Konarkowska et al., 2006; Liu et al.,
2011; Lorenzo et al., 1994; Marzban et al., 2003; Meier et al., 2006;
Meyer-Luehmann et al., 2008; Minter et al., 2016; Miranda et al.,
2000; Rival et al., 2009; Sengupta et al., 2016)). We note, however,
that although it is the larger ﬁbrils that are observable ultrami-
croscopically, there is evidence that it is the smaller ones that are
the more cytotoxic (Aitken et al., 2010; Baglioni et al., 2006;
Bucciantini et al., 2002; Dobson, 2013; F€andrich, 2012; Glabe,
2006; G€oransson et al., 2012; Haass and Selkoe, 2007; Janson
et al., 1999; Kayed et al., 2003; Konarkowska et al., 2006; Meier
et al., 2006; Pillay and Govender, 2013; Stefani, 2012; Trikha and
Jeremic, 2013; Uversky, 2010; Xue et al., 2009, 2010; Zhang et al.,
2014). As to the mechanism of cytotoxicity, membrane per-
meabilisation (followed by apoptosis) is certainly one (Cao et al.,
2013; Engel et al., 2008; Janson et al., 1999; Nanga et al., 2011).
15. Possible treatments for coagulopathies in the light of
their role in amyloidogenesis
Recognising that ‘dense matted deposits’ are actually amyloid
encourages one to access the literature designed to stop or reverse
amyloidogenesis in other ﬁelds such as Alzheimer's disease (e.g.
(Ahn et al., 2014; Bieschke, 2013; Brumshtein et al., 2015; Cheng
et al., 2012, 2013; Doig and Derreumaux, 2015; Eisele et al., 2015;
Estrada et al., 2006; Flemming, 2014; Hanaki et al., 2016; Hawkes
et al., 2009; Jucker and Walker, 2013; Lopez et al., 2012;
Murakami, 2014; Stamford and Strickland, 2013), and see also
(Cegelski et al., 2009; Cheng et al., 2016; Evans et al., 2015; Klein
and Hultgren, 2015)) or for transthyretin (Ankarcrona et al., 2016;
Galant et al., 2016), and thus it will be of interest to assess candi-
date anti-amyloidogenic molecules in the blood system, where it is
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(see (Kell, 2015; Kell et al., 2011, 2013; Kell and Oliver, 2014)).
In a complementary vein, if (anomalous) ﬁbrin clot formation is
signiﬁcant in AD one might suppose that inhibiting it might be of
value, and it is (Ahn et al., 2014). One might also expect that anti-
coagulant therapies might show beneﬁt, and there are some sig-
niﬁcant hints that this too might indeed be the case (Barber et al.,
2004; Murthy et al., 2009; Ratner et al., 1972; Walsh, 1996; Walsh
et al., 1978), to the extent that this would seem to be well worth
exploring properly. The success of the anticoagulant thrombomo-
dulin in sepsis/septic shock (Eguchi et al., 2014; Hayakawa et al.,
2016; Levi, 2015; Levi and Van Der Poll, 2013b; Mimuro et al.,
2013; Saito et al., 2007; Shirahata et al., 2014; Vincent et al.,
2013; Yamakawa et al., 2015; Yoshimura et al., 2015) also implies
an important role of coagulopathies there.
Since the levels of ﬁbrinogen themselves seem to correlate with
a propensity for AD (see above), and indeed for hypertension
(Bembde, 2012; Haenni and Lithell, 1996; Letcher et al., 1981;
Shankar et al., 2006), lowering them to more appropriate levels
(by means other than by converting them to amyloid forms of
ﬁbrin!) would seem to be a desirable aim in itself.
16. Quo vadis? e systems strategies
We have summarised much of the evidence to the effect that
under some circumstances the ﬁbrin ﬁbres formed by ﬁbrinogen
polymerisation are in fact amyloid in character (Fig 11). This opens
up the ﬁeld to testing this under the many different disease cir-
cumstances where this might be suspected, whether as a diagnostic
or a prognostic. Easy predictions are that the clots seen after stroke
and in any other hypercoagulable conditions will be amyloid and
thus stainable with thioﬂavin T or amyloid-selective dyes (noting
the need for suitable controls and caveats (Coelho-Cerqueira et al.,
2014; Hudson et al., 2009; Wong et al., 2016)). The many estab-
lishedmethods for b-amyloid detection include spectroscopies (e.g.
X-rays (Guilbaud and Saiani, 2011; Sawyer and Gras, 2013; SpencerFig. 11. An elementary systems biology model of how iron dysregulation can stimulate dorm
then trigger inﬂammation, leading to b-amyloid formation in ﬁbrin and ultimately to cell det al., 2015), NMR (Colvin et al., 2015; Karamanos et al., 2015; Su
et al., 2015; Tycko, 2011), mass (Riba et al., 2015; Young et al.,
2014, 2015), circular dichroism (Etienne et al., 2007; Howie and
Brewer, 2009), neutron (Valincius et al., 2008), vibrational (Dasari
et al., 2011; Middleton et al., 2012)) and microscopies (including
appropriate stains (Fig 11 and above)) will be of value in detection.
SEM and TEM (Iadanza et al., 2016) were discussed above, but there
is a clear role too for AFM (Volpatti et al., 2013). Similarly, a plethora
of small molecule studies will clearly be of value in seeking to
modulate such amyloid formation. As is common in modern
biology, strategies for pharmacological inhibition are usually done
piecemeal on the basis of speciﬁc hypotheses about individual
targets. Clearly this must change (Kell, 2013). We have highlighted
several ‘non-traditional’ targets here (e.g. iron metabolism, blood
clotting, ﬁbrinogen-Ab interactions, anti-amyloids) but they have
only been studied singly.
From a network or systems pharmacology perspective (e.g.
(Berger and Iyengar, 2009; Cucurull-Sanchez et al., 2012; Hopkins,
2008;Kell andGoodacre, 2014; vanderGraaf andBenson, 2011)),we
either need polypharmacology (one drug, multiple targets, e.g.
(Achenbach et al., 2011;Anighoro et al., 2014;HuandBajorath, 2010;
Kell, 2013; Kell and Goodacre, 2014; Kell and Oliver, 2014; Mestres
and Gregori-Puigjane, 2009; Peters, 2013; Reddy and Zhang, 2013;
Weinreb et al., 2011, 2012, 2010; Xie et al., 2012). or suitably com-
bined cocktails of individual drugs (e.g. (Borisy et al., 2003; Lehar
et al., 2007, 2008; Small et al., 2011; Zimmermann et al., 2007)).
Armed with these, and based on established mechanisms of action
that involve ﬁbrin(ogen), we may strongly hope to delay the pro-
gression of amyloidogenic diseases in our ageing populations.
In a related vein, we would be remiss not to recognise that an
understanding of how small trigger events can effect massive
conformational changes in designed proteins has potentially
massive beneﬁts for synthetic biotechnology (Currin et al., 2015; Li
et al., 2014), including self-assembling systems (Boothroyd et al.,
2014; Elsawy et al., 2016; Hickling et al., 2014). Nakano and col-
leagues provide a very nice biomaterials example with barnacleant bacterial growth that can in turn lead to antigen production (e.g. of LPS) that can
eath.
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Overall, the crux of the review is that we have indicated that
many more proteins than perhaps currently recognised, and in
particular ﬁbrin(ogen), can form genuine amyloid structures that
are likely to be signiﬁcant in toxicity and disease; clarifying the link
between their essential molecular structure/conformation and
their disease-causing potential is now key, and the ﬁelds of blood
clotting and amloidogenesis can learn much from each other to
mutual advantage.Acknowledgments
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Very recently, Sevigny et al. (2016) have shown that aducanu-
mab may clear Abeta plaques in a mouse model, with addendant
improvement in cognitive function.References
Aagaard, K., Ma, J., Antony, K.M., Ganu, R., Petrosino, J., Versalovic, J., 2014. The
placenta harbors a unique microbiome,. Sci. Transl. Med. 6, 237ra65.
Acestor, N., Goett, J., Lee, A., Herrick, T.M., Engelbrecht, S.M., Harner-Jay, C.M.,
Howell, B.J., Weigl, B.H., 2016. Towards biomarker-based tests that can facilitate
decisions about prevention and management of preeclampsia in low-resource
settings. Clin. Chem. Lab. Med. 54, 17e27.
Achenbach, J., Tiikkainen, P., Franke, L., Proschak, E., 2011. Computational tools for
polypharmacology and repurposing. Future Med. Chem. 3, 961e968.
Adam, S.S., Key, N.S., Greenberg, C.S., 2009. D-dimer antigen: current concepts and
future prospects. Blood 113, 2878e2887.
Afshari, A., Wikkelsø, A., Brok, J., Moller, A.M., Wetterslev, J., 2011. Thrombelastog-
raphy (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus
usual care in patients with massive transfusion. Cochrane Database Syst. Rev.
CD007871.
Aguzzi, A., Calella, A.M., 2009. Prions: protein aggregation and infectious diseases.
Physiol. Rev. 89, 1105e1152.
Aguzzi, A., Haass, C., 2003. Games played by rogue proteins in prion disorders and
Alzheimer's disease. Science 302, 814e818.
Aguzzi, A., Lakkaraju, A.K.K., 2016. Cell biology of prions and prionoids: a status
report. Trends Cell Biol. 26, 40e51.
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J.I., Van
Nostrand, W.E., Smith, S.O., 2010. Structural conversion of neurotoxic amyloid-
beta1-42 oligomers to ﬁbrils. Nat. Struct. Mol. Biol. 17, 561e567.
Ahn, H.J., Glickman, J.F., Poon, K.L., Zamolodchikov, D., Jno-Charles, O.C., Norris, E.H.,
Strickland, S., 2014. A novel Abeta-ﬁbrinogen interaction inhibitor rescues
altered thrombosis and cognitive decline in Alzheimer's disease mice. J. Exp.
Med. 211, 1049e1062.
Ahn, H.J., Zamolodchikov, D., Cortes-Canteli, M., Norris, E.H., Glickman, J.F.,
Strickland, S., 2010. Alzheimer's disease peptide beta-amyloid interacts with
ﬁbrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. 107,
21812e21817.
Airoldi, C., Colombo, L., Manzoni, C., Sironi, E., Natalello, A., Doglia, S.M., Forloni, G.,
Tagliavini, F., Del Favero, E., Cantu, L., Nicotra, F., Salmona, M., 2011. Tetracycline
prevents Abeta oligomer toxicity through an atypical supramolecular interac-
tion. Org. Biomol. Chem. 9, 463e472.
Aitken, J.F., Loomes, K.M., Scott, D.W., Reddy, S., Phillips, A.R.J., Prijic, G.,
Fernando, C., Zhang, S., Broadhurst, R., L'Huillier, P., Cooper, G.J.S., 2010. Tetra-
cycline treatment retards the onset and slows the progression of diabetes in
human amylin/islet amyloid polypeptide transgenic mice. Diabetes 59, 161e171.
Alavez, S., Vantipalli, M.C., Zucker, D.J., Klang, I.M., Lithgow, G.J., 2011. Amyloid-
binding compounds maintain protein homeostasis during ageing and extend
lifespan. Nature 472, 226e229.
Alexander, P.A., He, Y., Chen, Y., Orban, J., Bryan, P.N., 2009. A minimal sequence
code for switching protein structure and function. Proc. Natl. Acad. Sci. 106,21149e21154.
Anﬁnsen, C.B., 1973. Principles that govern the folding of protein chains. Science
181, 223e230.
Anﬁnsen, C.B., Haber, E., Sela, M., White, F.H., 1961. The kinetics of formation of
native ribonuclease during oxidation of the reduced polypeptide chain. Proc.
Natl. Acad. Sci. 47, 1309e1314.
Anighoro, A., Bajorath, J., Rastelli, G., 2014. Polypharmacology: challenges and op-
portunities in drug discovery. J. Med. Chem. 57, 7874e7887.
Ankarcrona, M., Winblad, B., Monteiro, C., Fearns, C., Powers, E.T., Johansson, J.,
Westermark, G.T., Presto, J., Ericzon, B.G., Kelly, J.W., 2016. Current and future
treatment of amyloid diseases. J. Intern Med. 280, 177e202.
Ari€ens, R.A.S., 2011. Elevated ﬁbrinogen causes thrombosis. Blood 117, 4687e4688.
Ari€ens, R.A.S., 2013. Fibrin(ogen) and thrombotic disease. J. Thromb. Haemost. 11
(Suppl. 1), 294e305.
Arnon, S., Litmanovitz, I., Regev, R.H., Bauer, S., Shainkin-Kestenbaum, R., Dolﬁn, T.,
2007. Serum amyloid A: an early and accurate marker of neonatal early-onset
sepsis. J. Perinatol. 27, 297e302.
Asakura, H., 2014. Classifying types of disseminated intravascular coagulation:
clinical and animal models. J. Intensive Care 2, 20.
Ashe, K.H., Aguzzi, A., 2013. Prions, prionoids and pathogenic proteins in Alzheimer
disease. Prion 7, 55e59.
Åslund, A., Herland, A., Hammarstr€om, P., Nilsson, K.P.R., Jonsson, B.H., Ingan€as, O.,
Konradsson, P., 2007. Studies of luminescent conjugated polythiophene de-
rivatives: enhanced spectral discrimination of protein conformational states.
Bioconjug Chem. 18, 1860e1868.
Åslund, A., Sigurdson, C.J., Klingstedt, T., Grathwohl, S., Bolmont, T., Dickstein, D.L.,
Glimsdal, E., Prokop, S., Lindgren, M., Konradsson, P., Holtzman, D.M., Hof, P.R.,
Heppner, F.L., Gandy, S., Jucker, M., Aguzzi, A., Hammarstr€om, P., Nilsson, K.P.R.,
2009. Novel pentameric thiophene derivatives for in vitro and in vivo optical
imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem.
Biol. 4, 673e684.
Austin, A.W., Wissmann, T., von Kanel, R., 2013. Stress and hemostasis: an update.
Semin. Thromb. Hemost. 39, 902e912.
Averett, L.E., Geer, C.B., Fuierer, R.R., Akhremitchev, B.B., Gorkun, O.V.,
Schoenﬁsch, M.H., 2008. Complexity of “A-a” knob-hole ﬁbrin interaction
revealed by atomic force spectroscopy. Langmuir 24, 4979e4988.
Averett, L.E., Schoenﬁsch, M.H., Akhremitchev, B.B., Gorkun, O.V., 2009. Kinetics of
the multistep rupture of ﬁbrin 'A-a' polymerization interactions measured us-
ing atomic force microscopy. Biophys. J. 97, 2820e2828.
Badiei, N., Sowedan, A.M., Curtis, D.J., Brown, M.R., Lawrence, M.J., Campbell, A.I.,
Sabra, A., Evans, P.A., Weisel, J.W., Chernysh, I.N., Nagaswami, C., Williams, P.R.,
Hawkins, K., 2015. Effects of unidirectional ﬂow shear stresses on the formation,
fractal microstructure and rigidity of incipient whole blood clots and ﬁbrin gels.
Clin. Hemorheol. Microcirc. 60, 451e464.
Baglioni, S., Casamenti, F., Bucciantini, M., Luheshi, L.M., Taddei, N., Chiti, F.,
Dobson, C.M., Stefani, M., 2006. Preﬁbrillar amyloid aggregates could be generic
toxins in higher organisms. J. Neurosci. 26, 8160e8167.
Baldwin, M.A., Pan, K.M., Nguyen, J., Huang, Z., Groth, D., Serban, A., Gasset, M.,
Mehlhorn, I., Fletterick, R.J., Cohen, F.E., et al., 1994. Spectroscopic character-
ization of conformational differences between PrPC and PrPSc: an alpha-helix to
beta-sheet transition. Philos. Trans. R. Soc. Lond B Biol. Sci. 343, 435e441.
Ban, T., Hamada, D., Hasegawa, K., Naiki, H., Goto, Y., 2003. Direct observation of
amyloid ﬁbril growth monitored by thioﬂavin T ﬂuorescence. J. Biol. Chem. 278,
16462e16465.
Barber, M., Tait, R.C., Scott, J., Rumley, A., Lowe, G.D., Stott, D.J., 2004. Dementia in
subjects with atrial ﬁbrillation: hemostatic function and the role of anti-
coagulation. J. Thromb. Haemost. 2, 1873e1878.
Basu, S., Mohan, M.L., Luo, X., Kundu, B., Kong, Q., Singh, N., 2007. Modulation of
proteinase K-resistant prion protein in cells and infectious brain homogenate by
redox iron: implications for prion replication and disease pathogenesis. Mol.
Biol. Cell. 18, 3302e3312.
Bateman, R.M., Ellis, C.G., Suematsu, M., Walley, K.R., 2012. S-nitrosoglutathione acts
as a small molecule modulator of human ﬁbrin clot architecture. PLoS One 7,
e43660.
Bates, S.M., Weitz, J.I., 2005. Coagulation assays. Circulation 112, e53e60.
Bely, M., Makovitzky, J., 2006. Sensitivity and speciﬁcity of Congo red staining ac-
cording to Romhanyi. Comparison with Puchtler's or Bennhold's methods. Acta
histochem. 108, 175e180.
Bembde, A.S., 2012. A study of plasma ﬁbrinogen level in type-2 diabetes mellitus
and its relation to glycemic control. Indian J. Hematol. Blood Transfus. 28,
105e108.
Bendit, E.G., 1957. The alpha-beta transformation in keratin. Nature 179, 535.
Bendit, E.G., 1960. A quantitative X-ray diffraction study of the alpha-beta trans-
formation in wool keratin. Text. Res. J. 30, 547e555.
Benditt, E.P., Eriksen, N., Hermodson, M.A., Ericsson, L.H., 1971. The major proteins
of human and monkey amyloid substance: common properties including un-
usual N-terminal amino acid sequences. FEBS Lett. 19, 169e173.
Bennhold, H., 1922. Eine speziﬁsche Amyloidf€arbung mit Kongorot Münch. Med.
Woch. 69, 1537e1538.
Benson, M.D., Liepnieks, J., Uemichi, T., Wheeler, G., Correa, R., 1993. Hereditary
renal amyloidosis associated with a mutant ﬁbrinogen alpha-chain. Nat. Genet.
3, 252e255.
Berg, I., Nilsson, K.P.R., Thor, S., Hammarstr€om, P., 2010. Efﬁcient imaging of amyloid
deposits in Drosophila models of human amyloidoses. Nat. Protoc. 5, 935e944.
Berger, S.I., Iyengar, R., 2009. Network analyses in systems pharmacology.
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e41 31Bioinformatics 25, 2466e2472.
Berntorp, E., Salvagno, G.L., 2008. Standardization and clinical utility of thrombin-
generation assays. Semin. Thromb. Hemost. 34, 670e682.
Berthoumieu, O., Nguyen, P.H., Castillo-Frias, M.P., Ferre, S., Tarus, B., Nasica-
Labouze, J., Noel, S., Saurel, O., Rampon, C., Doig, A.J., Derreumaux, P., Faller, P.,
2015. Combined experimental and simulation studies suggest a revised mode of
action of the anti-Alzheimer disease drug NQ-Trp. Chemistry 21, 12657e12666.
Bester, J., Buys, A.V., Lipinski, B., Kell, D.B., Pretorius, E., 2013. High ferritin levels
have major effects on the morphology of erythrocytes in Alzheimer's disease.
Front. Aging Neurosci. 5, 00088.
Bester, J., Soma, P., Kell, D.B., Pretorius, E., 2015. Viscoelastic and ultrastructural
characteristics of whole blood and plasma in Alzheimer-type dementia, and the
possible role of bacterial lipopolysaccharides (LPS). Oncotarget Gerontol. 6,
35284e35303.
Bhattacharjee, P., Bhattacharyya, D., 2015. An enzyme from Aristolochia indica de-
stabilizes ﬁbrin-beta amyloid Co-Aggregate: implication in cerebrovascular
diseases. PLoS One 10, e0141986.
Biancalana, M., Koide, S., 2010. Molecular mechanism of Thioﬂavin-T binding to
amyloid ﬁbrils. Biochim. Biophys. Acta 1804, 1405e1412.
Biancalana, M., Makabe, K., Koide, A., Koide, S., 2009. Molecular mechanism of
thioﬂavin-T binding to the surface of beta-rich peptide self-assemblies. J. Mol.
Biol. 385, 1052e1063.
Bick, R.L., 2002. Disseminated intravascular coagulation: a review of etiology,
pathophysiology, diagnosis, and management: guidelines for care. Clin. Appl.
Thromb. Hemost. 8, 1e31.
Bieschke, J., 2013. Natural compounds may open new routes to treatment of amy-
loid diseases. Neurotherapeutics 10, 429e439.
Billings, F., 1915. Focal Infection (Appleton, New York).
Blanco, L.P., Evans, M.L., Smith, D.R., Badtke, M.P., Chapman, M.R., 2012. Diversity,
biogenesis and function of microbial amyloids. Trends Microbiol. 20, 66e73.
Bolliger, D., Seeberger, M.D., Tanaka, K.A., 2012. Principles and practice of throm-
boelastography in clinical coagulation management and transfusion practice.
Transfus. Med. Rev. 26, 1e13.
Boothroyd, S., Saiani, A., Miller, A.F., 2014. Controlling network Topology and me-
chanical properties of Co-Assembling peptide hydrogels. Biopolymers 101,
669e680.
Borgna-Pignatti, C., Gamberini, M.R., 2011. Complications of thalassemia major and
their treatment. Expert Rev. Hematol. 4, 353e366.
Borisy, A.A., Elliott, P.J., Hurst, N.W., Lee, M.S., Lehar, J., Price, E.R., Serbedzija, G.,
Zimmermann, G.R., Foley, M.A., Stockwell, B.R., Keith, C.T., 2003. Systematic
discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U. S. A. 100,
7977e7982.
Bozinovski, S., Hutchinson, A., Thompson, M., Macgregor, L., Black, J., Giannakis, E.,
Karlsson, A.S., Silvestrini, R., Smallwood, D., Vlahos, R., Irving, L.B.,
Anderson, G.P., 2008. Serum amyloid a is a biomarker of acute exacerbations of
chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177,
269e278.
Bramanti, E., Benedetti, E., Sagripanti, A., Papineschi, F., Benedetti, E., 1997. Deter-
mination of secondary structure of normal ﬁbrin from human peripheral blood.
Biopolymers 41, 545e553.
Bridge, K.I., Philippou, H., Ari€ens, R.A.S., 2014. Clot properties and cardiovascular
disease. Thromb. Haemost. 112, 901e908.
Brumshtein, B., Esswein, S.R., Salwinski, L., Phillips, M.L., Ly, A.T., Cascio, D.,
Sawaya, M.R., Eisenberg, D.S., 2015. Inhibition by small-molecule ligands of
formation of amyloid ﬁbrils of an immunoglobulin light chain variable domain.
Elife 4, e10935.
Bucay, I., O'Brien 3rd, E.T., Wulfe, S.D., Superﬁne, R., Wolberg, A.S., Falvo, M.R.,
Hudson, N.E., 2015. Physical determinants of ﬁbrinolysis in single ﬁbrin ﬁbers.
PLoS One 10, e0116350.
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N.,
Ramponi, G., Dobson, C.M., Stefani, M., 2002. Inherent toxicity of aggregates
implies a common mechanism for protein misfolding diseases. Nature 416,
507e511.
Bush, A.I., 2003. The metallobiology of Alzheimer's disease. Trends Neurosci. 26,
207e214.
Bush, A.I., Tanzi, R.E., 2008. Therapeutics for Alzheimer's disease based on the metal
hypothesis. Neurotherapeutics 5, 421e432.
Bussiere, T., Bard, F., Barbour, R., Grajeda, H., Guido, T., Khan, K., Schenk, D.,
Games, D., Seubert, P., Buttini, M., 2004. Morphological characterization of
Thioﬂavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect
of passive Abeta immunotherapy on their clearance. Am. J. Pathol. 165,
987e995.
Campbell, R.A., Aleman, M., Gray, L.D., Falvo, M.R., Wolberg, A.S., 2010. Flow pro-
foundly inﬂuences ﬁbrin network structure: implications for ﬁbrin formation
and clot stability in haemostasis. Thromb. Haemost. 104, 1281e1284.
Cao, P., Marek, P., Noor, H., Patsalo, V., Tu, L.H., Wang, H., Abedini, A., Raleigh, D.P.,
2013. Islet amyloid: from fundamental biophysics to mechanisms of cytotox-
icity. FEBS Lett. 587, 1106e1118.
Carr Jr., M.E., Zekert, S.L., 1994. Abnormal clot retraction, altered ﬁbrin structure,
and normal platelet function in multiple myeloma. Am. J. Physiol. 266,
H1195eH1201.
Carter, M.C.D., Miller, D.S., Jennings, J., Wang, X.G., Mahanthappa, M.K., Abbott, N.L.,
Lynn, D.M., 2015. Synthetic Mimics of Bacterial Lipid A Trigger Optical Transi-
tions in Liquid Crystal Microdroplets at Ultra low Picogram-per-Milliliter Con-
centrations. Langmuir 31, 12850e12855.Caughey, B., Baron, G.S., Chesebro, B., Jeffrey, M., 2009. Getting a grip on prions:
oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Bio-
chem. 78, 177e204.
Cegelski, L., Pinkner, J.S., Hammer, N.D., Cusumano, C.K., Hung, C.S., Chorell, E.,
Åberg, V., Walker, J.N., Seed, P.C., Almqvist, F., Chapman, M.R., Hultgren, S.J.,
2009. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and
bioﬁlm formation. Nat. Chem. Biol. 5, 913e919.
Çetinkaya, M., €Ozkan, H., K€oksal, N., Çelebi, S., Hacımustafaoglu, M., 2009. Com-
parison of serum amyloid A concentrations with those of C-reactive protein and
procalcitonin in diagnosis and follow-up of neonatal sepsis in premature in-
fants. J. Perinatol. 29, 225e231.
Chapin, J.W., Becker, G.L., Hulbert, B.J., Newland, M.C., Cuka, D.J., Wood, R.P.,
Shaw Jr., B.W., 1989. Comparison of Thromboelastograph and Sonoclot coagu-
lation analyzer for assessing coagulation status during orthotopic liver trans-
plantation. Transpl. Proc. 21, 3539.
Chee, Y.L., 2014. Coagulation. J. R. Coll. Phys. Edinb 44, 42e45.
Cheng, B., Gong, H., Xiao, H., Petersen, R.B., Zheng, L., Huang, K., 2013. Inhibiting
toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein
misfolding diseases. Biochim. Biophys. Acta 1830, 4860e4871.
Cheng, P.N., Liu, C., Zhao, M., Eisenberg, D., Nowick, J.S., 2012. Amyloid beta-sheet
mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat.
Chem. 4, 927e933.
Cheng, S.B., Nakashima, A., Sharma, S., 2016. Understanding pre-eclampsia using
Alzheimer's etiology: an intriguing viewpoint. Am. J. Reprod. Immunol. 75,
372e381.
Chernysh, I.N., Nagaswami, C., Purohit, P.K., Weisel, J.W., 2012. Fibrin clots are
equilibrium polymers that can be remodeled without proteolytic digestion. Sci.
Rep. 2, 879.
Chien, P., DePace, A.H., Collins, S.R., Weissman, J.S., 2003. Generation of prion
transmission barriers by mutational control of amyloid conformations. Nature
424, 948e951.
Chien, P., Weissman, J.S., DePace, A.H., 2004. Emerging principles of conformation-
based prion inheritance. Annu. Rev. Biochem. 73, 617e656.
Chiti, F., Dobson, C.M., 2006. Protein misfolding, functional amyloid, and human
disease. Annu. Rev. Biochem. 75, 333e366.
Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., Dobson, C.M.,
1999. Designing conditions for in vitro formation of amyloid protoﬁlaments and
ﬁbrils. Proc. Natl. Acad. Sci. U. S. A. 96, 3590e3594.
Chitlur, M., 2012. Challenges in the laboratory analyses of bleeding disorders.
Thromb. Res. 130, 1e6.
Chu, A.J., Rauci, M., Nwobi, O.I., Mathews, S.T., Beydoun, S., 2003. Novel anticoag-
ulant activity of polyamino acid offsets bacterial endotoxin-induced extrinsic
hypercoagulation: downregulation of monocytic tissue factor-dependent FVII
activation. J. Cardiovasc Pharmacol. 42, 477e483.
Chu, A.J., Wang, Z.G., Raicu, M., Beydoun, S., Ramos, N., 2001. Protamine inhibits
tissue factor-initiated extrinsic coagulation. Br. J. Haematol. 115, 392e399.
Cicarelli, D.D., Vieira, J.E., Bensenor, F.E., 2008. Comparison of C-reactive protein and
serum amyloid a protein in septic shock patients. Mediat. Inﬂamm. 2008,
631414.
Cilia La Corte, A.L., Philippou, H., Ari€ens, R.A.S., 2011. Role of ﬁbrin structure in
thrombosis and vascular disease. Adv. Protein Chem. Struct. Biol. 83, 75e127.
Cines, D.B., Lebedeva, T., Nagaswami, C., Hayes, V., Massefski, W., Litvinov, R.I.,
Rauova, L., Lowery, T.J., Weisel, J.W., 2014. Clot contraction: compression of
erythrocytes into tightly packed polyhedra and redistribution of platelets and
ﬁbrin. Blood 123, 1596e1603.
Coelho-Cerqueira, E., Pinheiro, A.S., Follmer, C., 2014. Pitfalls associated with the use
of Thioﬂavin-T to monitor anti-ﬁbrillogenic activity. Bioorg Med. Chem. Lett. 24,
3194e3198.
Cohen, F.E., Prusiner, S.B., 1998. Pathologic conformations of prion proteins. Annu.
Rev. Biochem. 67, 793e819.
Colby, D.W., Prusiner, S.B., 2011. Prions. Cold Spring Harb. Perspect. Biol. 3, a006833.
Collet, J.P., Lesty, C., Montalescot, G., Weisel, J.W., 2003. Dynamic changes of ﬁbrin
architecture during ﬁbrin formation and intrinsic ﬁbrinolysis of ﬁbrin-rich clots.
J. Biol. Chem. 278, 21331e21335.
Collet, J.P., Park, D., Lesty, C., Soria, J., Soria, C., Montalescot, G., Weisel, J.W., 2000.
Inﬂuence of ﬁbrin network conformation and ﬁbrin ﬁber diameter on ﬁbrino-
lysis speed: dynamic and structural approaches by confocal microscopy. Arte-
rioscler. Thromb. Vasc. Biol. 20, 1354e1361.
Collinge, J., 2010. Prion strain mutation and selection. Science 328, 1111e1112.
Collinge, J., Clarke, A.R., 2007. A general model of prion strains and their pathoge-
nicity,. Science 318, 930e936.
Colvin, M.T., Silvers, R., Frohm, B., Su, Y., Linse, S., Grifﬁn, R.G., 2015. High resolution
structural characterization of Abeta42 amyloid ﬁbrils by magic angle spinning
NMR. J. Am. Chem. Soc. 137, 7509e7518.
Cortes-Canteli, M., Mattei, L., Richards, A.T., Norris, E.H., Strickland, S., 2015. Fibrin
deposited in the Alzheimer's disease brain promotes neuronal degeneration.
Neurobiol. Aging 36, 608e617.
Cortes-Canteli, M., Paul, J., Norris, E.H., Bronstein, R., Ahn, H.J., Zamolodchikov, D.,
Bhuvanendran, S., Fenz, K.M., Strickland, S., 2010. Fibrinogen and beta-amyloid
association alters thrombosis and ﬁbrinolysis: a possible contributing factor to
Alzheimer's disease. Neuron 66, 695e709.
Cortes-Canteli, M., Strickland, S., 2009. Fibrinogen, a possible key player in Alz-
heimer's disease. J. Thromb. Haemost. 7, 146e150.
Cortes-Canteli, M., Zamolodchikov, D., Ahn, H.J., Strickland, S., Norris, E.H., 2012.
Fibrinogen and altered hemostasis in Alzheimer's disease. J. Alzheimers Dis. 32,
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e4132599e608.
Crapper McLachlan, D.R., Dalton, A.J., Kruck, T.P., Bell, M.Y., Smith, W.L., Kalow, W.,
Andrews, D.F., 1991. Intramuscular desferrioxamine in patients with Alz-
heimer's disease. Lancet 337, 1304e1308.
Cucurull-Sanchez, L., Spink, K.G., Moschos, S.A., 2012. Relevance of systems phar-
macology in drug discovery. Drug Discov. Today 17, 665e670.
Currin, A., Swainston, N., Day, P.J., Kell, D.B., 2015. Synthetic biology for the directed
evolution of protein biocatalysts: navigating sequence space intelligently.
Chem. Soc. Rev. 44, 1172e1239.
Cushman, M., Johnson, B.S., King, O.D., Gitler, A.D., Shorter, J., 2010. Prion-like dis-
orders: blurring the divide between transmissibility and infectivity. J. Cell Sci.
123, 1191e1201.
Das, D., Sidiq, S., Pal, S.K., 2015. A simple quantitative method to study protein-
lipopolysaccharide interactions by using liquid crystals. ChemPhysChem. 16,
753e760.
Dasari, M., Espargaro, A., Sabate, R., Lopez del Amo, J.M., Fink, U., Grelle, G.,
Bieschke, J., Ventura, S., Reif, B., 2011. Bacterial inclusion bodies of Alzheimer's
disease beta-amyloid peptides can be employed to study native-like aggrega-
tion intermediate states. ChemBioChem. 12, 407e423.
Davalos, D., Akassoglou, K., 2012. Fibrinogen as a key regulator of inﬂammation in
disease. Semin. Immunopathol. 34, 43e62.
de Groot, N.S., Sabate, R., Ventura, S., 2009. Amyloids in bacterial inclusion bodies.
Trends Biochem. Sci. 34, 408e416.
de Villiers, S., Swanepoel, A., Bester, J., Pretorius, E., 2016. Novel diagnostic and
monitoring tools in stroke: an individualized patient-centered precision med-
icine approach. J. Atheroscler. Thromb. 23, 493e504.
Dember, L.M., 2006. Amyloidosis-associated kidney disease. J. Am. Soc. Nephrol. 17,
3458e3471.
Derebe, M.G., Zlatkov, C.M., Gattu, S., Ruhn, K.A., Vaishnava, S., Diehl, G.E.,
MacMillan, J.B., Williams, N.S., Hooper, L.V., 2014. Serum amyloid A is a retinol
binding protein that transports retinol during bacterial infection. Elife 3,
e03206.
Di Carlo, M.G., Minicozzi, V., Fodera, V., Militello, V., Vetri, V., Morante, S., Leone, M.,
2015. Thioﬂavin T templates amyloid beta(1-40) conformation and aggregation
pathway. Biophys. Chem. 206, 1e11.
Dickneite, G., Herwald, H., Korte, W., Allanore, Y., Denton, C.P., Matucci Cerinic, M.,
2015. Coagulation factor XIII: a multifunctional transglutaminase with clinical
potential in a range of conditions. Thromb. Haemost. 113, 686e697.
Dobson, C.M., 2013. The amyloid phenomenon and its signiﬁcance. In: Otzen, D.E.
(Ed.), Amyloid Fibrils and Preﬁbrillar Aggregates: Molecular and Biological
Properties. Wiley-VCH, Weinheim, pp. 1e19.
Dobson, P.D., Kell, D.B., 2008. Carrier-mediated cellular uptake of pharmaceutical
drugs: an exception or the rule? Nat. Rev. Drug Disc. 7, 205e220.
Doig, A.J., Derreumaux, P., 2015. Inhibition of protein aggregation and amyloid
formation by small molecules. Curr. Opin. Struct. Biol. 30, 50e56.
Domingue, G.J., 2010. Demystifying pleomorphic forms in persistence and expres-
sion of disease: are they bacteria, and is peptidoglycan the solution? Discov.
Med. 10, 234e246.
Domingue, G.J., Woody, H.B., 1997. Bacterial persistence and expression of disease.
Clin. Microbiol. Rev. 10, 320e344.
Draxler, D.F., Medcalf, R.L., 2015. The ﬁbrinolytic system-more than ﬁbrinolysis?,.
Transfus. Med. Rev. 29, 102e109.
Driscoll, I., Troncoso, J.C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M.A.,
Ferrucci, L., Mathis, C.A., Klunk, W.E., O'Brien, R.J., Davatzikos, C., Wong, D.F.,
Resnick, S.M., 2012. Correspondence between in vivo (11)C-PiB-PET amyloid
imaging and postmortem, region-matched assessment of plaques. Acta Neu-
ropathol. 124, 823e831.
Duburcq, T., Tournoys, A., Gnemmi, V., Hubert, T., Gmyr, V., Pattou, F., Jourdain, M.,
2015. Impact of obesity on endotoxin-induced disseminated intravascular
coagulation. Shock 44, 341e347.
Durant, J.L., Leland, B.A., Henry, D.R., Nourse, J.G., 2002. Reoptimization of MDL keys
for use in drug discovery. J. Chem. Inf. Comput. Sci. 42, 1273e1280.
Ebert, E.C., Nagar, M., 2008. Gastrointestinal manifestations of amyloidosis. Am. J.
Gastroenterol. 103, 776e787.
Eguchi, Y., Gando, S., Ishikura, H., Saitoh, D., Mimuro, J., Takahashi, H., Kitajima, I.,
Tsuji, H., Matsushita, T., Tsujita, R., Nagao, O., Sakata, Y., 2014. Post-marketing
surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-
induced disseminated intravascular coagulation. J. Intensive Care 2, 30.
Ehrnhoefer, D.E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R.,
Engemann, S., Pastore, A., Wanker, E.E., 2008. EGCG redirects amyloidogenic
polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol.
15, 558e566.
Eisele, Y.S., Monteiro, C., Fearns, C., Encalada, S.E., Wiseman, R.L., Powers, E.T.,
Kelly, J.W., 2015. Targeting protein aggregation for the treatment of degenera-
tive diseases. Nat. Rev. Drug Discov. 14, 759e780.
Eisenberg, D., Jucker, M., 2012. The amyloid state of proteins in human diseases,.
Cell 148, 1188e1203.
Elsawy, M.A., Smith, A.M., Hodson, N., Squires, A., Miller, A.F., Saiani, A., 2016.
Modiﬁcation of beta-sheet forming peptide Hydrophobic face: effect on self-
assembly and gelation. Langmuir 32, 4917e4923.
Engel, M.F.M., Khemtemourian, L., Kleijer, C.C., Meeldijk, H.J.D., Jacobs, J.,
Verkleij, A.J., de Kruijff, B., Killian, J.A., Hoppener, J.W.M., 2008. Membrane
damage by human islet amyloid polypeptide through ﬁbril growth at the
membrane. Proc. Natl. Acad. Sci. U. S. A. 105, 6033e6038.
ESHRE CAPRI Workshop Group, 2013. Venous thromboembolism in women: aspeciﬁc reproductive health risk. Hum. Reprod. Update 19, 471e482.
Estrada, L.D., Yowtak, J., Soto, C., 2006. Protein misfolding disorders and rational
design of antimisfolding agents. Methods Mol. Biol. 340, 277e293.
Etienne, M.A., Edwin, N.J., Aucoin, J.P., Russo, P.S., McCarley, R.L., Hammer, R.P., 2007.
Beta-amyloid protein aggregation. Methods Mol. Biol. 386, 203e225.
Evans, M.L., Chorell, E., Taylor, J.D., Aden, J., Gotheson, A., Li, F., Koch, M., Sefer, L.,
Matthews, S.J., Wittung-Stafshede, P., Almqvist, F., Chapman, M.R., 2015. The
bacterial curli system possesses a potent and selective inhibitor of amyloid
formation. Mol. Cell. 57, 445e455.
Falsey, A.R., Walsh, E.E., Francis, C.W., Looney, R.J., Kolassa, J.E., Hall, W.J.,
Abraham, G.N., 2001. Response of C-reactive protein and serum amyloid A to
inﬂuenza A infection in older adults. J. Infect. Dis. 183, 995e999.
F€andrich, M., 2012. Oligomeric intermediates in amyloid formation: structure
determination and mechanisms of toxicity. J. Mol. Biol. 421, 427e440.
F€andrich, M., Meinhardt, J., Grigorieff, N., 2009. Structural polymorphism of Alz-
heimer Abeta and other amyloid ﬁbrils. Prion 3, 89e93.
Fernandez, M.S., 2014. Human IAPP amyloidogenic properties and pancreatic beta-
cell death. Cell Calcium 56, 416e427.
Ferri, F., Greco, M., Arcovito, G., De Spirito, M., Rocco, M., 2002. Structure of ﬁbrin
gels studied by elastic light scattering techniques: dependence of fractal
dimension, gel crossover length, ﬁber diameter, and ﬁber density on monomer
concentration. Phys. Rev. E 66, 011913.
Ferry, J.D., Morrison, P.R., 1947. Preparation and properties of serum and plasma
proteins. IX. Human ﬁbrin in the form of an elastic ﬁlm. J. Am. Chem. Soc. 69,
400e409.
Feughelman, M., 2002. Natural protein ﬁbers. J. Appl. Polym. Sci. 83, 489e507.
Fiala, M., Liu, Q.N., Sayre, J., Pop, V., Brahmandam, V., Graves, M.C., Vinters, H.V.,
2002. Cyclooxygenase-2-positive macrophages inﬁltrate the Alzheimer's dis-
ease brain and damage the blood-brain barrier. Eur. J. Clin. Investig. 32,
360e371.
Fine, J.M., Baillargeon, A.M., Renner, D.B., Hoerster, N.S., Tokarev, J., Colton, S.,
Pelleg, A., Andrews, A., Sparley, K.A., Krogh, K.M., Frey, W.H., Hanson, L.R., 2012.
Intranasal deferoxamine improves performance in radial arm water maze,
stabilizes HIF-1 alpha, and phosphorylates GSK3 beta in P301L tau transgenic
mice. Exp. Brain Res. 219, 381e390.
Flemming, A., 2014. Alzheimer's disease: abeta-ﬁbrinogen interaction inhibitor
improves cognition in AD. Nat. Rev. Drug Discov. 13, 494.
Foguel, D., Suarez, M.C., Ferrao-Gonzales, A.D., Porto, T.C., Palmieri, L.,
Einsiedler, C.M., Andrade, L.R., Lashuel, H.A., Lansbury, P.T., Kelly, J.W., Silva, J.L.,
2003. Dissociation of amyloid ﬁbrils of alpha-synuclein and transthyretin by
pressure reveals their reversible nature and the formation of water-excluded
cavities. Proc. Natl. Acad. Sci. U. S. A. 100, 9831e9836.
Fowler, D.M., Koulov, A.V., Balch, W.E., Kelly, J.W., 2007. Functional amyloidefrom
bacteria to humans. Trends Biochem. Sci. 32, 217e224.
Fowler, W.E., Hantgan, R.R., Hermans, J., Erickson, H.P., 1981. Structure of the ﬁbrin
protoﬁbril. Proc. Natl. Acad. Sci. U. S. A. 78, 4872e4876.
Freire, S., de Araujo, M.H., Al-Souﬁ, W., Novo, M., 2014. Photophysical study of
Thioﬂavin T as ﬂuorescence marker of amyloid ﬁbrils. Dyes Pigments 110,
97e105.
Frid, P., Anisimov, S.V., Popovic, N., 2007. Congo red and protein aggregation in
neurodegenerative diseases. Brain Res. Rev. 53, 135e160.
Frost, B., Diamond, M.I., 2010. Prion-like mechanisms in neurodegenerative dis-
eases. Nat. Rev. Neurosci. 11, 155e159.
Galant, N.J., Bugyei-Twum, A., Rakhit, R., Walsh, P., Sharpe, S., Arslan, P.E.,
Westermark, P., Higaki, J.N., Torres, R., Tapia, J., Chakrabartty, A., 2016. Sub-
stoichiometric inhibition of transthyretin misfolding by immune-targeting
sparsely populated misfolding intermediates: a potential diagnostic and ther-
apeutic for TTR amyloidoses. Sci. Rep. 6, 25080.
Gando, S., 2010. Microvascular thrombosis and multiple organ dysfunction syn-
drome. Crit. Care Med. 38, S35eS42.
Ganter, M.T., Hofer, C.K., 2008. Coagulation monitoring: current techniques and
clinical use of viscoelastic point-of-care coagulation devices. Anesth. Analg. 106,
1366e1375.
Gavrin, L.K., Denny, R.A., Saiah, E., 2012. Small molecules that target protein mis-
folding. J. Med. Chem. 55, 10823e10843.
Gill, A.C., 2014. beta-hairpin-mediated formation of structurally distinct multimers
of neurotoxic prion peptides. PLoS One 9, e87354.
Gillmore, J.D., Lachmann, H.J., Rowczenio, D., Gilbertson, J.A., Zeng, C.H., Liu, Z.H.,
Li, L.S., Wechalekar, A., Hawkins, P.N., 2009. Diagnosis, pathogenesis, treatment,
and prognosis of hereditary ﬁbrinogen A alpha-chain amyloidosis. J. Am. Soc.
Nephrol. 20, 444e451.
Glabe, C.G., 2006. Common mechanisms of amyloid oligomer pathogenesis in
degenerative disease. Neurobiol. Aging 27, 570e575.
G€oransson, A.L., Nilsson, K.P.R., Kågedal, K., Brorsson, A.C., 2012. Identiﬁcation of
distinct physiochemical properties of toxic preﬁbrillar species formed by Abeta
peptide variants. Biochem. Biophys. Res. Commun. 420, 895e900.
Grassi, J., Creminon, C., Frobert, Y., Fretier, P., Turbica, I., Rezaei, H., Hunsmann, G.,
Comoy, E., Deslys, J.P., 2000. Speciﬁc determination of the proteinase K-resistant
form of the prion protein using two-site immunometric assays. Application to
the post-mortem diagnosis of BSE. Arch. Virol. 197e205.
Greenwald, J., Riek, R., 2010. Biology of amyloid: structure, function, and regulation.
Structure 18, 1244e1260.
Grimmer, T., Henriksen, G., Wester, H.J., F€orstl, H., Klunk, W.E., Mathis, C.A., Kurz, A.,
Drzezga, A., 2009. Clinical severity of Alzheimer's disease is associated with PIB
uptake in PET. Neurobiol. Aging 30, 1902e1909.
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e41 33Groenning, M., 2010. Binding mode of Thioﬂavin T and other molecular probes in
the context of amyloid ﬁbrils-current status. J. Chem. Biol. 3, 1e18.
Groenning, M., Olsen, L., van de Weert, M., Flink, J.M., Frokjaer, S., Jorgensen, F.S.,
2007. Study on the binding of Thioﬂavin T to beta-sheet-rich and non-beta-
sheet cavities. J. Struct. Biol. 158, 358e369.
Groveman, B.R., Dolan, M.A., Taubner, L.M., Kraus, A., Wickner, R.B., Caughey, B.,
2014. Parallel in-register intermolecular beta-sheet architectures for prion-
seeded prion protein (PrP) amyloids. J. Biol. Chem. 289, 24129e24142.
Groveman, B.R., Kraus, A., Raymond, L.D., Dolan, M.A., Anson, K.J., Dorward, D.W.,
Caughey, B., 2015. Charge neutralization of the central lysine cluster in prion
protein (PrP) promotes PrP(Sc)-like folding of recombinant PrP amyloids. J. Biol.
Chem. 290, 1119e1128.
Guilbaud, J.B., Saiani, A., 2011. Using small angle scattering (SAS) to structurally
characterise peptide and protein self-assembled materials. Chem. Soc. Rev. 40,
1200e1210.
Guo, C., Wang, P., Zhong, M.L., Wang, T., Huang, X.S., Li, J.Y., Wang, Z.Y., 2013.
Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the
Alzheimer transgenic mouse brain. Neurochem. Int. 62, 165e172.
Guo, Z., Park, S., Yoon, J., Shin, I., 2014. Recent progress in the development of near-
infrared ﬂuorescent probes for bioimaging applications. Chem. Soc. Rev. 43,
16e29.
Gupta, A., Watkins, A., Thomas, P., Majer, R., Habubi, N., Morris, G., Pansari, K., 2005.
Coagulation and inﬂammatory markers in Alzheimer's and vascular dementia.
Int. J. Clin. Pract. 59, 52e57.
Gursky, O., 2015. Lipids in Protein Misfolding. In: Book Lipids in protein Misfolding.
Springer, City.
Guthold, M., Liu, W., Sparks, E.A., Jawerth, L.M., Peng, L., Falvo, M., Superﬁne, R.,
Hantgan, R.R., Lord, S.T., 2007. A comparison of the mechanical and structural
properties of ﬁbrin ﬁbers with other protein ﬁbers,. Cell Biochem. Biophys. 49,
165e181.
Haass, C., Selkoe, D.J., 2007. Soluble protein oligomers in neurodegeneration: les-
sons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8,
101e112.
Haenni, A., Lithell, H., 1996. Urapidil treatment decreases plasma ﬁbrinogen con-
centration in essential hypertension. Metabolism 45, 1221e1229.
Haidinger, M., Werzowa, J., Kain, R., Antlanger, M., Hecking, M., Pfaffenberger, S.,
Mascherbauer, J., Gremmel, T., Gilbertson, J.A., Rowczenio, D., Weichhart, T.,
Kopecky, C., H€orl, W.H., Hawkins, P.N., S€aemann, M.D., 2013. Hereditary
amyloidosis caused by R554L ﬁbrinogen Aalpha-chain mutation in a Spanish
family and review of the literature. Amyloid 20, 72e79.
Hamidi Asl, L., Liepnieks, J.J., Uemichi, T., Rebibou, J.M., Justrabo, E., Droz, D.,
Mousson, C., Chalopin, J.M., Benson, M.D., Delpech, M., Grateau, G., 1997. Renal
amyloidosis with a frame shift mutation in ﬁbrinogen aalpha-chain gene pro-
ducing a novel amyloid protein. Blood 90, 4799e4805.
Hammarstr€om, P., Lindgren, M., Nilsson, K.P.R., 2013. Fluorescence spectroscopy as a
tool to characterize amyloid oligomers and ﬁbrils. In: Otzen, D.E. (Ed.), Amyloid
Fibrils and Preﬁbrillar Aggregates: Molecular and Biological Properties. Wiley-
VCH, Weinheim, pp. 211e243.
Hanaki, M., Murakami, K., Akagi, K., Irie, K., 2016. Structural insights into mecha-
nisms for inhibiting amyloid beta42 aggregation by non-catechol-type ﬂavo-
noids. Bioorg Med. Chem. 24, 304e313.
Hann, M.M., 2011. Molecular obesity, potency and other addictions in drug dis-
covery. MedChemComm 2, 349e355.
H€ard, T., Lendel, C., 2012. Inhibition of amyloid formation. J. Mol. Biol. 421, 441e465.
Hardy, J., 2009. The amyloid hypothesis for Alzheimer's disease: a critical reap-
praisal. J. Neurochem. 110, 1129e1134.
Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress
and problems on the road to therapeutics. Science 297, 353e356.
Hardy, J.A., Higgins, G.A., 1992. Alzheimer's disease: the amyloid cascade hypoth-
esis. Science 256, 184e185.
Harrison, P.M., Bamborough, P., Daggett, V., Prusiner, S.B., Cohen, F.E., 1997. The
prion folding problem. Curr. Opin. Struct. Biol. 7, 53e59.
Hawkes, C.A., Ng, V., McLaurin, J., 2009. Small molecule inhibitors of A beta-
aggregation and neurotoxicity. Drug Dev. Res. 70, 111e124.
Hayakawa, M., Yamakawa, K., Saito, S., Uchino, S., Kudo, D., Iizuka, Y., Sanui, M.,
Takimoto, K., Mayumi, T., Ono, K., Japan Septic Disseminated Intravascular
Coagulation study, g, 2016. Recombinant human soluble thrombomodulin and
mortality in sepsis-induced disseminated intravascular coagulation. A multi-
centre retrospective study. Thromb. Haemost. 115.
Hayne, D.J., Lim, S., Donnelly, P.S., 2014. Metal complexes designed to bind to
amyloid-beta for the diagnosis and treatment of Alzheimer's disease. Chem.
Soc. Rev. 43, 6701e6715.
Hearle, J.W.S., 2000. A critical review of the structural mechanics of wool and hair
ﬁbres. Int. J. Biol. Macromol. 27, 123e138.
Hefti, F., Goure, W.F., Jerecic, J., Iverson, K.S., Walicke, P.A., Krafft, G.A., 2013. The case
for soluble Abeta oligomers as a drug target in Alzheimer's disease. Trends
Pharmacol. Sci. 34, 261e266.
Henzler Wildman, K.A., Lee, D.K., Ramamoorthy, A., 2002. Determination of alpha-
helix and beta-sheet stability in the solid state: a solid-state NMR investigation
of poly(L-alanine). Biopolymers 64, 246e254.
Herczenik, E., Gebbink, M.F.B.G., 2008. Molecular and cellular aspects of protein
misfolding and disease. FASEB J. 22, 2115e2133.
Herrup, K., 2015. The case for rejecting the amyloid cascade hypothesis. Nat. Neu-
rosci. 18, 794e799.
Hethershaw, E.L., La Corte, A.L.C., Duval, C., Ali, M., Grant, P.J., Ari€ens, R.A.S.,Philippou, H., 2014. The effect of blood coagulation factor XIII on ﬁbrin clot
structure and ﬁbrinolysis. J. Thromb. Haemost. 12, 197e205.
Hett, D.A., Walker, D., Pilkington, S.N., Smith, D.C., 1995. Sonoclot analysis. Br. J.
Anaesth. 75, 771e776.
Hickling, C., Toogood, H.S., Saiani, A., Scrutton, N.S., Miller, A.F., 2014. Nanoﬁbrillar
Peptide hydrogels for the immobilization of biocatalysts for chemical trans-
formations. Macromol. Rapid Commun. 35, 868e874.
Hieken, T.J., Chen, J., Hoskin, T.L., Walther-Antonio, M., Johnson, S., Ramaker, S.,
Xiao, J., Radisky, D.C., Knutson, K.L., Kalari, K.R., Yao, J.Z., Baddour, L.M., Chia, N.,
Degnim, A.C., 2016. The microbiome of aseptically collected human breast tis-
sue in benign and malignant disease. Sci. Rep. 6, 30751.
Hill, J.M., Lukiw, W.J., 2015. Microbial-generated amyloids and Alzheimer's disease
(AD). Front. Aging Neurosci. 7, 9.
Hirohata, M., Hasegawa, K., Tsutsumi-Yasuhara, S., Ohhashi, Y., Ookoshi, T., Ono, K.,
Yamada, M., Naiki, H., 2007. The anti-amyloidogenic effect is exerted against
Alzheimer's beta-amyloid ﬁbrils in vitro by preferential and reversible binding
of ﬂavonoids to the amyloid ﬁbril structure. Biochemistry 46, 1888e1899.
Hobbs, J.R., Morgan, A.D., 1963. Fluorescence microscopy with thioﬂavine-T in the
diagnosis of amyloid. J. Pathol. Bacteriol. 86, 437e442.
Hopkins, A.L., 2008. Network pharmacology: the next paradigm in drug discovery.
Nat. Chem. Biol. 4, 682e690.
Howie, A.J., 2015. Green (or apple-green) birefringence'' of Congo red-stained am-
yloid. Amyloid 22, 205e206.
Howie, A.J., Brewer, D.B., 2009. Optical properties of amyloid stained by Congo red:
history and mechanisms. Micron 40, 285e301.
Howie, A.J., Brewer, D.B., Howell, D., Jones, A.P., 2008. Physical basis of colors seen in
Congo red-stained amyloid in polarized light. Lab. Investig. 88, 232e242.
Howie, A.J., Owen-Casey, M.P., 2010. Discrepancies between descriptions and il-
lustrations of colours in Congo red-stained amyloid, and explanation of
discrepant colours. Amyloid 17, 109e117.
Hu, R., Zhang, M., Chen, H., Jiang, B., Zheng, J., 2015. Cross-seeding interaction be-
tween beta-amyloid and human islet amyloid polypeptide. ACS Chem. Neurosci.
6, 1759e1768.
Hu, Y., Bajorath, J., 2010. Polypharmacology directed compound data mining:
identiﬁcation of promiscuous chemotypes with different activity proﬁles and
comparison to approved drugs. J. Chem. Inf. Model 50, 2112e2118.
Hudson, S.A., Ecroyd, H., Kee, T.W., Carver, J.A., 2009. The thioﬂavin T ﬂuorescence
assay for amyloid ﬁbril detection can be biased by the presence of exogenous
compounds. FEBS J. 276, 5960e5972.
Hultman, K., Strickland, S., Norris, E.H., 2013. The APOE ε4/ε4 genotype potentiates
vascular ﬁbrin(ogen) deposition in amyloid-laden vessels in the brains of Alz-
heimer's disease patients. J. Cereb. Blood Flow. Metab. 33, 1251e1258.
Iadanza, M.G., Jackson, M.P., Radford, S.E., Ranson, N.A., 2016. MpUL-multi: software
for Calculation of Amyloid Fibril Mass per Unit Length from TB-TEM Images. Sci.
Rep. 6, 21078.
Ikonomovic, M.D., Abrahamson, E.E., Isanski, B.A., Debnath, M.L., Mathis, C.A.,
Dekosky, S.T., Klunk, W.E., 2006. X-34 labeling of abnormal protein aggregates
during the progression of Alzheimer's disease. Methods Enzymol. 412, 123e144.
Inbar, P., Yang, J., 2006. Inhibiting protein-amyloid interactions with small mole-
cules: a surface chemistry approach. Bioorg Med. Chem. Lett. 16, 1076e1079.
Inouye, H., Kirschner, D.A., 2005. Alzheimer's beta-amyloid: insights into ﬁbril
formation and structure from Congo red binding. Subcell. Biochem. 38,
203e224.
Inouye, H., Nguyen, J.T., Fraser, P.E., Shinchuk, L.M., Packard, A.B., Kirschner, D.A.,
2000. Histidine residues underlie Congo red binding to A beta analogs. Amyloid
7, 179e188.
Itzhaki, R.F., Lathe, R., Balin, B.J., Ball, M.J., Braak, H., Bearer, E.L., Bullido, M.J.,
Carter, C., Clerici, M., Cosby, S.L., Del Tredici, K., Field, H., Fulop, T., Grassi, C.,
Grifﬁn, W.S.T., Haas, J., Hudson, A.P., Kamer, A., Kell, D.B., Licastro, F.,
Letenneur, L., L€ovheim, H., Mancuso, R., Miklossy, J., Otth, C., Palamara, A.T.,
Perry, G., Preston, C., Pretorius, E., Strandberg, T., Tabet, N., Taylor-Robinson, S.D.,
Whittum-Hudson, J.A., 2016. Microbes and Alzheimer's disease. J. Alzheimers
Dis. 51, 979e984.
Ivanova, M.I., Sawaya, M.R., Gingery, M., Attinger, A., Eisenberg, D., 2004. An
amyloid-forming segment of beta 2-microglobulin suggests a molecular model
for the ﬁbril. Proc. Natl. Acad. Sci. 101, 10584e10589.
Jack, E., Newsome, M., Stockley, P.G., Radford, S.E., Middleton, D.A., 2006. The or-
ganization of aromatic side groups in an amyloid ﬁbril probed by solid-state 2H
and 19F NMR spectroscopy. J. Am. Chem. Soc. 128, 8098e8099.
Jahn, T.R., Tennent, G.A., Radford, S.E., 2008. A common beta-sheet architecture
underlies in vitro and in vivo beta2-microglobulin amyloid ﬁbrils. J. Biol. Chem.
283, 17279e17286.
Jameson, L.P., Smith, N.W., Dzyuba, S.V., 2012. Dye-binding assays for evaluation of
the effects of small molecule inhibitors on amyloid (abeta) self-assembly. ACS
Chem. Neurosci. 3, 807e819.
Janson, J., Ashley, R.H., Harrison, D., McIntyre, S., Butler, P.C., 1999. The mechanism
of islet amyloid polypeptide toxicity is membrane disruption by intermediate-
sized toxic amyloid particles. Diabetes 48, 491e498.
Jha, S., Patil, S.M., Gibson, J., Nelson, C.E., Alder, N.N., Alexandrescu, A.T., 2011.
Mechanism of amylin ﬁbrillization enhancement by Heparin. J. Biol. Chem. 286,
22894e22904.
Jha, S., Snell, J.M., Sheftic, S.R., Patil, S.M., Daniels, S.B., Kolling, F.W.,
Alexandrescu, A.T., 2014. pH dependence of amylin ﬁbrillization. Biochemistry
53, 300e310.
Jiao, S.S., Yao, X.Q., Liu, Y.H., Wang, Q.H., Zeng, F., Lu, J.J., Liu, J., Zhu, C., Shen, L.L.,
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e4134Liu, C.H., Wang, Y.R., Zeng, G.H., Parikh, A., Chen, J., Liang, C.R., Xiang, Y., Bu, X.L.,
Deng, J., Li, J., Xu, J., Zeng, Y.Q., Xu, X., Xu, H.W., Zhong, J.H., Zhou, H.D.,
Zhou, X.F., Wang, Y.J., 2015. Edaravone alleviates Alzheimer's disease-type pa-
thologies and cognitive deﬁcits. Proc. Natl. Acad. Sci. U. S. A. 112, 5225e5230.
Johansson, P.I., Stissing, T., Bochsen, L., Ostrowski, S.R., 2009. Thrombelastography
and tromboelastometry in assessing coagulopathy in trauma. Scand. J. Trauma
Resusc. Emerg. Med. 17, 45.
Jomova, K., Valko, M., 2011. Importance of iron chelation in free radical-induced
oxidative stress and human disease. Curr. Pharm. Des. 17, 3460e3473.
Jonas, S.M., Deserno, T.M., Buhimschi, C.S., Makin, J., Choma, M.A., Buhimschi, I.A.,
2016. Smartphone-based diagnostic for preeclampsia: an mHealth solution for
administering the Congo Red Dot (CRD) test in settings with limited resources.
J. Am. Med. Inf. Assoc. 23, 166e173.
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S.,
Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A.,
Liu, Y., Lu, Y., Bhangale, T., Graham, R.R., Huttenlocher, J., Bjornsdottir, G.,
Andreassen, O.A., Jonsson, E.G., Palotie, A., Behrens, T.W., Magnusson, O.T.,
Kong, A., Thorsteinsdottir, U., Watts, R.J., Stefansson, K., 2012. A mutation in APP
protects against Alzheimer's disease and age-related cognitive decline. Nature
488, 96e99.
Jucker, M., Walker, L.C., 2013. Self-propagation of pathogenic protein aggregates in
neurodegenerative diseases. Nature 501, 45e51.
Kammerer, R.A., Kostrewa, D., Zurdo, J., Detken, A., Garcia-Echeverría, C., Green, J.D.,
Müller, S.A., Meier, B.H., Winkler, F.K., Dobson, C.M., Steinmetz, M.O., 2004.
Exploring amyloid formation by a de novo design. Proc. Natl. Acad. Sci. U. S. A.
101, 4435e4440.
Kammerer, R.A., Steinmetz, M.O., 2006. De novo design of a two-stranded coiled-coil
switch peptide. J. Struct. Biol. 155, 146e153.
Kaneko, T., Wada, H., 2011. Diagnostic criteria and laboratory tests for disseminated
intravascular coagulation. J. Clin. Exp. Hematop 51, 67e76.
Kang, J., Han, K., 2001. The amide derivatives of chrysamine G bind to the beta-
amyloid ﬁbril. Bull. Korean Chem. Soc. 22, 1065e1066.
Kaprelyants, A.S., Gottschal, J.C., Kell, D.B., 1993. Dormancy in non-sporulating
bacteria. FEMS Microbiol. Rev. 10, 271e286.
Kaprelyants, A.S., Kell, D.B., 1992. Rapid assessment of bacterial viability and vitality
using rhodamine 123 and ﬂow cytometry. J. Appl. Bacteriol. 72, 410e422.
Kaprelyants, A.S., Kell, D.B., 1993. Dormancy in stationary-phase cultures of
Micrococcus luteus: ﬂow cytometric analysis of starvation and resuscitation.
Appl. Env. Microbiol. 59, 3187e3196.
Karamanos, T.K., Kalverda, A.P., Thompson, G.S., Radford, S.E., 2015. Mechanisms of
amyloid formation revealed by solution NMR. Prog. Nucl. Magn. Reson Spec-
trosc. 88e89, 86e104.
Karran, E., Hardy, J., 2014. A critique of the drug discovery and phase 3 clinical
programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol.
76, 185e205.
Karran, E., Mercken, M., De Strooper, B., 2011. The amyloid cascade hypothesis for
Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev.
Drug Discov. 10, 698e712.
Kasahara, K., Kaneda, M., Miki, T., Iida, K., Sekino-Suzuki, N., Kawashima, I.,
Suzuki, H., Shimonaka, M., Arai, M., Ohno-Iwashita, Y., Kojima, S., Abe, M.,
Kobayashi, T., Okazaki, T., Souri, M., Ichinose, A., Yamamoto, N., 2013. Clot
retraction is mediated by factor XIII-dependent ﬁbrin-alphaIIbbeta3-myosin
axis in platelet sphingomyelin-rich membrane rafts. Blood 122, 3340e3348.
Kasahara, K., Souri, M., Kaneda, M., Miki, T., Yamamoto, N., Ichinose, A., 2010.
Impaired clot retraction in factor XIII A subunit-deﬁcient mice. Blood 115,
1277e1279.
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W.,
Glabe, C.G., 2003. Common structure of soluble amyloid oligomers implies
common mechanism of pathogenesis. Science 300, 486e489.
Kayed, R., Lasagna-Reeves, C.A., 2013. Molecular mechanisms of amyloid oligomers
toxicity. J. Alzheimers Dis. 33 (Suppl. 1), S67eS78.
Kelenyi, G., 1967. Thioﬂavin S ﬂuorescent and Congo red anisotropic stainings in the
histologic demonstration of amyloid. Acta Neuropathol. 7, 336e348.
Kell, D.B., 2009. Iron behaving badly: inappropriate iron chelation as a major
contributor to the aetiology of vascular and other progressive inﬂammatory and
degenerative diseases. BMC Med. Genom 2, 2.
Kell, D.B., 2010. Towards a unifying, systems biology understanding of large-scale
cellular death and destruction caused by poorly liganded iron: Parkinson's,
Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others
as examples. Arch. Toxicol. 577, 825e889.
Kell, D.B., 2012. Scientiﬁc discovery as a combinatorial optimisation problem: how
best to navigate the landscape of possible experiments? Bioessays 34, 236e244.
Kell, D.B., 2013. Finding novel pharmaceuticals in the systems biology era using
multiple effective drug targets, phenotypic screening, and knowledge of
transporters: where drug discovery went wrong and how to ﬁx it. FEBS J. 280,
5957e5980.
Kell, D.B., 2015. The transporter-mediated cellular uptake of pharmaceutical drugs
is based on their metabolite-likeness and not on their bulk biophysical prop-
erties: Towards a systems pharmacology. Perspect. Sci. 6, 66e83.
Kell, D.B., Dobson, P.D., Bilsland, E., Oliver, S.G., 2013. The promiscuous binding of
pharmaceutical drugs and their transporter-mediated uptake into cells: what
we (need to) know and how we can do so,. Drug Disc Today 18, 218e239.
Kell, D.B., Dobson, P.D., Oliver, S.G., 2011. Pharmaceutical drug transport: the issues
and the implications that it is essentially carrier-mediated only. Drug Disc
Today 16, 704e714.Kell, D.B., Goodacre, R., 2014. Metabolomics and systems pharmacology: why and
how to model the human metabolic network for drug discovery. Drug Disc
Today 19, 171e182.
Kell, D.B., Kenny, L.C., 2016. A dormant microbial component in the development of
pre-eclampsia. BioRxiv Prepr. bioRxiv 057356.
Kell, D.B., Oliver, S.G., 2014. How drugs get into cells: tested and testable predictions
to help discriminate between transporter-mediated uptake and lipoidal bilayer
diffusion. Front. Pharmacol. 5, 231.
Kell, D.B., Potgieter, M., Pretorius, E., 2015. Individuality, phenotypic differentiation,
dormancy and ‘persistence’ in culturable bacterial systems: commonalities
shared by environmental, laboratory, and clinical microbiology. F1000Research
4, 179.
Kell, D.B., Pretorius, E., 2015a. On the translocation of bacteria and their lipopoly-
saccharides between blood and peripheral locations in chronic, inﬂammatory
diseases: the central roles of LPS and LPS-induced cell death. Integr. Biol. 7,
1339e1377.
Kell, D.B., Pretorius, E., 2015b. The simultaneous occurrence of both hypercoagu-
lability and hypoﬁbrinolysis in blood and serum during systemic inﬂammation,
and the roles of iron and ﬁbrin(ogen). Integr. Biol. 7, 24e52.
Kell, D.B., Pretorius, E., 2016. Substoichiometric molecular control and ampliﬁcation
of the initiation and nature of amyloid ﬁbril formation: lessons from and for
blood clotting. bioRxiv Prepr. Biorxiv. 054734.
Khurana, R., Coleman, C., Ionescu-Zanetti, C., Carter, S.A., Krishna, V., Grover, R.K.,
Roy, R., Singh, S., 2005. Mechanism of thioﬂavin T binding to amyloid ﬁbrils.
J. Struct. Biol. 151, 229e238.
Kim, O.V., Litvinov, R.I., Weisel, J.W., Alber, M.S., 2014. Structural basis for the
nonlinear mechanics of ﬁbrin networks under compression. Biomaterials 35,
6739e6749.
Kjellberg, U., Hellgren, M., 2000. Sonoclot signature during normal pregnancy.
Intensive Care Med. 26, 206e211.
Klein, R.D., Hultgren, S.J., 2015. Chaos controlled: discovery of a powerful amyloid
inhibitor. Mol. Cell. 57, 391e393.
Klement, K., Wieligmann, K., Meinhardt, J., Hortschansky, P., Richter, W.,
F€andrich, M., 2007. Effect of different salt ions on the propensity of aggregation
and on the structure of Alzheimer's abeta(1-40) amyloid ﬁbrils. J. Mol. Biol. 373,
1321e1333.
Klingstedt, T., Åslund, A., Simon, R.A., Johansson, L.B.G., Mason, J.J., Nystr€om, S.,
Hammarstr€om, P., Nilsson, K.P.R., 2011. Synthesis of a library of oligothiophenes
and their utilization as ﬂuorescent ligands for spectral assignment of protein
aggregates. Org. Biomol. Chem. 9, 8356e8370.
Klingstedt, T., Blechschmidt, C., Nogalska, A., Prokop, S., Haggqvist, B.,
Danielsson, O., Engel, W.K., Askanas, V., Heppner, F.L., Nilsson, K.P.R., 2013a.
Luminescent conjugated oligothiophenes for sensitive ﬂuorescent assignment
of protein inclusion bodies. Chembiochem 14, 607e616.
Klingstedt, T., Nilsson, K.P., 2012. Luminescent conjugated poly- and oligo-
thiophenes: optical ligands for spectral assignment of a plethora of protein
aggregates. Biochem. Soc. Trans. 40, 704e710.
Klingstedt, T., Shirani, H., Åslund, K.O.A., Cairns, N.J., Sigurdson, C.J., Goedert, M.,
Nilsson, K.P.R., 2013b. The structural basis for optimal performance of
oligothiophene-based ﬂuorescent amyloid ligands: conformational ﬂexibility is
essential for spectral assignment of a diversity of protein aggregates. Chemistry
19, 10179e10192.
Klingstedt, T., Shirani, H., Mahler, J., Wegenast-Braun, B.M., Nystr€om, S., Goedert, M.,
Jucker, M., Nilsson, K.P.R., 2015. Distinct Spacing Between Anionic Groups: An
Essential Chemical Determinant for Achieving Thiophene-Based Ligands to
Distinguish beta-Amyloid or Tau Polymorphic Aggregates. Chemistry 21,
9072e9082.
Klunk, W.E., Debnath, M.L., Pettegrew, J.W., 1994. Development of small molecule
probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol. Aging 15,
691e698.
Knowles, T.P.J., Vendruscolo, M., Dobson, C.M., 2014. The amyloid state and its as-
sociation with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384e396.
Koch, L., Hofer, S., Weigand, M.A., Frommhold, D., Poeschl, J., 2009. Lipopolysac-
charide-induced activation of coagulation in neonatal cord and adult blood
monitored by thrombelastography. Thromb. Res. 124, 463e467.
Kodali, R., Williams, A.D., Chemuru, S., Wetzel, R., 2010. Abeta(1-40) forms ﬁve
distinct amyloid structures whose beta-sheet contents and ﬁbril stabilities are
correlated. J. Mol. Biol. 401, 503e517.
Kollmer, M., Meinhardt, K., Haupt, C., Liberta, F., Wulff, M., Linder, J., Handl, L.,
Heinrich, L., Loos, C., Schmidt, M., Syrovets, T., Simmet, T., Westermark, P.,
Westermark, G.T., Horn, U., Schmidt, V., Walther, P., F€andrich, M., 2016. Electron
tomography reveals the ﬁbril structure and lipid interactions in amyloid de-
posits. Proc. Natl. Acad. Sci. 113, 5604e5609.
Konarkowska, B., Aitken, J.F., Kistler, J., Zhang, S., Cooper, G.J.S., 2006. The aggre-
gation potential of human amylin determines its cytotoxicity towards islet beta-
cells. FEBS J. 273, 3614e3624.
Kovalska, V.B., Losytskyy, M.Y., Tolmachev, O.I., Slominskii, Y.L., Segers-Nolten, G.M.,
Subramaniam, V., Yarmoluk, S.M., 2012. Tri- and pentamethine cyanine dyes for
ﬂuorescent detection of alpha-synuclein oligomeric aggregates. J. Fluoresc. 22,
1441e1448.
Kranenburg, O., Bouma, B., Kroon-Batenburg, L.M.J., Reijerkerk, A., Wu, Y.P.,
Voest, E.E., Gebbink, M.F.B.G., 2002. Tissue-type plasminogen activator is a
multiligand cross-beta structure receptor. Curr. Biol. 12, 1833e1839.
Krebs, M.R.H., Bromley, E.H., Donald, A.M., 2005. The binding of thioﬂavin-T to
amyloid ﬁbrils: localisation and implications. J. Struct. Biol. 149, 30e37.
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e41 35Kreplak, L., Doucet, J., Dumas, P., Briki, F., 2004. New aspects of the alpha-helix to
beta-sheet transition in stretched hard alpha-keratin ﬁbers. Biophys. J. 87,
640e647.
Krishnan, R., Tsubery, H., Proschitsky, M.Y., Asp, E., Lulu, M., Gilead, S., Gartner, M.,
Waltho, J.P., Davis, P.J., Hounslow, A.M., Kirschner, D.A., Inouye, H., Myszka, D.G.,
Wright, J., Solomon, B., Fisher, R.A., 2014. A bacteriophage capsid protein pro-
vides a general amyloid interaction motif (GAIM) that binds and remodels
misfolded protein assemblies. J. Mol. Biol. 426, 2500e2519.
Kunitada, S., FitzGerald, G.A., Fitzgerald, D.J., 1992. Inhibition of clot lysis and
decreased binding of tissue-type plasminogen activator as a consequence of clot
retraction. Blood 79, 1420e1427.
Kuznetsova, I.M., Sulatskaya, A.I., Maskevich, A.A., Uversky, V.N., Turoverov, K.K.,
2016. High Fluorescence Anisotropy of Thioﬂavin T in Aqueous Solution
Resulting from Its Molecular Rotor Nature. Anal. Chem. 88, 718e724.
Kuznetsova, I.M., Sulatskaya, A.I., Uversky, V.N., Turoverov, K.K., 2012a. Analyzing
thioﬂavin T binding to amyloid ﬁbrils by an equilibrium microdialysis-based
technique. PLoS One 7, e30724.
Kuznetsova, I.M., Sulatskaya, A.I., Uversky, V.N., Turoverov, K.K., 2012b. A new trend
in the experimental methodology for the analysis of the thioﬂavin T binding to
amyloid ﬁbrils. Mol. Neurobiol. 45, 488e498.
Lackner, H., Hunt, V., Zucker, M.B., Pearson, J., 1970. Abnormal ﬁbrin ultrastructure,
polymerization, and clot retraction in multiple myeloma. Br. J. Haematol. 18,
625e636.
Ladner-Keay, C.L., Grifﬁth, B.J., Wishart, D.S., 2014. Shaking alone induces de novo
conversion of recombinant prion proteins to beta-sheet rich oligomers and ﬁ-
brils. PLoS One 9, e98753.
Landsem, A., Fure, H., Christiansen, D., Nielsen, E.W., Østerud, B., Mollnes, T.E.,
Brekke, O.L., 2015. The key roles of complement and tissue factor in Escherichia
coli-induced coagulation in human whole blood. Clin. Exp. Immunol. 182,
81e89.
Lang, E., Bissinger, R., Fajol, A., Salker, M.S., Singh, Y., Zelenak, C., Ghashghaeinia, M.,
Gu, S., Jilani, K., Lupescu, A., Reyskens, K.M., Ackermann, T.F., Foller, M.,
Schleicher, E., Shefﬁeld, W.P., Arthur, J.S., Lang, F., Qadri, S.M., 2015a. Accelerated
apoptotic death and in vivo turnover of erythrocytes in mice lacking functional
mitogen- and stress-activated kinase MSK1/2. Sci. Rep. 5, 17316.
Lang, E., Qadri, S.M., Lang, F., 2012. Killing me softly - Suicidal erythrocyte death. Int.
J. Biochem. Cell Biol. 44, 1236e1243.
Lang, E., Zelenak, C., Eberhard, M., Bissinger, R., Rotte, A., Ghashghaeinia, M.,
Lupescu, A., Lang, F., Qadri, S.M., 2015b. Impact of cyclin-dependent kinase
CDK4 inhibition on eryptosis. Cell Physiol. Biochem. 37, 1178e1186.
Langkilde, A.E., Morris, K.L., Serpell, L.C., Svergun, D.I., Vestergaard, B., 2015. The
architecture of amyloid-like peptide ﬁbrils revealed by X-ray scattering,
diffraction and electron microscopy. Acta Crystallogr. D. Biol. Crystallogr. 71,
882e895.
Lannergård, A., Larsson, A., Friman, G., Ewald, U., 2008. Human serum amyloid A
(SAA) and high sensitive C-reactive protein (hsCRP) in preterm newborn infants
with nosocomial infections. Acta Paediatr. 97, 1061e1065.
Lannergård, A., Viberg, A., Cars, O., Karlsson, M.O., Sandstr€om, M., Larsson, A., 2009.
The time course of body temperature, serum amyloid A protein, C-reactive
protein and interleukin-6 in patients with bacterial infection during the initial 3
days of antibiotic therapy. Scand. J. Infect. Dis. 41, 663e671.
Le, N.T., Narkiewicz, J., Aulic, S., Salzano, G., Tran, H.T., Scaini, D., Moda, F.,
Giachin, G., Legname, G., 2015. Synthetic prions and other human neurode-
generative proteinopathies. Virus Res. 207, 25e37.
Lee, J.W., Namkoong, H., Kim, H.K., Kim, S., Hwang, D.W., Na, H.R., Ha, S.A., Kim, J.R.,
Kim, J.W., 2007. Fibrinogen gamma-A chain precursor in CSF: a candidate
biomarker for Alzheimer's disease. BMC Neurol. 7, 14.
Lehar, J., Stockwell, B.R., Giaever, G., Nislow, C., 2008. Combination chemical ge-
netics. Nat. Chem. Biol. 4, 674e681.
Lehar, J., Zimmermann, G.R., Krueger, A.S., Molnar, R.A., Ledell, J.T., Heilbut, A.M.,
Short 3rd, G.F., Giusti, L.C., Nolan, G.P., Magid, O.A., Lee, M.S., Borisy, A.A.,
Stockwell, B.R., Keith, C.T., 2007. Chemical combination effects predict con-
nectivity in biological systems. Mol. Syst. Biol. 3, 80.
Letcher, R.L., Chien, S., Pickering, T.G., Sealey, J.E., Laragh, J.H., 1981. Direct rela-
tionship between blood pressure and blood viscosity in normal and hyper-
tensive subjects. Role of ﬁbrinogen and concentration. Am. J. Med. 70,
1195e1202.
Levi, M., 2015. Recombinant soluble thrombomodulin: coagulation takes another
chance to reduce sepsis mortality. J. Thromb. Haemost. 13, 505e507.
Levi, M., van der Poll, T., 2013a. Disseminated intravascular coagulation: a review for
the internist. Int. Emerg. Med. 8, 23e32.
Levi, M., Van Der Poll, T., 2013b. Thrombomodulin in sepsis. Minerva Anestesiol. 79,
294e298.
Levine, D.J., St€ohr, J., Falese, L.E., Ollesch, J., Wille, H., Prusiner, S.B., Long, J.R., 2015.
Mechanism of scrapie prion precipitation with phosphotungstate anions. ACS
Chem. Biol. 10, 1269e1277.
LeVine 3rd, H., 1993. Thioﬂavine T interaction with synthetic Alzheimer's disease
beta-amyloid peptides: detection of amyloid aggregation in solution. Protein
Sci. 2, 404e410.
LeVine 3rd, H., 1997. Stopped-ﬂow kinetics reveal multiple phases of thioﬂavin T
binding to Alzheimer beta (1-40) amyloid ﬁbrils. Arch. Biochem. Biophys. 342,
306e316.
LeVine 3rd, H., 1999. Quantiﬁcation of beta-sheet amyloid ﬁbril structures with
thioﬂavin T. Methods Enzymol. 309, 274e284.
LeVine 3rd, H., Ding, Q., Walker, J.A., Voss, R.S., Augelli-Szafran, C.E., 2009. Clioquinoland other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly.
Neurosci. Lett. 465, 99e103.
Li, D., Jones, E.M., Sawaya, M.R., Furukawa, H., Luo, F., Ivanova, M., Sievers, S.A.,
Wang, W., Yaghi, O.M., Liu, C., Eisenberg, D.S., 2014. Structure-based design of
functional amyloid materials. J. Am. Chem. Soc. 136, 18044e18051.
Lin, I.H., Miller, D.S., Bertics, P.J., Murphy, C.J., de Pablo, J.J., Abbott, N.L., 2011.
Endotoxin-induced structural transformations in liquid crystalline droplets.
Science 332, 1297e1300.
Lindberg, D.J., Esbjorner, E.K., 2016. Detection of amyloid-beta ﬁbrils using the DNA-
intercalating dye YOYO-1: Binding mode and ﬁbril formation kinetics. Biochem.
Biophys. Res. Commun. 469, 313e318.
Lindberg, D.J., Wranne, M.S., Gilbert Gatty, M., Westerlund, F., Esbj€orner, E.K., 2015.
Steady-state and time-resolved Thioﬂavin-T ﬂuorescence can report on
morphological differences in amyloid ﬁbrils formed by Abeta(1-40) and
Abeta(1-42). Biochem. Biophys. Res. Commun. 458, 418e423.
Link, C.D., Johnson, C.J., Fonte, V., Paupard, M., Hall, D.H., Styren, S., Mathis, C.A.,
Klunk, W.E., 2001. Visualization of ﬁbrillar amyloid deposits in living, transgenic
Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neuro-
biol. Aging 22, 217e226.
Lipinski, B., Pretorius, E., 2012. Hydroxyl radical-modiﬁed ﬁbrinogen as a marker of
thrombosis: the role of iron. Hematology 17, 241e247.
Lipinski, B., Pretorius, E., 2013a. Iron-induced ﬁbrin in cardiovascular disease. Curr.
Neurovasc. Res. 10, 269e274.
Lipinski, B., Pretorius, E., 2013b. The role of iron-induced ﬁbrin in the pathogenesis
of Alzheimer's disease and the protective role of magnesium,. Front. Hum.
Neurosci. 7, 735.
Lipinski, B., Pretorius, E., Oberholzer, H.M., van der Spuy, W.J., 2012a. Interaction of
ﬁbrin with red blood cells: the role of iron. Ultrastruct. Pathol. 36, 79e84.
Lipinski, B., Pretorius, E., Oberholzer, H.M., Van Der Spuy, W.J., 2012b. Iron enhances
generation of ﬁbrin ﬁbers in human blood: Implications for pathogenesis of
stroke. Microsc. Res. Tech. 75, 1185e1190.
Little, C.S., Hammond, C.J., MacIntyre, A., Balin, B.J., Appelt, D.M., 2004. Chlamydia
pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice.
Neurobiol. Aging 25, 419e429.
Litvinov, R.I., Faizullin, D.A., Zuev, Y.F., Weisel, J.W., 2012. The alpha-helix to beta-
sheet transition in stretched and compressed hydrated ﬁbrin clots. Biophys. J.
103, 1020e1027.
Litvinov, R.I., Yakovlev, S., Tsurupa, G., Gorkun, O.V., Medved, L., Weisel, J.W., 2007.
Direct evidence for speciﬁc interactions of the ﬁbrinogen alphaC-domains with
the central E region and with each other. Biochemistry 46, 9133e9142.
Liu, B., Moloney, A., Meehan, S., Morris, K., Thomas, S.E., Serpell, L.C., Hider, R.,
Marciniak, S.J., Lomas, D.A., Crowther, D.C., 2011. Iron promotes the toxicity of
amyloid beta peptide by impeding its ordered aggregation. J. Biol. Chem. 286,
4248e4256.
Liu, W., Carlisle, C.R., Sparks, E.A., Guthold, M., 2010. The mechanical properties of
single ﬁbrin ﬁbers,. J. Thromb. Haemost. 8, 1030e1036.
Liu, Y., Cui, D., Hoshii, Y., Kawano, H., Une, Y., Gondo, T., Ishihara, T., 2007. Induction
of murine AA amyloidosis by various homogeneous amyloid ﬁbrils and
amyloid-like synthetic peptides. Scand. J. Immunol. 66, 495e500.
Longstaff, C., Kolev, K., 2015. Basic mechanisms and regulation of ﬁbrinolysis.
J. Thromb. Haemost. 13 (Suppl. 1), S98eS105.
Lopez, L.C., Dos-Reis, S., Espargaro, A., Carrodeguas, J.A., Maddelein, M.L., Ventura, S.,
Sancho, J., 2012. Discovery of novel inhibitors of amyloid beta-peptide 1-42
aggregation. J. Med. Chem. 55, 9521e9530.
Lorenzo, A., Razzaboni, B., Weir, G.C., Yankner, B.A., 1994. Pancreatic islet cell
toxicity of amylin associated with type-2 diabetes mellitus. Nature 368,
756e760.
Lowe, A.M., Abbott, N.L., 2012. Liquid Crystalline Materials for Biological Applica-
tions. Chem. Mater 24, 746e758.
Lundmark, K., Westermark, G.T., Nystrom, S., Murphy, C.L., Solomon, A.,
Westermark, P., 2002. Transmissibility of systemic amyloidosis by a prion-like
mechanism. Proc. Natl. Acad. Sci. U. S. A. 99, 6979e6984.
Lundmark, K., Westermark, G.T., Olsen, A., Westermark, P., 2005. Protein ﬁbrils in
nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a
disease mechanism. Proc. Natl. Acad. Sci. U. S. A. 102, 6098e6102.
Ly, P.T.T., Cai, F., Song, W., 2011. Detection of neuritic plaques in Alzheimer's disease
mouse model. J. Vis. Exp. 53.
Maezawa, I., Hong, H.S., Liu, R., Wu, C.Y., Cheng, R.H., Kung, M.P., Kung, H.F.,
Lam, K.S., Oddo, S., Laferla, F.M., Jin, L.W., 2008. Congo red and thioﬂavin-T
analogs detect Abeta oligomers. J. Neurochem. 104, 457e468.
Magnusson, K., Simon, R., Sjolander, D., Sigurdson, C.J., Hammarstrom, P.,
Nilsson, K.P., 2014. Multimodal ﬂuorescence microscopy of prion strain speciﬁc
PrP deposits stained by thiophene-based amyloid ligands. Prion 8, 319e329.
Maji, S.K., Wang, L., Greenwald, J., Riek, R., 2009. Structure-activity relationship of
amyloid ﬁbrils. FEBS Lett. 583, 2610e2617.
Makarava, N., Baskakov, I.V., 2008. The same primary structure of the prion protein
yields two distinct self-propagating states. J. Biol. Chem. 283, 15988e15996.
Malecki, E.A., Connor, J.R., 2002. The case for iron chelation and/or antioxidant
therapy in Alzheimer's disease. Drug Dev. Res. 56, 526e530.
Malle, E., De Beer, F.C., 1996. Human serum amyloid A (SAA) protein: a prominent
acute-phase reactant for clinical practice. Eur. J. Clin. Investig. 26, 427e435.
Mangin, M., Sinha, R., Fincher, K., 2014. Inﬂammation and vitamin D: the infection
connection. Inﬂamm. Res. 63, 803e819.
Marioni, R.E., Stewart, M.C., Murray, G.D., Deary, I.J., Fowkes, F.G., Lowe, G.D.,
Rumley, A., Price, J.F., 2009. Peripheral levels of ﬁbrinogen, C-reactive protein,
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e4136and plasma viscosity predict future cognitive decline in individuals without
dementia. Psychosom. Med. 71, 901e906.
Marzban, L., Park, K., Verchere, C.B., 2003. Islet amyloid polypeptide and type 2
diabetes. Exp. Gerontol. 38, 347e351.
Mathis, C.A., Lopresti, B.J., Klunk, W.E., 2007. Impact of amyloid imaging on drug
development in Alzheimer's disease. Nucl. Med. Biol. 34, 809e822.
Mathis, C.A., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W.E., 2003.
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as
amyloid imaging agents. J. Med. Chem. 46, 2740e2754.
Mattman, L., 2001. Cell Wall Deﬁcient Forms: Stealth Pathogens, third ed. CRC Press,
Boca Raton.
McKoy, A.F., Chen, J., Schupbach, T., Hecht, M.H., 2012. A novel inhibitor of amyloid
beta (Abeta) peptide aggregation: from high throughput screening to efﬁcacy in
an animal model of Alzheimer disease. J. Biol. Chem. 287, 38992e39000.
McMichael, M.A., Smith, S.A., 2011. Viscoelastic coagulation testing: technology,
applications, and limitations. Veterinary Clin. Pathol. Am. Soc. Veterinary Clin.
Pathol. 40, 140e153.
Medved, L., Nieuwenhuizen, W., 2003. Molecular mechanisms of initiation of
ﬁbrinolysis by ﬁbrin. Thromb. Haemost. 89, 409e419.
Meier, J.J., Kayed, R., Lin, C.Y., Gurlo, T., Haataja, L., Jayasinghe, S., Langen, R.,
Glabe, C.G., Butler, P.C., 2006. Inhibition of human IAPP ﬁbril formation does not
prevent beta-cell death: evidence for distinct actions of oligomers and ﬁbrils of
human IAPP. Am. J. Physiol. Endocrinol. Metab. 291, E1317eE1324.
Meinhardt, J., Sachse, C., Hortschansky, P., Grigorieff, N., F€andrich, M., 2009.
Abeta(1-40) ﬁbril polymorphism implies diverse interaction patterns in amy-
loid ﬁbrils. J. Mol. Biol. 386, 869e877.
Mestres, J., Gregori-Puigjane, E., 2009. Conciliating binding efﬁciency and poly-
pharmacology. Trends Pharmacol. Sci. 30, 470e474.
Meyer-Luehmann, M., Spires-Jones, T.L., Prada, C., Garcia-Alloza, M., de Calignon, A.,
Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D.M., Bacskai, B.J.,
Hyman, B.T., 2008. Rapid appearance and local toxicity of amyloid-beta plaques
in a mouse model of Alzheimer's disease. Nature 451, 720e724.
Middleton, C.T., Marek, P., Cao, P., Chiu, C.C., Singh, S., Woys, A.M., de Pablo, J.J.,
Raleigh, D.P., Zanni, M.T., 2012. Two-dimensional infrared spectroscopy reveals
the complex behaviour of an amyloid ﬁbril inhibitor. Nat. Chem. 4, 355e360.
Miklossy, J., 2008. Chronic inﬂammation and amyloidogenesis in Alzheimer's dis-
ease e role of Spirochetes. J. Alzheimers Dis. 13, 381e391.
Miklossy, J., 2011. Alzheimer's disease - a neurospirochetosis. Analysis of the evi-
dence following Koch's and Hill's criteria. J. Neuroinﬂammation 8, 90.
Miklossy, J., Kis, A., Radenovic, A., Miller, L., Forro, L., Martins, R., Reiss, K.,
Darbinian, N., Darekar, P., Mihaly, L., Khalili, K., 2006. Beta-amyloid deposition
and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol. Aging
27, 228e236.
Miller, D.S., Abbott, N.L., 2013. Inﬂuence of droplet size, pH and ionic strength on
endotoxin-triggered ordering transitions in liquid crystalline droplets. Soft
Matter 9, 374e382.
Mimuro, J., Takahashi, H., Kitajima, I., Tsuji, H., Eguchi, Y., Matsushita, T., Kuroda, T.,
Sakata, Y., 2013. Impact of recombinant soluble thrombomodulin (thrombo-
modulin alfa) on disseminated intravascular coagulation. Thromb. Res. 131,
436e443.
Minter, M.R., Taylor, J.M., Crack, P.J., 2016. The contribution of neuroinﬂammation to
amyloid toxicity in Alzheimer's disease. J. Neurochem. 136, 457e474.
Miranda, S., Opazo, C., Larrondo, L.F., Munoz, F.J., Ruiz, F., Leighton, F., Inestrosa, N.C.,
2000. The role of oxidative stress in the toxicity induced by amyloid beta-
peptide in Alzheimer's disease. Progr Neurobiol. 62, 633e648.
Miserez, A., Guerette, P.A., 2013. Phase transition-induced elasticity of alpha-helical
bioelastomeric ﬁbres and networks. Chem. Soc. Rev. 42, 1973e1995.
Mishra, R.S., Basu, S., Gu, Y., Luo, X., Zou, W.Q., Mishra, R., Li, R., Chen, S.G.,
Gambetti, P., Fujioka, H., Singh, N., 2004. Protease-resistant human prion pro-
tein and ferritin are cotransported across Caco-2 epithelial cells: implications
for species barrier in prion uptake from the intestine. J. Neurosci. 24,
11280e11290.
Moda, F., Le, T.N., Aulic, S., Bistaffa, E., Campagnani, I., Virgilio, T., Indaco, A.,
Palamara, L., Andreoletti, O., Tagliavini, F., Legname, G., 2015. Synthetic prions
with novel strain-speciﬁed properties. PLoS Pathog. 11, e1005354.
Monroe, D.M., Key, N.S., 2007. The tissue factor-factor VIIa complex: procoagulant
activity, regulation, and multitasking. J. Thromb. Haemost. 5, 1097e1105.
Morales, R., Callegari, K., Soto, C., 2015. Prion-like features of misfolded Abeta and
tau aggregates. Virus Res. 207, 106e112.
Morales, R., Moreno-Gonzalez, I., Soto, C., 2013. Cross-Seeding of Misfolded Pro-
teins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases.
PLoS Pathog. 9.
Morell, M., Bravo, R., Espargaro, A., Sisquella, X., Aviles, F.X., Fernandez-Busquets, X.,
Ventura, S., 2008. Inclusion bodies: speciﬁcity in their aggregation process and
amyloid-like structure. Biochim. Biophys. Acta 1783, 1815e1825.
Moreno-Gonzalez, I., Soto, C., 2011. Misfolded protein aggregates: Mechanisms,
structures and potential for disease transmission. Seminars Cell & Dev. Biol. 22,
482e487.
Morris, K.L., Serpell, L.C., 2012. X-ray ﬁbre diffraction studies of amyloid ﬁbrils.
Methods Mol. Biol. 849, 121e135.
Mukamolova, G.V., Kaprelyants, A.S., Kell, D.B., Young, M., 2003. Adoption of the
transiently non-culturable state - a bacterial survival strategy? Adv. Micr.
Physiol. 47, 65e129.
Mukamolova, G.V., Kaprelyants, A.S., Young, D.I., Young, M., Kell, D.B., 1998.
A bacterial cytokine. Proc. Natl. Acad. Sci. 95, 8916e8921.Mukamolova, G.V., Murzin, A.G., Salina, E.G., Demina, G.R., Kell, D.B.,
Kaprelyants, A.S., Young, M., 2006. Muralytic activity of Micrococcus luteus Rpf
and its relationship to physiological activity in promoting bacterial growth and
resuscitation. Mol. Microbiol. 59, 84e98.
Mukamolova, G.V., Turapov, O.A., Kazarian, K., Telkov, M., Kaprelyants, A.S.,
Kell, D.B., Young, M., 2002a. The rpf gene of Micrococcus luteus encodes an
essential secreted growth factor. Mol. Microbiol. 46, 611e621.
Mukamolova, G.V., Turapov, O.A., Young, D.I., Kaprelyants, A.S., Kell, D.B., Young, M.,
2002b. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol.
Microbiol. 46, 623e635.
Münster, S., Jawerth, L.M., Fabry, B., Weitz, D.A., 2013. Structure and mechanics of
ﬁbrin clots formed under mechanical perturbation. J. Thromb. Haemost. 11,
557e560.
Murakami, K., 2014. Conformation-speciﬁc antibodies to target amyloid beta olig-
omers and their application to immunotherapy for Alzheimer's disease. Biosci.
Biotechnol. Biochem. 78, 1293e1305.
Murakami, T., Inoshima, Y., Ishiguro, N., 2015. Systemic AA amyloidosis as a prion-
like disorder. Virus Res. 207, 76e81.
Murakami, T., Ishiguro, N., Higuchi, K., 2014. Transmission of systemic AA
amyloidosis in animals. Vet. Pathol. 51, 363e371.
Murray, M.E., Lowe, V.J., Graff-Radford, N.R., Liesinger, A.M., Cannon, A.,
Przybelski, S.A., Rawal, B., Parisi, J.E., Petersen, R.C., Kantarci, K., Ross, O.A.,
Duara, R., Knopman, D.S., Jack Jr., C.R., Dickson, D.W., 2015. Clinicopathologic
and 11C-Pittsburgh compound B implications of Thal amyloid phase across the
Alzheimer's disease spectrum. Brain 138, 1370e1381.
Murthy, S.B., Jawaid, A., Qureshi, S.U., Schulz, P.E., Schulz, P.E., 2009. The apolipo-
protein 2 allele in Alzheimer's disease: suggestions for a judicious use of anti-
platelet and anticoagulant medications. J. Am. Geriatr. Soc. 57, 1124e1125.
Naiki, H., Higuchi, K., Hosokawa, M., Takeda, T., 1989. Fluorometric determination of
amyloid ﬁbrils in vitro using the ﬂuorescent dye, thioﬂavin T1. Anal. Biochem.
177, 244e249.
Nakano, M., Kamino, K., 2015. Amyloid-like conformation and interaction for the
self-assembly in barnacle underwater cement. Biochemistry 54, 826e835.
Nanga, R.P.R., Brender, J.R., Vivekanandan, S., Ramamoorthy, A., 2011. Structure and
membrane orientation of IAPP in its natively amidated form at physiological pH
in a membrane environment. Biochim. Biophys. Acta 1808, 2337e2342.
Nedelkov, D., Kiernan, U.A., Niederkoﬂer, E.E., Tubbs, K.A., Nelson, R.W., 2005.
Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. U. S. A.
102, 10852e10857.
Neeves, K.B., Illing, D.A., Diamond, S.L., 2010. Thrombin ﬂux and wall shear rate
regulate ﬁbrin ﬁber deposition state during polymerization under ﬂow. Bio-
phys. J. 98, 1344e1352.
Nicolay, J.P., Gatz, S., Liebig, G., Gulbins, E., Lang, F., 2007. Amyloid induced suicidal
erythrocyte death. Cell Physiol. Biochem. 19, 175e184.
Nicolson, G.L., Haier, J., 2009. Role of chronic bacterial and viral infections in
neurodegenerative, neurobehavioural, psychiatric, autoimmune and fatiguing
illnesses: part 1. Br. J. Med. Pract. 2, 20e28.
Nicolson, G.L., Haier, J., 2010. Role of chronic bacterial and viral infections in
neurodegenerative, neurobehavioural, psychiatric, autoimmune and fatiguing
illnesses: part 2. Br. J. Med. Pract. 3, 301e310.
Nielsen, L., Frokjaer, S., Brange, J., Uversky, V.N., Fink, A.L., 2001a. Probing the
mechanism of insulin ﬁbril formation with insulin mutants. Biochemistry 40,
8397e8409.
Nielsen, L., Frokjaer, S., Carpenter, J.F., Brange, J., 2001b. Studies of the structure of
insulin ﬁbrils by Fourier transform infrared (FTIR) spectroscopy and electron
microscopy. J. Pharm. Sci. 90, 29e37.
Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V.N.,
Fink, A.L., 2001c. Effect of environmental factors on the kinetics of insulin ﬁbril
formation: elucidation of the molecular mechanism. Biochemistry 40,
6036e6046.
Nielsen, V.G., Jacobsen, W.K., 2016. Iron modulates the alpha chain of ﬁbrinogen.
Biometals 29, 235e238.
Nielsen, V.G., Pretorius, E., 2014a. Iron-enhanced coagulation is attenuated by
chelation: thrombelastographic and ultrastructural analysis. Blood Coagul.
Fibrinolysis 25, 845e850.
Nielsen, V.G., Pretorius, E., 2014b. Iron and carbon monoxide enhance coagulation
and attenuate ﬁbrinolysis by different mechanisms. Blood Coagul. Fibrinolysis
25, 695e702.
Nielsen, V.G., Pretorius, E., Bester, J., Jacobsen, W.K., Boyle, P.K., Reinhard, J.P., 2015.
Carbon monoxide and iron modulate plasmatic coagulation in Alzheimer's
disease. Curr. Neurovasc. Res. 12, 31e39.
Nienhuis, H.L.A., Bijzet, J., Hazenberg, B.P.C., 2016. The Prevalence and Management
of Systemic Amyloidosis in Western Countries. Kidney Dis. 2, 10e19.
Nieuwenhuizen, W., 2001. Fibrin-mediated plasminogen activation. Ann. N. Y. Acad.
Sci. 936, 237e246.
Nilsson, K.P., Åslund, A., Berg, I., Nystr€om, S., Konradsson, P., Herland, A., Ingan€as, O.,
Stabo-Eeg, F., Lindgren, M., Westermark, G.T., Lannfelt, L., Nilsson, L.N.G.,
Hammarstr€om, P., 2007. Imaging distinct conformational states of amyloid-beta
ﬁbrils in Alzheimer's disease using novel luminescent probes. ACS Chem. Biol. 2,
553e560.
Nilsson, K.P., Lindgren, M., Hammarstr€om, P., 2012. A pentameric luminescent-
conjugated oligothiophene for optical imaging of in vitro-formed amyloid ﬁ-
brils and protein aggregates in tissue sections. Methods Mol. Biol. 849,
425e434.
Nilsson, K.P.R., 2009. Small organic probes as amyloid speciﬁc ligandsepast and
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e41 37recent molecular scaffolds. FEBS Lett. 583, 2593e2599.
Nilsson, K.P.R., Hammarstr€om, P., Ahlgren, F., Herland, A., Schnell, E.A., Lindgren, M.,
Westermark, G.T., Ingan€as, O., 2006. Conjugated polyelectrolyteseconforma
tion-sensitive optical probes for staining and characterization of amyloid de-
posits. Chembiochem 7, 1096e1104.
Nilsson, K.P.R., Herland, A., Hammarstr€om, P., Ingan€as, O., 2005. Conjugated poly-
electrolytes: conformation-sensitive optical probes for detection of amyloid
ﬁbril formation. Biochemistry 44, 3718e3724.
Nilsson, K.P.R., Ikenberg, K., Åslund, A., Fransson, S., Konradsson, P., R€ocken, C.,
Moch, H., Aguzzi, A., 2010. Structural typing of systemic amyloidoses by
luminescent-conjugated polymer spectroscopy. Am. J. Pathol. 176, 563e574.
Nilsson, M.R., 2004. Techniques to study amyloid ﬁbril formation in vitro. Methods
34, 151e160.
Noguchi, M., Sato, T., Nagai, K., Utagawa, I., Suzuki, I., Arito, M., Iizuka, N.,
Suematsu, N., Okamoto, K., Kato, T., Yamaguchi, N., Kurokawa, M.S., 2014. Roles
of serum ﬁbrinogen alpha chain-derived peptides in Alzheimer's disease. Int. J.
Geriatr. Psychiatry 29, 808e818.
Nussbaum, J.M., Seward, M.E., Bloom, G.S., 2013. Alzheimer disease: a tale of two
prions. Prion 7, 14e19.
O'Brien, S.H., 2014. Contraception-related venous thromboembolism in adolescents.
Semin. Thromb. Hemost. 40, 66e71.
O'Hagan, S., Kell, D.B., 2015. Understanding the foundations of the structural sim-
ilarities between marketed drugs and endogenous human metabolites. Front.
Pharmacol. 6, 105.
O'Hagan, S., Kell, D.B., 2016. MetMaxStruct: a Tversky-similarity-based strategy for
analysing the (sub)structural similarities of drugs and endogenous metabolites.
Front. Pharmacol. 7, 266.
O'Hagan, S., Swainston, N., Handl, J., Kell, D.B., 2015. A ‘rule of 0.50 for the
metabolite-likeness of approved pharmaceutical drugs. Metabolomics 11,
323e339.
Obici, L., Perfetti, V., Palladini, G., Moratti, R., Merlini, G., 2005. Clinical aspects of
systemic amyloid diseases. Biochim. Biophys. Acta 1753, 11e22.
Okada, A., Yoshikawa, Y., Watanabe, K., Orino, K., 2015. Analysis of the binding of
bovine and human ﬁbrinogen to ferritin: evidence that ﬁbrinogen is a common
ferritin-binding protein in mammals. Biometals 28, 679e685.
Olanow, C.W., Brundin, P., 2013. Parkinson's disease and alpha synuclein: is Par-
kinson's disease a prion-like disorder? Mov. Disord. 28, 31e40.
Ono, K., Takahashi, R., Ikeda, T., Yamada, M., 2012a. Cross-seeding effects of amyloid
beta-protein and alpha-synuclein. J. Neurochem. 122, 883e890.
Ono, M., Watanabe, H., Kimura, H., Saji, H., 2012b. BODIPY-based molecular probe
for imaging of cerebral beta-amyloid plaques. ACS Chem. Neurosci. 3, 319e324.
Ow, S.Y., Dunstan, D.E., 2014. A brief overview of amyloids and Alzheimer's disease.
Protein Sci. 23, 1315e1331.
Ozawa, D., Kaji, Y., Yagi, H., Sakurai, K., Kawakami, T., Naiki, H., Goto, Y., 2011.
Destruction of amyloid ﬁbrils of keratoepithelin peptides by laser irradiation
coupled with amyloid-speciﬁc thioﬂavin T. J. Biol. Chem. 286, 10856e10863.
Palhano, F.L., Lee, J., Grimster, N.P., Kelly, J.W., 2013. Toward the molecular mecha-
nism(s) by which EGCG treatment remodels mature amyloid ﬁbrils. J. Am.
Chem. Soc. 135, 7503e7510.
Pan, K.M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I.,
Huang, Z., Fletterick, R.J., Cohen, F.E., et al., 1993. Conversion of alpha-helices
into beta-sheets features in the formation of the scrapie prion proteins. Proc.
Natl. Acad. Sci. U. S. A. 90, 10962e10966.
Paquin, R., Colomban, P., 2007. Nanomechanics of single keratin ﬁbres: A Raman
study of the alpha-helix ->beta-sheet transition and the effect of water.
J. Raman Spectrosc. 38, 504e514.
Patel, V., Zhang, X., Tautiva, N.A., Nyabera, A.N., Owa, O.O., Baidya, M., Sung, H.C.,
Taunk, P.S., Abdollahi, S., Charles, S., Gonnella, R.A., Gadi, N., Duong, K.T.,
Fawver, J.N., Ran, C., Jalonen, T.O., Murray, I.V., 2015. Small molecules and Alz-
heimer's disease: misfolding, metabolism and imaging. Curr. Alzheimer Res. 12,
445e461.
Paul, J., Strickland, S., Melchor, J.P., 2007. Fibrin deposition accelerates neurovascular
damage and neuroinﬂammation in mouse models of Alzheimer's disease. J. Exp.
Med. 204, 1999e2008.
Pawlicki, S., Le Bechec, A., Delamarche, C., 2008. AMYPdb: a database dedicated to
amyloid precursor proteins. BMC Bioinforma. 9, 273.
Peters, J.U., 2013. Polypharmacology - Foe or Friend? J. Med. Chem. 56, 8955e8971.
Petkova, A.T., Leapman, R.D., Guo, Z., Yau, W.M., Mattson, M.P., Tycko, R., 2005. Self-
propagating, molecular-level polymorphism in Alzheimer's beta-amyloid ﬁbrils.
Science 307, 262e265.
Phillips, M., Dickneite, G., Metzner, H., 2003. Fibrin sealants in supporting surgical
techniques: strength in factor XIII. Cardiovasc Surg. 11 (Suppl. 1), 13e16.
Piana, S., Klepeis, J.L., Shaw, D.E., 2014. Assessing the accuracy of physical models
used in protein-folding simulations: quantitative evidence from long molecular
dynamics simulations. Curr. Opin. Struct. Biol. 24, 98e105.
Piana, S., Lindorff-Larsen, K., Shaw, D.E., 2012. Protein folding kinetics and ther-
modynamics from atomistic simulation. Proc. Natl. Acad. Sci. 109, 17845e17850.
Piana, S., Lindorff-Larsen, K., Shaw, D.E., 2013. Atomic-level description of ubiquitin
folding. Proc. Natl. Acad. Sci. 110, 5915e5920.
Picken, M.M., 2010. Fibrinogen amyloidosis: the clot thickens! Blood 115,
2985e2986.
Picken, M.M., Herrera, G.A., 2012. Thioﬂavin T Stain: An Easier and More Sensitive
Method for Amyloid Detection. Curr. Clin. Pathol. 187e189.
Pillay, K., Govender, P., 2013. Amylin uncovered: a review on the polypeptide
responsible for type II diabetes. Biomed. Res. Int. 2013, 826706.Pinotsi, D., Michel, C.H., Buell, A.K., Laine, R.F., Mahou, P., Dobson, C.M.,
Kaminski, C.F., Kaminski Schierle, G.S., 2016. Nanoscopic insights into seeding
mechanisms and toxicity of alpha-synuclein species in neurons. Proc. Natl.
Acad. Sci. U. S. A. 113, 3815e3819.
Pizzini, C., Mussap, M., Plebani, M., Fanos, V., 2000. C-reactive protein and serum
amyloid A protein in neonatal infections. Scand. J. Infect. Dis. 32, 229e235.
Poggiolini, I., Saverioni, D., Parchi, P., 2013. Prion protein misfolding, strains, and
neurotoxicity: an update from studies on mammalian prions. Int. J. Cell Biol.
2013, 910314.
Potgieter, M., Bester, J., Kell, D.B., Pretorius, E., 2015. The dormant blood microbiome
in chronic, inﬂammatory diseases. FEMS Microbiol. Rev. 39, 567e591.
Prade, E., Barucker, C., Sarkar, R., Althoff-Ospelt, G., Lopez Del Amo, J.M., Hossain, S.,
Zhong, Y., Multhaup, G., Reif, B., 2016. Sulindac Sulﬁde Induces the Formation of
Large Oligomeric Aggregates of the Alzheimer's Disease Amyloid-beta Peptide
Which Exhibit Reduced Neurotoxicity. Biochemistry 55, 1839e1849.
Pretorius, E., 2011. The use of a desktop scanning electron microscope as a diag-
nostic tool in studying ﬁbrin networks of thrombo-embolic ischemic stroke.
Ultrastruct. Pathol. 35, 245e250.
Pretorius, E., Bester, J., Kell, D.B., 2016a. A bacterial component to Alzheimer-type
dementia seen via a systems biology approach that links iron dysregulation
and inﬂammagen shedding to disease. J. Alzheimers Dis. 53, 1237e1256.
Pretorius, E., Bester, J., Vermeulen, N., Alummoottil, S., Soma, P., Buys, A.V., Kell, D.B.,
2015. Poorly controlled type 2 diabetes is accompanied by signiﬁcant
morphological and ultrastructural changes in both erythrocytes and in
thrombin-generated ﬁbrin: implications for diagnostics. Cardiovasc Diabetol.
13, 30.
Pretorius, E., Bester, J., Vermeulen, N., Lipinski, B., Gericke, G.S., Kell, D.B., 2014a.
Profound morphological changes in the erythrocytes and ﬁbrin networks of
patients with hemochromatosis or with hyperferritinemia, and their normali-
zation by iron chelators and other agents. PLoS One 9, e85271.
Pretorius, E., du Plooy, J., Soma, P., Gasparyan, A.Y., 2014b. An ultrastructural analysis
of platelets, erythrocytes, white blood cells, and ﬁbrin network in systemic
lupus erythematosus. Rheumatol. Int. 34, 1005e1009.
Pretorius, E., Kell, D.B., 2014. Diagnostic morphology: biophysical indicators for
iron-driven inﬂammatory diseases. Integr. Biol. 6, 486e510.
Pretorius, E., Lipinski, B., 2013a. Differences in morphology of ﬁbrin clots induced
with thrombin and ferric ions and its pathophysiological consequences. Heart
Lung Circ. 22, 447e449.
Pretorius, E., Lipinski, B., 2013b. Iron alters red blood cell morphology. Blood 121, 9.
Pretorius, E., Lipinski, B., 2013c. Thromboembolic ischemic stroke changes red blood
cell morphology. Cardiovasc Pathol. 22, 241e242.
Pretorius, E., Mbotwe, S., Bester, J., Robinson, C., Kell, D.B., 2016b. Acute induction of
anomalous and amyloidogenic blood clotting by molecular ampliﬁcation of
highly substoichiometric levels of bacterial lipopolysaccharide. J. R. Soc. Inter-
face. 13, 20160539.
Pretorius, E., Mbotwe, S., Bester, J., Robinson, C., Kell, D.B., 2016c. Acute induction of
anomalous blood clotting by highly substoichiometric levels of bacterial lipo-
polysaccharide (LPS). bioRxiv 2016, 053538v1.
Pretorius, E., Oberholzer, H.M., 2009. Ultrastructural changes of platelets and ﬁbrin
networks in human asthma: a qualitative case study. Blood Coag Fibrinol. 20,
146e149.
Pretorius, E., Oberholzer, H.M., van der Spuy, W.J., Meiring, J.H., 2010a. The changed
ultrastructure of ﬁbrin networks during use of oral contraception and hormone
replacement. J. Thromb. Thrombolysis 30, 502e506.
Pretorius, E., Oberholzer, H.M., van der Spuy, W.J., Swanepoel, A.C., Soma, P., 2011a.
Qualitative scanning electron microscopy analysis of ﬁbrin networks and
platelet abnormalities in diabetes. Blood Coagul. Fibrinol. 22, 463e467.
Pretorius, E., Olivier, J., Oberholzer, H.M., Van der Spuy, W.J., 2011b. Scanning
electron microscopy investigation of ﬁbrin networks after thermal injury.
Onderstepoort J. Vet. Res. 78, 244.
Pretorius, E., Olumuyiwa-Akeredolu, O.O., Mbotwe, S., Bester, J., 2016d. Erythrocytes
and their role as health indicator: Using structure in a patient-orientated pre-
cision medicine approach. Blood Rev. 30, 263e274.
Pretorius, E., Steyn, H., Engelbrecht, M., Swanepoel, A.C., Oberholzer, H.M., 2011c.
Differences in ﬁbrin ﬁber diameters in healthy individuals and thromboembolic
ischemic stroke patients. Blood Coagul. Fibrinolysis 22, 696e700.
Pretorius, E., Swanepoel, A.C., Buys, A.V., Vermeulen, N., Duim, W., Kell, D.B., 2014c.
Eryptosis as a marker of Parkinson's disease. Aging 6, 788e819.
Pretorius, E., Vermeulen, N., Bester, J., Lipinski, B., Kell, D.B., 2013. A novel method
for assessing the role of iron and its functional chelation in ﬁbrin ﬁbril for-
mation: the use of scanning electron microscopy. Toxicol. Mech. Methods 23,
352e359.
Pretorius, E., Windberger, U.B., Oberholzer, H.M., Auer, R.E., 2010b. Comparative
ultrastructure of ﬁbrin networks of a dog after thrombotic ischaemic stroke.
Onderstepoort J. Vet. Res. 77, E1eE4.
Price, W.A., 1923. Dental infections oral and systemic, being a contribution to the
pathology of dental infections, focal infections and the degenerative diseases,
Parts I and II. Penton Press, Cleveland.
Proal, A.D., Albert, P.J., Blaney, G.P., Lindseth, I.A., Benediktsson, C., Marshall, T.G.,
2011. Immunostimulation in the era of the metagenome. Cell Mol. Immunol. 8,
213e225.
Proal, A.D., Albert, P.J., Marshall, T., 2009. Autoimmune disease in the era of the
metagenome. Autoimmun. Rev. 8, 677e681.
Proal, A.D., Albert, P.J., Marshall, T.G., 2013. The human microbiome and autoim-
munity,. Curr. Opin. Rheumatol. 25, 234e240.
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e4138Proal, A.D., Albert, P.J., Marshall, T.G., 2014. Inﬂammatory disease and the human
microbiome. Discov. Med. 17, 257e265.
Protopopova, A.D., Barinov, N.A., Zavyalova, E.G., Kopylov, A.M., Sergienko, V.I.,
Klinov, D.V., 2015. Visualization of ﬁbrinogen alphaC regions and their
arrangement during ﬁbrin network formation by high-resolution AFM.
J. Thromb. Haemost. 13, 570e579.
Prusiner, S.B., 1998. Prions. Proc. Natl. Acad. Sci. 95, 13363e13383.
Prusiner, S.B., Woerman, A.L., Mordes, D.A., Watts, J.C., Rampersaud, R., Berry, D.B.,
Patel, S., Oehler, A., Lowe, J.K., Kravitz, S.N., Geschwind, D.H., Glidden, D.V.,
Halliday, G.M., Middleton, L.T., Gentleman, S.M., Grinberg, L.T., Giles, K., 2015.
Evidence for alpha-synuclein prions causing multiple system atrophy in
humans with parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 112, E5308eE5317.
Puchtler, H., Sweat, F., 1966. A review of early concepts of amyloid in context with
contemporary chemical literature from 1839 to 1859,. J. Histochem Cytochem
14, 123e134.
Qadri, S.M., Donkor, D.A., Bhakta, V., Eltringham-Smith, L.J., Dwivedi, D.J.,
Moore, J.C., Pepler, L., Ivetic, N., Nazi, I., Fox-Robichaud, A.E., Liaw, P.C.,
Shefﬁeld, W.P., 2016. Phosphatidylserine externalization and procoagulant
activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor
pyocyanin. J. Cell Mol. Med. 20, 710e720.
Qin, Z., Buehler, M.J., 2010. Molecular dynamics simulation of the alpha-helix to
beta-sheet transition in coiled protein ﬁlaments: evidence for a critical ﬁlament
length scale. Phys. Rev. Lett. 104, 198304.
Rajasekhar, K., Narayanaswamy, N., Murugan, N.A., Kuang, G., Agren, H.,
Govindaraju, T., 2016. A High Afﬁnity Red Fluorescence and Colorimetric Probe
for Amyloid beta Aggregates. Sci. Rep. 6, 23668.
Rambaran, R.N., Serpell, L.C., 2008. Amyloid ﬁbrils: abnormal protein assembly.
Prion 2, 112e117.
Ratner, J., Rosenberg, G., Kral, V.A., Engelsmann, F., 1972. Anticoagulant therapy for
senile dementia. J. Am. Geriatr. Soc. 20, 556e559.
Reddy, A.S., Zhang, S., 2013. Polypharmacology: drug discovery for the future.
Expert Rev. Clin. Pharmacol. 6, 41e47.
Reese, J.A., Bougie, D.W., Curtis, B.R., Terrell, D.R., Vesely, S.K., Aster, R.H.,
George, J.N., 2015. Drug-induced thrombotic microangiopathy: Experience of
the Oklahoma Registry and the BloodCenter of Wisconsin. Am. J. Hematol. 90,
406e410.
Reikvam, H., Steien, E., Hauge, B., Liseth, K., Hagen, K.G., Storkson, R., Hervig, T.,
2009. Thrombelastography. Transfus. Apher. Sci. 40, 119e123.
Reinke, A.A., Gestwicki, J.E., 2011. Insight into amyloid structure using chemical
probes. Chem. Biol. Drug Des. 77, 399e411.
Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., Dannals, R.F., Mathis, C.A.,
Klunk, W.E., Ferrucci, L., Kraut, M.A., Wong, D.F., 2010. Longitudinal cognitive
decline is associated with ﬁbrillar amyloid-beta measured by [11C]PiB.
Neurology 74, 807e815.
Reuter, M., Dryden, D.T.F., 2010. The kinetics of YOYO-1 intercalation into single
molecules of double-stranded DNA. Biochem. Biophys. Res. Commun. 403,
225e229.
Riba, I., Barran, P.E., Cooper, G.J.S., Unwin, R.D., 2015. On the structure of the copper-
amylin complex. Int. J. Mass Spectrom. 391, 47e53.
Richardson, V.R., Cordell, P., Standeven, K.F., Carter, A.M., 2013. Substrates of Factor
XIII-A: roles in thrombosis and wound healing. Clin. Sci. (Lond) 124, 123e137.
Ries, J., Udayar, V., Soragni, A., Hornemann, S., Nilsson, K.P., Riek, R., Hock, C.,
Ewers, H., Aguzzi, A.A., Rajendran, L., 2013. Superresolution imaging of amyloid
ﬁbrils with binding-activated probes. ACS Chem. Neurosci. 4, 1057e1061.
Rival, T., Page, R.M., Chandraratna, D.S., Sendall, T.J., Ryder, E., Liu, B., Lewis, H.,
Rosahl, T., Hider, R., Camargo, L.M., Shearman, M.S., Crowther, D.C., Lomas, D.A.,
2009. Fenton chemistry and oxidative stress mediate the toxicity of the beta-
amyloid peptide in a Drosophila model of Alzheimer's disease. Eur. J. Neuro-
sci. 29, 1335e1347.
Robbins, K.J., Liu, G., Selmani, V., Lazo, N.D., 2012. Conformational analysis of thi-
oﬂavin T bound to the surface of amyloid ﬁbrils. Langmuir 28, 16490e16495.
R€ocken, C., Shakespeare, A., 2002. Pathology, diagnosis and pathogenesis of AA
amyloidosis. Virchows Arch. 440, 111e122.
Rood, K., Tagare, H., Patterson, J., Jones, S., Buhimschi, C., Buhimschi, I., 2015. Congo
red dot test quantkit: a smartphone application to measure congophilia in the
urine of women screened for preeclampsia (PE). Am. J. Obs. Gynecol. 212,
S290eS291.
Rosove, M.H., 2014. Thrombotic microangiopathies. Semin. Arthritis Rheum. 43,
797e805.
Ryan, T.M., Friedhuber, A., Lind, M., Howlett, G.J., Masters, C., Roberts, B.R., 2012.
Small amphipathic molecules modulate secondary structure and amyloid ﬁbril-
forming kinetics of Alzheimer disease peptide Abeta(1-42). J. Biol. Chem. 287,
16947e16954.
Ryu, J.K., McLarnon, J.G., 2009. A leaky blood-brain barrier, ﬁbrinogen inﬁltration
and microglial reactivity in inﬂamed Alzheimer's disease brain. J. Cell Mol. Med.
13, 2911e2925.
Saa, P., Cervenakova, L., 2015. Protein misfolding cyclic ampliﬁcation (PMCA):
Current status and future directions. Virus Res. 207, 47e61.
Sabate, R., Ventura, S., 2013. Cross-beta-sheet supersecondary structure in amyloid
folds: techniques for detection and characterization. Methods Mol. Biol. 932,
237e257.
Sabovic, M., Blinc, A., 2000. Biochemical and biophysical conditions for blood clot
lysis. Pﬂugers Arch. 440, R134eR136.
Sabovic, M., Lijnen, H.R., Keber, D., Collen, D., 1989. Effect of retraction on the lysis of
human clots with ﬁbrin speciﬁc and non-ﬁbrin speciﬁc plasminogen activators.Thromb. Haemost. 62, 1083e1087.
Sadati, M., Apik, A.I., Armas-Perez, J.C., Martinez-Gonzalez, J., Hernandez-Ortiz, J.P.,
Abbott, N.L., de Pablo, J.J., 2015. Liquid Crystal Enabled Early Stage Detection of
Beta Amyloid Formation on Lipid Monolayers. Adv. Funct. Mater 25,
6050e6060.
Saito, H., Maruyama, I., Shimazaki, S., Yamamoto, Y., Aikawa, N., Ohno, R.,
Hirayama, A., Matsuda, T., Asakura, H., Nakashima, M., Aoki, N., 2007. Efﬁcacy
and safety of recombinant human soluble thrombomodulin (ART-123) in
disseminated intravascular coagulation: results of a phase III, randomized,
double-blind clinical trial. J. Thromb. Haemost. 5, 31e41.
Saleem, F., Bjorndahl, T.C., Ladner, C.L., Perez-Pineiro, R., Ametaj, B.N., Wishart, D.S.,
2014. Lipopolysaccharide induced conversion of recombinant prion protein.
Prion 8, 221e232.
Salter, S.J., Cox, M.J., Turek, E.M., Calus, S.T., Cookson, W.O., Moffatt, M.F., Turner, P.,
Parkhill, J., Loman, N.J., Walker, A.W., 2014. Reagent and laboratory contami-
nation can critically impact sequence-based microbiome analyses. BMC Biol. 12,
87.
Sankarankutty, A., Nascimento, B., Teodoro da Luz, L., Rizoli, S., 2012. TEG(R) and
ROTEM(R) in trauma: similar test but different results? World J. Emerg. Surg. 7
(Suppl. 1), S3.
Sano, K., Atarashi, R., Ishibashi, D., Nakagaki, T., Satoh, K., Nishida, N., 2014.
Conformational properties of prion strains can be transmitted to recombinant
prion protein ﬁbrils in real-time quaking-induced conversion. J. Virol. 88,
11791e11801.
Sarkar, S., Raymick, J., Ray, B., Lahiri, D.K., Paule, M.G., Schmued, L., 2015. Oral
Administration of Thioﬂavin T Prevents Beta Amyloid Plaque Formation in
Double Transgenic AD Mice. Curr. Alzheimer Res. 12, 837e846.
Saverioni, D., Notari, S., Capellari, S., Poggiolini, I., Giese, A., Kretzschmar, H.A.,
Parchi, P., 2013. Analyses of protease resistance and aggregation state of
abnormal prion protein across the spectrum of human prions. J. Biol. Chem. 288,
27972e27985.
Sawyer, E.B., Gras, S.L., 2013. Self-assembling nanomaterials: monitoring the for-
mation of amyloid ﬁbrils, with a focus on small-angle X-ray scattering. Methods
Mol. Biol. 996, 77e101.
Selkoe, D.J., Hardy, J., 2016. The amyloid hypothesis of Alzheimer's disease at 25
years. EMBO Mol. Med. 8, 595e608.
Sengupta, U., Nilson, A.N., Kayed, R., 2016. The Role of Amyloid-beta Oligomers in
Toxicity, Propagation, and Immunotherapy. EBioMedicine 6, 42e49.
Serpell, L.C., 2000. Alzheimer's amyloid ﬁbrils: structure and assembly. Biochim.
Biophys. Acta 1502, 16e30.
Serpell, L.C., Benson, M., Liepnieks, J.J., Fraser, P.E., 2007. Structural analyses of
ﬁbrinogen amyloid ﬁbrils. Amyloid 14, 199e203.
Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P.H., Williams, L., Maier, M., Dunstan, R.,
Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M.,
Chollate, S., Brennan, M.S., Quintero-Monzon, O., Scannevin, R.H., Arnold, H.M.,
Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C.,
Nitsch, R.M., Sandrock, A., 2016. The antibody aducanumab reduces Abeta
plaques in Alzheimer's disease. Nature. 537, 50e56.
Shah, N., Welsby, I.J., Fielder, M.A., Jacobsen, W.K., Nielsen, V.G., 2015. Sickle cell
disease is associated with iron mediated hypercoagulability. J. Thromb.
Thrombolysis 40, 182e185.
Shankar, A., Wang, J.J., Rochtchina, E., Mitchell, P., 2006. Positive association be-
tween plasma ﬁbrinogen level and incident hypertension among men:
population-based cohort study. Hypertension 48, 1043e1049.
Sharma, S., Uprichard, J., Moretti, A., Boyce, H., Szydlo, R., Stocks, G., 2013. Use of
thromboelastography to assess the combined role of pregnancy and obesity on
coagulation: a prospective study. Int. J. Obstet. Anesth. 22, 113e118.
Shirahata, A., Mimuro, J., Takahashi, H., Kitajima, I., Tsuji, H., Eguchi, Y.,
Matsushita, T., Kajiki, M., Honda, G., Sakata, Y., 2014. Recombinant soluble hu-
man thrombomodulin (thrombomodulin alfa) in the treatment of neonatal
disseminated intravascular coagulation. Eur. J. Pediatr. 173, 303e311.
Shirani, H., Linares, M., Sigurdson, C.J., Lindgren, M., Norman, P., Nilsson, K.P.R., 2015.
A Palette of Fluorescent Thiophene-Based Ligands for the Identiﬁcation of
Protein Aggregates. Chemistry 21, 15133e15137.
Silva, C.J., Vazquez-Fernandez, E., Onisko, B., Requena, J.R., 2015. Proteinase K and
the structure of PrPSc: The good, the bad and the ugly. Virus Res. 207, 120e126.
Silva, J.L., Vieira, T.C.R.G., Gomes, M.P.B., Rangel, L.P., Scapin, S.M.N., Cordeiro, Y.,
2011. Experimental approaches to the interaction of the prion protein with
nucleic acids and glycosaminoglycans: Modulators of the pathogenic conver-
sion. Methods 53, 306e317.
Simon, R.A., Shirani, H., Åslund, K.O.A., B€ack, M., Haroutunian, V., Gandy, S.,
Nilsson, K.P.R., 2014. Pentameric thiophene-based ligands that spectrally
discriminate amyloid-beta and tau aggregates display distinct solvatochromism
and viscosity-induced spectral shifts. Chemistry 20, 12537e12543.
Sipe, J., 1999. Revised nomenclature for serum amyloid A (SAA). Nomenclature
Committee of the International Society of Amyloidosis. Part 2. Amyloid 6,
67e70.
Sipe, J.D., 2000. Serum amyloid A: from ﬁbril to function. Current status. Amyloid 7,
10e12.
Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S., Merlini, G., Saraiva, M.J.,
Westermark, P., 2014. Nomenclature 2014: Amyloid ﬁbril proteins and clinical
classiﬁcation of the amyloidosis. Amyloid 21, 221e224.
Sipe, J.D., Cohen, A.S., 2000. Review: history of the amyloid ﬁbril. J. Struct. Biol. 130,
88e98.
Sj€olander, D., Bijzet, J., Hazenberg, B.P.C., Nilsson, K.P., Hammarstr€om, P., 2015.
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e41 39Sensitive and rapid assessment of amyloid by oligothiophene ﬂuorescence in
subcutaneous fat tissue. Amyloid 22, 19e25.
Sj€olander, D., R€ocken, C., Westermark, P., Westermark, G.T., Nilsson, K.P.R.,
Hammarstr€om, P., 2016. Establishing the ﬂuorescent amyloid ligand h-FTAA for
studying human tissues with systemic and localized amyloid. Amyloid 23,
98e108.
Slotta, J.E., Braun, O.€O., Menger, M.D., Thorlacius, H., 2008. Central role of rho kinase
in lipopolysaccharide-induced platelet capture on venous endothelium.
J. Investig. Med. 56, 720e725.
Small, B.G., McColl, B.W., Allmendinger, R., Pahle, R., Lopez-Castejon, G.,
Rothwell, N.J., Knowles, J., Mendes, P., Brough, D., Kell, D.B., 2011. Efﬁcient
discovery of anti-inﬂammatory small molecule combinations using evolu-
tionary computing. Nat. Chem. Biol. 7, 902e908.
Smith, M.A., Harris, P.L.R., Sayre, L.M., Perry, G., 1997. Iron accumulation in Alz-
heimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci.
94, 9866e9868.
Smith, M.A., Zhu, X., Tabaton, M., Liu, G., McKeel Jr., D.W., Cohen, M.L., Wang, X.,
Siedlak, S.L., Dwyer, B.E., Hayashi, T., Nakamura, M., Nunomura, A., Perry, G.,
2010. Increased iron and free radical generation in preclinical Alzheimer disease
and mild cognitive impairment. J. Alzheimers Dis. 19, 363e372.
Sørensen, B., Ingerslev, J., 2005. Tailoring haemostatic treatment to patient re-
quirements - an update on monitoring haemostatic response using thrombe-
lastography. Haemophilia 11 (Suppl. 1), 1e6.
Soto, C., 2012. Transmissible Proteins: Expanding the Prion Heresy. Cell 149,
968e977.
Soto, C., Estrada, L., Castilla, J., 2006. Amyloids, prions and the inherent infectious
nature of misfolded protein aggregates. Trends Biochem. Sci. 31, 150e155.
Spencer, R.K., Kreutzer, A.G., Salveson, P.J., Li, H., Nowick, J.S., 2015. X-ray Crystal-
lographic Structures of Oligomers of Peptides Derived from beta2-
Microglobulin. J. Am. Chem. Soc. 137, 6304e6311.
Sponarova, J., Nystr€om, S.N., Westermark, G.T., 2008. AA-amyloidosis can be
transferred by peripheral blood monocytes. PLoS One 3, e3308.
Staderini, M., Martin, M.A., Bolognesi, M.L., Menendez, J.C., 2015. Imaging of beta-
amyloid plaques by near infrared ﬂuorescent tracers: a new frontier for
chemical neuroscience. Chem. Soc. Rev. 44, 1807e1819.
Stamford, A., Strickland, C., 2013. Inhibitors of BACE for treating Alzheimer's dis-
ease: a fragment-based drug discovery story. Cur Opin. Chem. Biol. 17, 320e328.
Standeven, K.F., Carter, A.M., Grant, P.J., Weisel, J.W., Chernysh, I., Masova, L.,
Lord, S.T., Ari€ens, R.A.S., 2007. Functional analysis of ﬁbrin {gamma}-chain
cross-linking by activated factor XIII: determination of a cross-linking pattern
that maximizes clot stiffness. Blood 110, 902e907.
Stangou, A.J., Banner, N.R., Hendry, B.M., Rela, M., Portmann, B., Wendon, J.,
Monaghan, M., Maccarthy, P., Buxton-Thomas, M., Mathias, C.J., Liepnieks, J.J.,
O'Grady, J., Heaton, N.D., Benson, M.D., 2010. Hereditary ﬁbrinogen A alpha-
chain amyloidosis: phenotypic characterization of a systemic disease and the
role of liver transplantation. Blood 115, 2998e3007.
Steensma, D.P., 2001. Congo'' red: out of Africa? Arch. Pathol. Lab. Med. 125,
250e252.
Stefani, M., 2012. Structural features and cytotoxicity of amyloid oligomers: im-
plications in Alzheimer's disease and other diseases with amyloid deposits.
Prog. Neurobiol. 99, 226e245.
Stefansson, S., Adams, D.L., Tang, C.M., 2012. Common benzothiazole and benzox-
azole ﬂuorescent DNA intercalators for studying Alzheimer Abeta1-42 and
prion amyloid peptides. Biotechniques 52.
Stempler, S., Levy-Sakin, M., Frydman-Marom, A., Amir, Y., Scherzer-Attali, R.,
Buzhansky, L., Gazit, E., Senderowitz, H., 2011. Quantitative structure-activity
relationship analysis of beta-amyloid aggregation inhibitors. J. Comput. Aided
Mol. Des. 25, 135e144.
Stromer, T., Serpell, L.C., 2005. Structure and morphology of the Alzheimer's amy-
loid ﬁbril. Microsc. Res. Tech. 67, 210e217.
Styren, S.D., Hamilton, R.L., Styren, G.C., Klunk, W.E., 2000. X-34, a ﬂuorescent de-
rivative of Congo red: a novel histochemical stain for Alzheimer's disease pa-
thology. J. Histochem Cytochem 48, 1223e1232.
Su, Y., Andreas, L., Grifﬁn, R.G., 2015. Magic angle spinning NMR of proteins: high-
frequency dynamic nuclear polarization and (1)H detection. Annu. Rev. Bio-
chem. 84, 465e497.
Suga, N., Miura, N., Kitagawa, W., Morita, H., Banno, S., Imai, H., 2012. Differential
diagnosis of localized and systemic amyloidosis based on coagulation and
ﬁbrinolysis parameters. Amyloid 19, 61e65.
Sulatskaya, A.I., Kuznetsova, I.M., Turoverov, K.K., 2011. Interaction of thioﬂavin T
with amyloid ﬁbrils: stoichiometry and afﬁnity of dye binding, absorption
spectra of bound dye. J. Phys. Chem. B 115, 11519e11524.
Sulatskaya, A.I., Kuznetsova, I.M., Turoverov, K.K., 2012. Interaction of thioﬂavin T
with amyloid ﬁbrils: ﬂuorescence quantum yield of bound dye. J. Phys. Chem. B
116, 2538e2544.
Sun, A., Nguyen, X.V., Bing, G., 2002. Comparative analysis of an improved
thioﬂavin-S stain, Gallyas silver stain, and immunohistochemistry for neuroﬁ-
brillary tangle demonstration on the same sections. J. Histochem Cytochem 50,
463e472.
Swainston, N., Mendes, P., Kell, D.B., 2013. An analysis of a ‘community-driven’
reconstruction of the human metabolic network. Metabolomics 9, 757e764.
Swainston, N., Smallbone, K., Hefzi, H., Dobson, P.D., Brewer, J., Hanscho, M.,
Zielinski, D.C., Ang, K.S., Gardiner, N.J., Gutierrez, J.M., Kyriakopoulos, S.,
Lakshmanan, M., Li, S., Liu, J.K., Martínez, V.S., Orellana, C.A., Quek, L.-E.,
Thomas, A., Zanghellini, J., Borth, N., Lee, D.-Y., Nielsen, L.K., Kell, D.B.,Lewis, N.E., Mendes, P., 2016. Recon 2.2: from reconstruction to model of human
metabolism. Metabolomics 12, 109.
Swanepoel, A.C., Lindeque, B.G., Swart, P.J., Abdool, Z., Pretorius, E., 2014. Estrogen
causes ultrastructural changes of ﬁbrin networks during the menstrual cycle: a
qualitative investigation. Microsc. Res. Tech. 77, 594e601.
Swanepoel, A.C., Nielsen, V.G., Pretorius, E., 2015. Viscoelasticity and Ultrastructure
in Coagulation and Inﬂammation: Two Diverse Techniques, One Conclusion.
Inﬂammation 38, 1707e1726.
Tan, L.N., Wiepz, G.J., Miller, D.S., Shusta, E.V., Abbott, N.L., 2014. Liquid crystal
droplet-based ampliﬁcation of microvesicles that are shed by mammalian cells.
Analyst 139, 2386e2396.
Tao, W., Yoon, G., Cao, P., Eom, K., Park, H.S., 2015. beta-sheet-like formation during
the mechanical unfolding of prion protein. J. Chem. Phys. 143, 125101.
Tasaki, M., Ueda, M., Ochiai, S., Tanabe, Y., Murata, S., Misumi, Y., Su, Y., Sun, X.,
Shinriki, S., Jono, H., Shono, M., Obayashi, K., Ando, Y., 2010. Transmission of
circulating cell-free AA amyloid oligomers in exosomes vectors via a prion-like
mechanism. Biochem. Biophys. Res. Commun. 400, 559e562.
Taylor, J.D., Matthews, S.J., 2015. New insight into the molecular control of bacterial
functional amyloids. Front. Cell Infect. Microbiol. 5, 33.
Thiele, I., Swainston, N., Fleming, R.M.T., Hoppe, A., Sahoo, S., Aurich, M.K.,
Haraldsdottír, H., Mo, M.L., Rolfsson, O., Stobbe, M.D., Thorleifsson, S.G.,
Agren, R., B€olling, C., Bordel, S., Chavali, A.K., Dobson, P., Dunn, W.B., Endler, L.,
Goryanin, I., Hala, D., Hucka, M., Hull, D., Jameson, D., Jamshidi, N., Jones, J.,
Jonsson, J.J., Juty, N., Keating, S., Nookaew, I., Le Novere, N., Malys, N., Mazein, A.,
Papin, J.A., Patel, Y., Price, N.D., Selkov Sr., E., Sigurdsson, M.I., Simeonidis, E.,
Sonnenschein, N., Smallbone, K., Sorokin, A., Beek, H.V., Weichart, D.,
Nielsen, J.B., Westerhoff, H.V., Kell, D.B., Mendes, P., Palsson, B.Ø, 2013. A
community-driven global reconstruction of human metabolism, Nat. Bio-
technol. 31, 419e425.
Tipping, K.W., van Oosten-Hawle, P., Hewitt, E.W., Radford, S.E., 2015. Amyloid Fi-
bres: Inert End-Stage Aggregates or Key Players in Disease? Trends Biochem.
Sci. 40, 719e727.
Toyama, B.H., Kelly, M.J.S., Gross, J.D., Weissman, J.S., 2007. The structural basis of
yeast prion strain variants. Nature 449, 233e237.
Toyama, B.H., Weissman, J.S., 2011. Amyloid structure: conformational diversity and
consequences. Annu. Rev. Biochem. 80, 557e585.
Trikha, S., Jeremic, A.M., 2013. Distinct internalization pathways of human amylin
monomers and its cytotoxic oligomers in pancreatic cells. PLoS One 8, e73080.
Tsemekhman, K., Goldschmidt, L., Eisenberg, D., Baker, D., 2007. Cooperative
hydrogen bonding in amyloid formation. Protein Sci. 16, 761e764.
Twist, C.R., Winson, M.K., Rowland, J.J., Kell, D.B., 2004. SNP detection using
nanomolar nucleotides and single molecule ﬂuorescence. Anal. Biochem. 327,
35e44.
Tycko, R., 2011. Solid-state NMR studies of amyloid ﬁbril structure. Annu. Rev. Phys.
Chem. 62, 279e299.
Tycko, R., 2014. Physical and structural basis for polymorphism in amyloid ﬁbrils.
Protein Sci. 23, 1528e1539.
Tycko, R., 2015. Amyloid polymorphism: structural basis and neurobiological rele-
vance. Neuron 86, 632e645.
Tycko, R., Wickner, R.B., 2013. Molecular structures of amyloid and prion ﬁbrils:
consensus versus controversy. Acc. Chem. Res. 46, 1487e1496.
Tzotzos, S., Doig, A.J., 2010. Amyloidogenic sequences in native protein structures.
Protein Sci. 19, 327e348.
Undas, A., 2014. Fibrin clot properties and their modulation in thrombotic disorders.
Thromb. Haemost. 112, 32e42.
Undas, A., Ari€ens, R.A.S., 2011. Fibrin clot structure and function: a role in the
pathophysiology of arterial and venous thromboembolic diseases. Arterioscler.
Thromb. Vasc. Biol. 31, e88e99.
Undas, A., Nowakowski, T., Ciesla-Dul, M., Sadowski, J., 2011. Abnormal plasma
ﬁbrin clot characteristics are associated with worse clinical outcome in patients
with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis
215, 481e486.
Undas, A., Szuldrzynski, K., Stepien, E., Zalewski, J., Godlewski, J., Tracz, W.,
Pasowicz, M., Zmudka, K., 2008. Reduced clot permeability and susceptibility to
lysis in patients with acute coronary syndrome: effects of inﬂammation and
oxidative stress. Atherosclerosis 196, 551e557.
Urbaniak, C., Cummins, J., Brackstone, M., Macklaim, J.M., Gloor, G.B., Baban, C.K.,
Scott, L., O'Hanlon, D.M., Burton, J.P., Francis, K.P., Tangney, M., Reid, G., 2014.
Microbiota of human breast tissue. Appl. Environ. Microbiol. 80, 3007e3014.
Urieli-Shoval, S., Linke, R.P., Matzner, Y., 2000. Expression and function of serum
amyloid A, a major acute-phase protein, in normal and disease states. Curr.
Opin. Hematol. 7, 64e69.
Uversky, V.N., 2010. Mysterious oligomerization of the amyloidogenic proteins.
FEBS J. 277, 2940e2953.
Uversky, V.N., Li, J., Fink, A.L., 2001. Evidence for a partially folded intermediate in
alpha-synuclein ﬁbril formation. J. Biol. Chem. 276, 10737e10744.
Valincius, G., Heinrich, F., Budvytyte, R., Vanderah, D.J., McGillivray, D.J., Sokolov, Y.,
Hall, J.E., Losche, M., 2008. Soluble amyloid beta-oligomers affect dielectric
membrane properties by bilayer insertion and domain formation: implications
for cell toxicity. Biophys. J. 95, 4845e4861.
Valko, M., Jomova, K., Rhodes, C.J., Kuca, K., Musílek, K., 2016. Redox- and non-
redox-metal-induced formation of free radicals and their role in human dis-
ease. Arch. Toxicol. 90, 1e37.
van der Graaf, P.H., Benson, N., 2011. Systems pharmacology: bridging systems
biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e4140and development. Pharm. Res. 28, 1460e1464.
Van Gerven, N., Klein, R.D., Hultgren, S.J., Remaut, H., 2015. Bacterial amyloid for-
mation: structural insights into curli biogensis. Trends Microbiol. 23, 693e706.
van Oijen, M., Witteman, J.C., Hofman, A., Koudstaal, P.J., Breteler, M.M., 2005.
Fibrinogen is associated with an increased risk of Alzheimer disease and
vascular dementia. Stroke 36, 2637e2641.
van Veen, J.J., Gatt, A., Bowyer, A.E., Cooper, P.C., Kitchen, S., Makris, M., 2009.
Calibrated automated thrombin generation and modiﬁed thromboelastometry
in haemophilia A. Thromb. Res. 123, 895e901.
Varjú, I., Sotonyi, P., Machovich, R., Szabo, L., Tenekedjiev, K., Silva, M.M.C.G.,
Longstaff, C., Kolev, K., 2011. Hindered dissolution of ﬁbrin formed under me-
chanical stress. J. Thromb. Haemost. 9, 979e986.
Veklich, Y., Francis, C.W., White, J., Weisel, J.W., 1998. Structural studies of ﬁbrino-
lysis by electron microscopy. Blood 92, 4721e4729.
Ventura, S., Villaverde, A., 2006. Protein quality in bacterial inclusion bodies. Trends
Biotechnol. 24, 179e185.
Verel, R., Tomka, I.T., Bertozzi, C., Cadalbert, R., Kammerer, R.A., Steinmetz, M.O.,
Meier, B.H., 2008. Polymorphism in an amyloid-like ﬁbril-forming model pep-
tide. Angew. Chem. Int. Ed. Engl. 47, 5842e5845.
Verma, A., Wenzel, W., 2009. A free-energy approach for all-atom protein simula-
tion,. Biophys. J. 96, 3483e3494.
Vincent, J.L., Ramesh, M.K., Ernest, D., LaRosa, S.P., Pachl, J., Aikawa, N., Hoste, E.,
Levy, H., Hirman, J., Levi, M., Daga, M., Kutsogiannis, D.J., Crowther, M.,
Bernard, G.R., Devriendt, J., Puigserver, J.V., Blanzaco, D.U., Esmon, C.T.,
Parrillo, J.E., Guzzi, L., Henderson, S.J., Pothirat, C., Mehta, P., Fareed, J., Talwar, D.,
Tsuruta, K., Gorelick, K.J., Osawa, Y., Kaul, I., 2013. A randomized, double-blind,
placebo-controlled, Phase 2b study to evaluate the safety and efﬁcacy of re-
combinant human soluble thrombomodulin, ART-123, in patients with sepsis
and suspected disseminated intravascular coagulation. Crit. Care Med. 41,
2069e2079.
Vinters, H.V., 1987. Cerebral amyloid angiopathy. A critical review. Stroke 18,
311e324.
Volpatti, L.R., Vendruscolo, M., Dobson, C.M., Knowles, T.P.J., 2013. A Clear View of
Polymorphism, Twist, and Chirality in Amyloid Fibril Formation. ACS Nano 7,
10443e10448.
von Hutten, H., Mihatsch, M., Lobeck, H., Rudolph, B., Eriksson, M., Rocken, C., 2009.
Prevalence and origin of amyloid in kidney biopsies. Am. J. Surg. Pathol. 33,
1198e1205.
von K€anel, R., 2015. Acute mental stress and hemostasis: When physiology becomes
vascular harm. Thromb. Res. 135 (Suppl. 1), S52eS55.
Votyakova, T.V., Kaprelyants, A.S., Kell, D.B., 1994. Inﬂuence of viable cells on the
resuscitation of dormant cells in Micrococcus luteus cultures held in extended
stationary phase. The population effect. Appl. Env. Microbiol. 60, 3284e3291.
Wada, H., Matsumoto, T., Yamashita, Y., Hatada, T., 2014. Disseminated intravascular
coagulation: testing and diagnosis. Clin. Chim. Acta 436, 130e134.
Walker, J.B., Nesheim, M.E., 1999. The molecular weights, mass distribution, chain
composition, and structure of soluble ﬁbrin degradation products released from
a ﬁbrin clot perfused with plasmin. J. Biol. Chem. 274, 5201e5212.
Walsh, A.C., 1996. Anticoagulant therapy for Alzheimer's disease. J. Neuropsychiatry
Clin. Neurosci. 8, 361e362.
Walsh, A.C., Walsh, B.H., Melaney, C., 1978. Senile-presenile dementia: follow-up
data on an effective psychotherapy-anticoagulant regimen. J. Am. Geriatr. Soc.
26, 467e470.
Walton, B.L., Byrnes, J.R., Wolberg, A.S., 2015. Fibrinogen, red blood cells, and factor
XIII in venous thrombosis. J. Thromb. Haemost. 13 (Suppl. 1), S208eS215.
Wang, L., 2009. Towards revealing the structure of bacterial inclusion bodies. Prion
3, 139e145.
Wang, L., Maji, S.K., Sawaya, M.R., Eisenberg, D., Riek, R., 2008. Bacterial inclusion
bodies contain amyloid-like structure. PLoS Biol. 6, e195.
Wang, W., 2005. Protein aggregation and its inhibition in biopharmaceutics. Int. J.
Pharm. 289, 1e30.
Watanabe, H., Ono, M., Matsumura, K., Yoshimura, M., Kimura, H., Saji, H., 2013.
Molecular imaging of beta-amyloid plaques with near-infrared boron dipyrro-
methane (BODIPY)-based ﬂuorescent probes. Mol. Imaging 12, 338e347.
Weigandt, K.M., White, N., Chung, D., Ellingson, E., Wang, Y., Fu, X.Y., Pozzo, D.C.,
2012. Fibrin Clot Structure and Mechanics Associated with Speciﬁc Oxidation of
Methionine Residues in Fibrinogen. Biophys. J. 103, 2399e2407.
Weinreb, O., Amit, T., Bar-Am, O., Youdim, M.B.H., 2011. A novel anti-Alzheimer's
disease drug, ladostigil neuroprotective, multimodal brain-selective mono-
amine oxidase and cholinesterase inhibitor. Int. Rev. Neurobiol. 100, 191e215.
Weinreb, O., Amit, T., Bar-Am, O., Youdim, M.B.H., 2012. Ladostigil: a novel multi-
modal neuroprotective drug with cholinesterase and brain-selective mono-
amine oxidase inhibitory activities for Alzheimer's disease treatment. Curr.
Drug Targets 13, 483e494.
Weinreb, O., Amit, T., Mandel, S., Kupershmidt, L., Youdim, M.B., 2010. Neuro-
protective multifunctional iron chelators: from redox-sensitive process to novel
therapeutic opportunities. Antioxid. Redox Signal 13, 919e949.
Weisel, J.W., 1986. Fibrin assembly. Lateral aggregation and the role of the two pairs
of ﬁbrinopeptides. Biophys. J. 50, 1079e1093.
Weisel, J.W., 2005. Fibrinogen and ﬁbrin. Adv. Protein Chem. 70, 247e299.
Weisel, J.W., 2007. Structure of ﬁbrin: impact on clot stability. J. Thromb. Haemost. 5
(Suppl. 1), 116e124.
Weisel, J.W., 2011. Stressed ﬁbrin lysis. J. Thromb. Haemost. 9, 977e978.
Weisel, J.W., Litvinov, R.I., 2008. The biochemical and physical process of ﬁbrinolysis
and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol.Agents Med. Chem. 6, 161e180.
Weissmann, C., 2005. Birth of a prion: spontaneous generation revisited. Cell. 122,
165e168.
Westermark, G.T., Westermark, P., 2011. Localized amyloids important in diseases
outside the brainelessons from the islets of Langerhans and the thoracic aorta.
FEBS J. 278, 3918e3929.
Westermark, P., Lundmark, K., Westermark, G.T., 2009. Fibrils from designed non-
amyloid-related synthetic peptides induce AA-amyloidosis during inﬂamma-
tion in an animal model. PLoS One 4, e6041.
Wickner, R.B., Edskes, H.K., Bateman, D.A., Kelly, A.C., Gorkovskiy, A., Dayani, Y.,
Zhou, A., 2014. Amyloid diseases of yeast: prions are proteins acting as genes.
Essays Biochem. 56, 193e205.
Wiltzius, J.J.W., Landau, M., Nelson, R., Sawaya, M.R., Apostol, M.I., Goldschmidt, L.,
Soriaga, A.B., Cascio, D., Rajashankar, K., Eisenberg, D., 2009. Molecular mech-
anisms for protein-encoded inheritance. Nat. Struct. Mol. Biol. 16, 973e978.
Wolberg, A.S., 2007. Thrombin generation and ﬁbrin clot structure. Blood Rev. 21,
131e142.
Wolberg, A.S., 2012. Determinants of ﬁbrin formation, structure, and function. Curr.
Opin. Hematol. 19, 349e356.
Wolfe, L.S., Calabrese, M.F., Nath, A., Blaho, D.V., Miranker, A.D., Xiong, Y., 2010.
Protein-induced photophysical changes to the amyloid indicator dye thioﬂavin
T. Proc. Natl. Acad. Sci. U. S. A. 107, 16863e16868.
Wong, A.G., Wu, C., Hannaberry, E., Watson, M.D., Shea, J.E., Raleigh, D.P., 2016.
Analysis of the Amyloidogenic Potential of Pufferﬁsh (Takifugu rubripes) Islet
Amyloid Polypeptide Highlights the Limitations of Thioﬂavin-T Assays and the
Difﬁculties in Deﬁning Amyloidogenicity. Biochemistry 55, 510e518.
Woods, L.A., Platt, G.W., Hellewell, A.L., Hewitt, E.W., Homans, S.W., Ashcroft, A.E.,
Radford, S.E., 2011. Ligand binding to distinct states diverts aggregation of an
amyloid-forming protein. Nat. Chem. Biol. 7, 730e739.
Woolard, M.D., Frelinger, J.A., 2008. Outsmarting the host: bacteria modulating the
immune response. Immunol. Res. 41, 188e202.
Wozniak, M.A., Itzhaki, R.F., Shipley, S.J., Dobson, C.B., 2007. Herpes simplex virus
infection causes cellular beta-amyloid accumulation and secretase upregula-
tion. Neurosci. Lett. 429, 95e100.
Wu, C., Biancalana, M., Koide, S., Shea, J.E., 2009. Binding modes of thioﬂavin-T to
the single-layer beta-sheet of the peptide self-assembly mimics. J. Mol. Biol.
394, 627e633.
Wu, C., Bowers, M.T., Shea, J.E., 2011. On the origin of the stronger binding of PIB
over thioﬂavin T to protoﬁbrils of the Alzheimer amyloid-beta peptide: a mo-
lecular dynamics study. Biophys. J. 100, 1316e1324.
Wu, C., Scott, J., Shea, J.E., 2012a. Binding of Congo red to amyloid protoﬁbrils of the
Alzheimer Abeta(9-40) peptide probed by molecular dynamics simulations.
Biophys. J. 103, 550e557.
Wu, C., Wei, J., Gao, K., Wang, Y., 2007. Dibenzothiazoles as novel amyloid-imaging
agents. Bioorg Med. Chem. 15, 2789e2796.
Wu, L.C., Lin, X., Sun, H., 2012b. Tanshinone IIA protects rabbits against LPS-induced
disseminated intravascular coagulation (DIC). Acta Pharmacol. Sin. 33,
1254e1259.
Wu, Z., Li, J.N., Bai, Z.Q., Lin, X., 2014. Antagonism by salvianolic acid B of
lipopolysaccharide-induced disseminated intravascular coagulation in rabbits.
Clin. Exp. Pharmacol. Physiol. 41, 502e508.
Xie, L., Xie, L., Kinnings, S.L., Bourne, P.E., 2012. Novel computational approaches to
polypharmacology as a means to deﬁne responses to individual drugs. Annu.
Rev. Pharmacol. Toxicol. 52, 361e379.
Xu, G., Zhang, H., Zhang, S., Fan, X., Liu, X., 2008. Plasma ﬁbrinogen is associated
with cognitive decline and risk for dementia in patients with mild cognitive
impairment. Int. J. Clin. Pract. 62, 1070e1075.
Xue, W.F., Hellewell, A.L., Gosal, W.S., Homans, S.W., Hewitt, E.W., Radford, S.E.,
2009. Fibril fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 284,
34272e34282.
Xue, W.F., Hellewell, A.L., Hewitt, E.W., Radford, S.E., 2010. Fibril fragmentation in
amyloid assembly and cytotoxicity: when size matters. Prion 4, 20e25.
Yamada, T., 1999. Serum amyloid A (SAA): a concise review of biology, assay
methods and clinical usefulness. Clin. Chem. Lab. Med. 37, 381e388.
Yamakawa, K., Aihara, M., Ogura, H., Yuhara, H., Hamasaki, T., Shimazu, T., 2015.
Recombinant human soluble thrombomodulin in severe sepsis: a systematic
review and meta-analysis. J. Thromb. Haemost. 13, 508e519.
Yang, Z., Kollman, J.M., Pandi, L., Doolittle, R.F., 2001. Crystal structure of native
chicken ﬁbrinogen at 2.7 Å resolution. Biochemistry 40, 12515e12523.
Yermolenko, I.S., Lishko, V.K., Ugarova, T.P., Magonov, S.N., 2011. High-resolution
visualization of ﬁbrinogen molecules and ﬁbrin ﬁbers with atomic force mi-
croscopy. Biomacromolecules 12, 370e379.
Yeromonahos, C., Polack, B., Caton, F., 2010. Nanostructure of the ﬁbrin clot. Biophys.
J. 99, 2018e2027.
Yoshimura, J., Yamakawa, K., Ogura, H., Umemura, Y., Takahashi, H., Morikawa, M.,
Inoue, Y., Fujimi, S., Tanaka, H., Hamasaki, T., Shimazu, T., 2015. Beneﬁt proﬁle of
recombinant human soluble thrombomodulin in sepsis-induced disseminated
intravascular coagulation: a multicenter propensity score analysis. Crit. Care 19,
78.
Younan, N.D., Viles, J.H., 2015. A Comparison of Three Fluorophores for the Detec-
tion of Amyloid Fibers and Preﬁbrillar Oligomeric Assemblies. ThT (Thioﬂavin
T); ANS (1-Anilinonaphthalene-8-sulfonic Acid); and bisANS (4,4'-Dianilino-
1,1'-binaphthyl-5,5'-disulfonic Acid). Biochemistry 54, 4297e4306.
Young, L.M., Cao, P., Raleigh, D.P., Ashcroft, A.E., Radford, S.E., 2014. Ion mobility
spectrometry-mass spectrometry deﬁnes the oligomeric intermediates in
D.B. Kell, E. Pretorius / Progress in Biophysics and Molecular Biology 123 (2017) 16e41 41amylin amyloid formation and the mode of action of inhibitors. J. Am. Chem.
Soc. 136, 660e670.
Young, L.M., Saunders, J.C., Mahood, R.A., Revill, C.H., Foster, R.J., Tu, L.H.,
Raleigh, D.P., Radford, S.E., Ashcroft, A.E., 2015. Screening and classifying small-
molecule inhibitors of amyloid formation using ion mobility spectrometry-
mass spectrometry. Nat. Chem. 7, 73e81.
Yu, P.X., Zhou, Q.J., Zhu, W.W., Wu, Y.H., Wu, L.C., Lin, X., Chen, M.H., Qiu, B.T., 2013.
Effects of quercetin on LPS-induced disseminated intravascular coagulation
(DIC) in rabbits. Thromb. Res. 131, e270e3.
Yuan, H., Huang, J., Lv, B., Yan, W., Hu, G., Wang, J., Shen, B., 2013a. Diagnosis value of
the serum amyloid A test in neonatal sepsis: a meta-analysis. Biomed. Res. Int.
2013, 520294.
Yuan, L., Lin, W., Zheng, K., He, L., Huang, W., 2013b. Far-red to near infrared analyte-
responsive ﬂuorescent probes based on organic ﬂuorophore platforms for
ﬂuorescence imaging. Chem. Soc. Rev. 42, 622e661.
Zamolodchikov, D., Strickland, S., 2012. Abeta delays ﬁbrin clot lysis by altering
ﬁbrin structure and attenuating plasminogen binding to ﬁbrin. Blood 119,
3342e3351.
Zhang, M., Hu, R., Chen, H., Chang, Y., Ma, J., Liang, G., Mi, J., Wang, Y., Zheng, J.,
2015a. Polymorphic cross-seeding amyloid assemblies of amyloid-beta andhuman islet amyloid polypeptide. Phys. Chem. Chem. Phys. 17, 23245e23256.
Zhang, S., Liu, H., Chuang, C.L., Li, X., Au, M., Zhang, L., Phillips, A.R., Scott, D.W.,
Cooper, G.J., 2014. The pathogenic mechanism of diabetes varies with the de-
gree of overexpression and oligomerization of human amylin in the pancreatic
islet beta cells. FASEB J. 28, 5083e5096.
Zhang, X., Ran, C., 2013. Dual Functional Small Molecule Probes as Fluorophore and
Ligand for Misfolding Proteins. Curr. Org. Chem. 17.
Zhang, X., Tian, Y., Zhang, C., Tian, X., Ross, A.W., Moir, R.D., Sun, H., Tanzi, R.E.,
Moore, A., Ran, C., 2015b. Near-infrared ﬂuorescence molecular imaging of
amyloid beta species and monitoring therapy in animal models of Alzheimer's
disease. Proc. Natl. Acad. Sci. U. S. A. 112, 9734e9739.
Zhmurov, A., Brown, A.E., Litvinov, R.I., Dima, R.I., Weisel, J.W., Barsegov, V., 2011.
Mechanism of ﬁbrin(ogen) forced unfolding. Structure 19, 1615e1624.
Zhmurov, A., Kononova, O., Litvinov, R.I., Dima, R.I., Barsegov, V., Weisel, J.W., 2012.
Mechanical transition from alpha-helical coiled coils to beta-sheets in ﬁbrin(-
ogen). J. Am. Chem. Soc. 134, 20396e20402.
Zhou, Y., Blanco, L.P., Smith, D.R., Chapman, M.R., 2012. Bacterial amyloids. Methods
Mol. Biol. 849, 303e320.
Zimmermann, G.R., Lehar, J., Keith, C.T., 2007. Multi-target therapeutics: when the
whole is greater than the sum of the parts. Drug Disc Today 12, 34e42.
